US20230203537A1 - Stable pseudotyped lentiviral particles and uses thereof - Google Patents
Stable pseudotyped lentiviral particles and uses thereof Download PDFInfo
- Publication number
- US20230203537A1 US20230203537A1 US17/929,816 US202217929816A US2023203537A1 US 20230203537 A1 US20230203537 A1 US 20230203537A1 US 202217929816 A US202217929816 A US 202217929816A US 2023203537 A1 US2023203537 A1 US 2023203537A1
- Authority
- US
- United States
- Prior art keywords
- cells
- syncytin
- gene
- pseudotyped
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002245 particle Substances 0.000 title claims abstract description 145
- 210000004027 cell Anatomy 0.000 claims abstract description 275
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 159
- 102100021696 Syncytin-1 Human genes 0.000 claims abstract description 143
- 108010037253 syncytin Proteins 0.000 claims abstract description 101
- 239000013612 plasmid Substances 0.000 claims abstract description 55
- 210000002865 immune cell Anatomy 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 51
- 238000001415 gene therapy Methods 0.000 claims abstract description 30
- 230000001177 retroviral effect Effects 0.000 claims abstract description 21
- 108700004029 pol Genes Proteins 0.000 claims abstract description 15
- 108700004026 gag Genes Proteins 0.000 claims abstract description 14
- 108700004030 rev Genes Proteins 0.000 claims abstract description 13
- 238000003306 harvesting Methods 0.000 claims abstract description 10
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 129
- 238000010361 transduction Methods 0.000 claims description 77
- 230000026683 transduction Effects 0.000 claims description 76
- 108700038581 vectofusin-1 Proteins 0.000 claims description 73
- 102100021742 Syncytin-2 Human genes 0.000 claims description 63
- 241001529936 Murinae Species 0.000 claims description 58
- 208000015181 infectious disease Diseases 0.000 claims description 48
- 101000820789 Homo sapiens Syncytin-2 Proteins 0.000 claims description 47
- 101000820777 Homo sapiens Syncytin-1 Proteins 0.000 claims description 45
- 241000005822 Human endogenous retrovirus W Species 0.000 claims description 45
- 230000002458 infectious effect Effects 0.000 claims description 39
- 101710106152 Syncytin-A Proteins 0.000 claims description 32
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 32
- 210000004443 dendritic cell Anatomy 0.000 claims description 23
- 108010002586 Interleukin-7 Proteins 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 238000004806 packaging method and process Methods 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 14
- 238000002560 therapeutic procedure Methods 0.000 claims description 14
- 230000002463 transducing effect Effects 0.000 claims description 14
- 238000000338 in vitro Methods 0.000 claims description 13
- 108060003951 Immunoglobulin Proteins 0.000 claims description 10
- 102000018358 immunoglobulin Human genes 0.000 claims description 10
- 210000000066 myeloid cell Anatomy 0.000 claims description 10
- 101710106153 Syncytin-B Proteins 0.000 claims description 8
- 230000007812 deficiency Effects 0.000 claims description 8
- 230000005784 autoimmunity Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 210000001616 monocyte Anatomy 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 7
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- 238000009169 immunotherapy Methods 0.000 claims description 6
- 229940072221 immunoglobulins Drugs 0.000 claims description 5
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 239000013598 vector Substances 0.000 abstract description 128
- 210000000601 blood cell Anatomy 0.000 abstract description 11
- 102000003886 Glycoproteins Human genes 0.000 abstract description 9
- 108090000288 Glycoproteins Proteins 0.000 abstract description 9
- 239000006228 supernatant Substances 0.000 abstract description 8
- 241000282414 Homo sapiens Species 0.000 description 58
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 50
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 37
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 37
- 230000014509 gene expression Effects 0.000 description 37
- 239000005090 green fluorescent protein Substances 0.000 description 37
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 36
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 36
- 238000002474 experimental method Methods 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 29
- 238000001727 in vivo Methods 0.000 description 26
- 238000004519 manufacturing process Methods 0.000 description 25
- 239000002609 medium Substances 0.000 description 25
- 108700019146 Transgenes Proteins 0.000 description 23
- 102100034349 Integrase Human genes 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 238000012546 transfer Methods 0.000 description 21
- 241000700605 Viruses Species 0.000 description 20
- 102000000704 Interleukin-7 Human genes 0.000 description 18
- 101710091284 Syncytin-2 Proteins 0.000 description 18
- 201000010099 disease Diseases 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 102000005962 receptors Human genes 0.000 description 18
- 108020003175 receptors Proteins 0.000 description 18
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 17
- 101710121417 Envelope glycoprotein Proteins 0.000 description 16
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 16
- 102100022297 Integrin alpha-X Human genes 0.000 description 16
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 16
- 230000004913 activation Effects 0.000 description 16
- 238000000684 flow cytometry Methods 0.000 description 15
- 238000001890 transfection Methods 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 14
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 13
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 13
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 13
- 230000000799 fusogenic effect Effects 0.000 description 13
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 12
- 102100027207 CD27 antigen Human genes 0.000 description 12
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 12
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 11
- 238000011529 RT qPCR Methods 0.000 description 11
- 238000010362 genome editing Methods 0.000 description 11
- 108010029697 CD40 Ligand Proteins 0.000 description 10
- 102100032937 CD40 ligand Human genes 0.000 description 10
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 10
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000012894 fetal calf serum Substances 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 208000012827 T-B+ severe combined immunodeficiency due to gamma chain deficiency Diseases 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 210000002826 placenta Anatomy 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000004448 titration Methods 0.000 description 9
- 239000000654 additive Substances 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000003720 plasmablast Anatomy 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 7
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 210000004989 spleen cell Anatomy 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 238000003146 transient transfection Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 239000013603 viral vector Substances 0.000 description 7
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 6
- 102000007327 Protamines Human genes 0.000 description 6
- 108010007568 Protamines Proteins 0.000 description 6
- 201000007146 X-linked severe combined immunodeficiency Diseases 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000003169 placental effect Effects 0.000 description 6
- 229950008679 protamine sulfate Drugs 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 241000713666 Lentivirus Species 0.000 description 5
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 5
- 239000001506 calcium phosphate Substances 0.000 description 5
- 229910000389 calcium phosphate Inorganic materials 0.000 description 5
- 235000011010 calcium phosphates Nutrition 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000012937 correction Methods 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 5
- 238000005199 ultracentrifugation Methods 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 description 4
- 102100026234 Cytokine receptor common subunit gamma Human genes 0.000 description 4
- 102000006354 HLA-DR Antigens Human genes 0.000 description 4
- 108010058597 HLA-DR Antigens Proteins 0.000 description 4
- 101001055227 Homo sapiens Cytokine receptor common subunit gamma Proteins 0.000 description 4
- 241001213909 Human endogenous retroviruses Species 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000004907 flux Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 210000001806 memory b lymphocyte Anatomy 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000010415 tropism Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 108700026220 vif Genes Proteins 0.000 description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- 102000004039 Caspase-9 Human genes 0.000 description 3
- 108090000566 Caspase-9 Proteins 0.000 description 3
- 208000006332 Choriocarcinoma Diseases 0.000 description 3
- 108010002947 Connectin Proteins 0.000 description 3
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 3
- 108020004437 Endogenous Retroviruses Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 101001125170 Homo sapiens Sodium-dependent lysophosphatidylcholine symporter 1 Proteins 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 241000713887 Human endogenous retrovirus Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000714177 Murine leukemia virus Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 241000713311 Simian immunodeficiency virus Species 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- 102100029462 Sodium-dependent lysophosphatidylcholine symporter 1 Human genes 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 102100026260 Titin Human genes 0.000 description 3
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 238000005571 anion exchange chromatography Methods 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010322 bone marrow transplantation Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 210000003098 myoblast Anatomy 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 201000011461 pre-eclampsia Diseases 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 208000037914 B-cell disorder Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 206010068051 Chimerism Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 241000713730 Equine infectious anemia virus Species 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108020005004 Guide RNA Proteins 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 241000224016 Plasmodium Species 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 101150023625 WAS gene Proteins 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 241000021375 Xenogenes Species 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000005975 antitumor immune response Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000016532 chronic granulomatous disease Diseases 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 102000046769 human ERVFRD-1 Human genes 0.000 description 2
- -1 icasp9 Proteins 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 239000012117 Alexa Fluor 700 Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 101800002011 Amphipathic peptide Proteins 0.000 description 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000133640 Aspergillus multicolor Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 102100035634 B-cell linker protein Human genes 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101150008012 Bcl2l1 gene Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 208000011038 Cold agglutinin disease Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 101500023984 Drosophila melanogaster Synapsin-1 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150110187 ERVFRD-1 gene Proteins 0.000 description 1
- 101150009682 ERVW-1 gene Proteins 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000289695 Eutheria Species 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241001663880 Gammaretrovirus Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000282418 Hominidae Species 0.000 description 1
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101001109465 Homo sapiens NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 description 1
- 101000655246 Homo sapiens Neutral amino acid transporter A Proteins 0.000 description 1
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- 241000829111 Human polyomavirus 1 Species 0.000 description 1
- 241000714192 Human spumaretrovirus Species 0.000 description 1
- 206010020633 Hyperglobulinaemia Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 241001272173 Laurasiatheria Species 0.000 description 1
- 241000283960 Leporidae Species 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 101150053046 MYD88 gene Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699729 Muridae Species 0.000 description 1
- 101100381525 Mus musculus Bcl6 gene Proteins 0.000 description 1
- 101000821259 Mus musculus Syncytin-A Proteins 0.000 description 1
- 101000821260 Mus musculus Syncytin-B Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 description 1
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 description 1
- 108010082739 NADPH Oxidase 2 Proteins 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 102100032884 Neutral amino acid transporter A Human genes 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 206010053854 Opsoclonus myoclonus Diseases 0.000 description 1
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241001631648 Polyomaviridae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000031951 Primary immunodeficiency Diseases 0.000 description 1
- 108010059278 Pyrin Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 206010056131 Tinea versicolour Diseases 0.000 description 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000907316 Zika virus Species 0.000 description 1
- 208000020329 Zika virus infectious disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 230000003443 anti-oncogenic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 210000000649 b-lymphocyte subset Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000003390 bioluminescence detection Methods 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 229940076006 cell cycle modulator Drugs 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 244000078703 ectoparasite Species 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 101150047047 gag-pol gene Proteins 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000001102 germinal center b cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 101150019075 neuA gene Proteins 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002707 regulatory b cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 101150098213 rev gene Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 101150057501 synA gene Proteins 0.000 description 1
- 230000017960 syncytium formation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000024664 tolerance induction Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000004271 weak anion exchange chromatography Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4612—B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Definitions
- the present invention relates to stable pseudotyped lentiviral particles and uses thereof, particularly in therapy.
- the invention also refers to a method for preparing such stable pseudotyped lentiviral particles.
- the invention also relates to an in vitro method to transduce human peripheral blood naive B cells and monocytic cells, preferably with minimal or no pre-activation, using such pseudotyped lentiviral particles, in the presence of vectofusin.
- Retroviral vectors and in particular human immunodeficiency virus 1 (HIV-1)-based lentiviral vectors (LVs) are promising vehicles for gene therapy. These vectors are used currently in clinical applications to treat various diseases such as immune deficiencies, neurodegenerative or neurological diseases, anemias or HIV infection.
- HIV-1 human immunodeficiency virus 1
- LVs lentiviral vectors
- LVs are used to transduce T lymphocytes to generate long-lived CAR-T cells for the treatment of cancers such as refractory chronic lymphocytic leukemia (CLL) (Porter et al, Science Transl. Med. 7: 303ra139 2015).
- CLL chronic lymphocytic leukemia
- LV are used to transduce CD34+ cells for autologous gene therapy of a variety of immune, blood, metabolic or neurodegenerative disorders of genetic origin (Wagemaker G. Hum Gene Ther. 2014 October; 25(10):862-5. doi: 10.1089/hum.2014).
- Lentiviral vectors are versatile tools that can be pseudotyped with various viral envelope glycoproteins, thereby conferring specific cellular tropism characteristics to the particles (Buchholz et al. Trends Biotechnol. 2015 December; 33(12):777-90. doi: 10.1016/j.tibtech.2015.09.008.).
- a limiting factor with the use of recombinant lentiviral particles is the capacity to obtain highly infectious titers during production of recombinant lentiviral particles.
- One way to circumvent this limitation is to concentrate the viral supernatant during the purification steps.
- purification protocols are difficult to establish for some LVs, depending on the envelope glycoproteins used to pseudotype viral particles. Therefore, many lentiviral vector preparations have low titer and transduction efficacy is limited.
- Another limiting factor is that it is difficult to transduce primary cells, thus they must often be activated to be transduced, thereby losing their naive status.
- lentiviral vector itself to infect target cells.
- envelope glycoproteins such as VSV-G or RD114TR can be used to pseudotype lentiviral vectors and have variable infectivity on target cells such as CD34+ cells and primary blood cells.
- Syncytins are endogenous retroviral virus (ERV syncytins) envelope glycoproteins which have fusogenic properties (Dupressoir et al., 2005; Lavialle et al., 2013).
- the glycoprotein encoded by the ERVFRD-1 gene (ENSG00000244476; also known as syncytin-2, or HERV-FRD) was used to pseudotype SIV vectors and reportedly works as HIV or MLV pseudotype but at very low titers precluding functional studies and little information is available on the HERV-FRD HIV pseudotype (Blaise et al, Journal of Virology, January 2004, p. 1050-1054).
- a virus or viral vector particularly a stable virus or viral vector, for example for improving delivery of a gene into specific target cells.
- a virus or viral vector which would be stable, and could thus be obtained at an industrial scale.
- a stable vector which could be used in vitro, or in vivo, as a tool presenting new biological properties.
- lentiviral particles pseudotyped with a specific envelope glycoprotein which are stable and which may be frozen.
- Said lentiviral pseudotyped particles also improve the transduction of selected target cells, in particular immune cells; this broadens the therapeutic scope of said particles.
- Said pseudotyped lentiviral particles are indeed efficient for transducing immune cells, and particularly B cells, T cells and dendritic cells and allow functional correction of cell deficiency.
- these lentiviral pseudotyped vectors can be administered in vivo where they lead to detectable, stable and well-tolerated gene transfer in spleen and bone marrow with evidence of CD19 + spleen B cell transduction.
- pseudotyped lentiviral particles are a promising strategy for patients suffering from placental dysfunction, cancers, infectious diseases, immune deficiencies, auto-immunity or for gene therapy or as vaccines or as biotechnology engineering tool.
- the invention relates to a method for obtaining stable pseudotyped lentiviral particles including a heterologous gene of interest, comprising the following steps:
- the method according to the invention allows obtaining high physical titers, as well as high infectious titers, of stable pseudotyped lentiviral particles including a heterologous gene of interest.
- stable lentiviral particles pseudotyped with an ERV syncytin and packaging a heterologous gene of interest may be obtainable or obtained by the method described in the above paragraph.
- Said stable pseudotyped lentiviral particles may be useful as a medicament.
- said stable pseudotyped lentiviral particles may be useful in gene therapy or in immunotherapy, particularly as a vaccine or in immunoprophylaxis.
- the present invention also relates to lentiviral particles pseudotyped with an ERV syncytin including a heterologous gene of interest, preferably stable lentiviral particles pseudotyped with an ERV syncytin including a heterologous gene of interest, for use for therapy by transducing cells which express the cognate receptors such as for example ASCT2, ASCT1 or MFSD2a respectively for syncytin-1 (HERV-W) and syncytin-2 (HERV-1-RD), such as human choriocarcinoma cells, human epithelial cells, or human immune cells such as B cells, T cells, or CD11c+ cells such as myeloid cells (e.g.: granulocytes, monocytes and their progenitor cells).
- the invention also relates to the ability to use the lentiviral particles pseudotyped with an ERV syncytin to efficiently transduce murine B cells and T cells.
- the present invention also relates to lentiviral particles pseudotyped with an ERV syncytin including a gene of interest, preferably stable lentiviral particles pseudotyped with an ERV syncytin including a heterologous gene of interest, for use for treating immune deficiencies, auto-immunities, infectious diseases, placental dysfunction (such as pre-eclampsia), diseases involving the blood-brain barrier, or cancers including B cell-related cancers, or to make models of these diseases in mice.
- the stable lentiviral particles pseudotyped with an ERV syncytin including a heterologous gene of interest may also be useful for the in vitro transduction of immune cells, preferably B cells or CD11c+ cells such as myeloid cells (e.g.: granulocytes, monocytes and their progenitor cells).
- immune cells preferably B cells or CD11c+ cells such as myeloid cells (e.g.: granulocytes, monocytes and their progenitor cells).
- the transduction of immune cells may find applications in biotechnology engineering, for example in the production of immunoglobulins, or in immune cell, preferably B cell engineering.
- the present invention also relates to an ex vivo process for obtaining immune cells modified to express a heterologous gene of interest, comprising a step of infecting immune cells with lentiviral particles pseudotyped with an ERV syncytin including a heterologous gene of interest, preferably stable lentiviral particles pseudotyped with an ERV syncytin including a heterologous gene of interest, preferably in the presence of a LAH4 peptide or a functional derivative thereof.
- the present invention also relates to the use of the stable lentiviral particles pseudotyped with an ERV syncytin including a heterologous gene of interest, preferably stable lentiviral particles pseudotyped with an ERV syncytin including a heterologous gene of interest, for biotechnology engineering. Particularly, they may be used for generating cell lines, preferably B cell lines, in order to produce a specific product, such as immunoglobulins.
- the stable particles of the present invention may also be used to generate models of study, particularly in mice (so as to obtain murine models). This may be useful for exploring disease mechanisms, particularly B cell diseases or B cell-mediated diseases, generating dendritic cells and/or myeloid cells expressing a product for the purpose of vaccination, or producing products with specific therapeutic effects.
- the ERV syncytin is selected from the group consisting of HERV-W, HERV-FRD, murine syncytin-A, murine syncytin-B, syncytin-Ory1, syncytin-Car1 and syncytin-Rum1 and their functional orthologs, preferably the ERV syncytin is selected from the group consisting of HERV-W, HERV-FRD and murine syncytin-A and even more preferably the ERV syncytin is HERV-W or HERV-FRD.
- ERV syncytins which have high fusogenic properties, such as the human syncytin-1 (HERV-W), the human syncytin-2 (HERV-FRD) and the murine syncytin A, may be used for obtaining pseudotypes for recombinant HIV-1 derived lentivirus.
- HERV-W human syncytin-1
- HERV-FRD human syncytin-2
- murine syncytin A may be used for obtaining pseudotypes for recombinant HIV-1 derived lentivirus.
- the results show that it is possible to produce stable and infectious lentiviral particles comprising a gene of interest, which have selective tropism on cell lines.
- syncytin-pseudotyped lentiviral particles are able to efficiently transduce human primary B lymphocytes and CD11c+ myeloid and/or dendritic cells notably in the presence of Vectofusin-1, a cationic transduction additive.
- the inventors have elaborated a method for obtaining lentiviral particles pseudotyped with an ERV syncytin, which are stable, infectious and which may be frozen.
- the lentiviral pseudotyped particles improve the transduction of selected target cells, in particular immune cells, and particularly B cells, T cells and dendritic cells.
- the present invention relates to a method for obtaining stable pseudotyped lentiviral particles including a heterologous gene of interest, comprising the following steps:
- step c) of the method according to the invention comprises harvesting, concentrating and/or purifying the stable lentiviral particles produced in step b), from the supernatant.
- the concentration of step c) comprises centrifugating and/or purifying the harvested stable lentiviral particles obtained in b).
- Said harvest may be performed according to well-known methods in the art.
- the lentiviral vectors are harvested before fusion of the transfected cells, more preferably between 20 hours and 72 hours post-transfection, preferably after 24 hours.
- the harvesting step consists of a single lentivirus harvest, preferably implemented between 20 and 72 hours post-transfection, preferably between 20 and 30 hours post-transfection, more preferably after 24 hours.
- ERV syncytins refer to highly fusogenic envelope glycoproteins from eutherian mammals, which belong to the family of Endogenous Retroviruses (ERVs). These proteins are encoded by genes, which display a preferential expression in placenta and induce syncytium formation when introduced into cultured cells (Lavialle et al., 2013).
- ERVs syncytins can be selected from human syncytins (e.g.: HERV-W and HERV-FRD), murine syncytins (e.g.: syncytin-A and syncytin-B), syncytin-Ory1, syncytin-Car1, syncytin-Rum1 or their functional orthologs (Dupressoir et al., 2005; Lavialle et al., 2013).
- human syncytins e.g.: HERV-W and HERV-FRD
- murine syncytins e.g.: syncytin-A and syncytin-B
- syncytin-Ory1 e.g.: syncytin-Ory1
- syncytin-Car1 syncytin-Rum1 or their functional orthologs
- orthologs proteins encoded by orthologs genes and that exhibit fusogenic properties. Fusogenic properties may be assessed in fusion assays as described in Dupressoir et al. (PNAS 2005). Briefly, cells are transfected for example by using Lipofectamine (Invitrogen) and about 1-2 ⁇ g of DNA for 5 ⁇ 10 5 cells or calcium phosphate precipitation (Invitrogen, 5-20 ⁇ g of DNA for 5 ⁇ 10 5 cells). Plates are generally inspected for cell fusion 24-48 h after transfection.
- Lipofectamine Invitrogen
- Ca phosphate precipitation Invitrogen, 5-20 ⁇ g of DNA for 5 ⁇ 10 5 cells
- Syncytia can be visualized by using May-Grünwald and Giemsa staining (Sigma) and the fusion index calculated as [(N ⁇ S)/T] ⁇ 100, where N is the number of nuclei in the syncytia, S is the number of syncytia, and T is the total number of nuclei counted.
- HERV-W Human syncytins encompasses HERV-W and HERV-FRD. Functional orthologs of these proteins can be found in Hominidae.
- HERV-W refers to a highly fusogenic membrane glycoprotein belonging to the family of Human Endogenous Retroviruses (HERVs).
- HERV-W is an envelope glycoprotein; it is also called Syncytin-1. It has the sequence indicated in Ensembl database, corresponding to Transcript ERVW-1-001, ENST00000493463.
- the corresponding cDNA has the sequence listed in SEQ ID NO: 1.
- HERV-FRD also refers to a highly fusogenic membrane glycoprotein belonging to the family of Human Endogenous Retroviruses (HERVs).
- HERV-FRD is an envelope glycoprotein, also called Syncytin-2. It has the sequence indicated in Ensembl database, corresponding to Transcript ERVFRD-1, ENSG00000244476. The corresponding cDNA has the sequence listed in SEQ ID NO:2.
- Murine syncytins encompasses murine syncytin-A (i.e.: mus musculus syncytin-A, synA) and murine syncytin-B (i.e.: mus musculus syncytin-B, synB). Functional orthologs of these proteins can be found in the Muridae family.
- Murine syncytin-A is encoded by the syncytin-A gene.
- Syncytin-A has the sequence indicated in Ensembl database Syna ENSMUSG00000085957.
- the corresponding cDNA has the sequence listed in SEQ ID NO:40.
- Murine syncytin-B is encoded by the syncytin-B gene.
- Syncytin-B has the sequence indicated in Ensembl databaseSynb ENSMUSG00000047977.
- the corresponding cDNA has the sequence listed in SEQ ID NO:41.
- the syncytin-Ory1 is encoded by the syncytin-Ory1 gene. Functional orthologs of syncytin-Ory1 can be found in the Leporidae family (typically rabbit and hare).
- the syncytin-Car1 is encoded by the syncytin-Car1 gene. Functional orthologs of syncytin-Car1 can be found in carnivores mammals from the Laurasiatheria superorder (Cornelis et al., 2012; Lavialle et al., 2013).
- the syncytin-Rum1 is encoded by the syncytin-Rum1 gene. Functional orthologs of syncytin Rum-1 can be found in ruminant mammals.
- the ERV syncytin according to the invention can be typically selected from the group consisting of HERV-W, HERV-FRD, syncytin-A, syncytin-B, syncytin-Ory1, syncytin-Car1 and syncytin-Rum1 and their functional orthologs; preferably the ERV syncytin is selected from the group consisting of HERV-W, HERV-FRD, murine syncytin-A and their functional orthologs, more preferably the ERV syncytin is selected from the group consisting of HERV-W, HERV-FRD and murine syncytin-A and even more preferably the ERV syncytin is HERV-W or HERV-FRD.
- the method according to the invention allows obtaining high physical titers, as well as high infectious titers, of stable pseudotyped lentiviral particles including a heterologous gene of interest.
- the stable pseudotyped lentiviral particles including a heterologous gene of interest are obtained at a high physical titer thanks to the method of the invention, and are infectious, thus efficient, particularly for transducing B cells, or myeloid cells.
- physical titer it is meant the number of lentiviral particles which are produced.
- the physical titer may be measured according to classical methods known in the art, and which are commonly used to quantify lentiviral particles, for example by p24 ELISA, which is illustrated in the examples, by direct particle counting with an automated counter such as the Nanosight NS300 instrument from Malvern using the manufacturer's instructions, by RT (reverse transcriptase) ELISA (as described in Ciré et al, Plosone, July 2014, Vol. 9, Issue 7, Immunization of mice with lentiviral vectors targeted to MHC class II+ cells is due to preferential transduction of dendritic cells in vivo) or by viral RNA RT-qPCR.
- high physical titer it is meant a titer of particles produced at the end of step b) higher than 200 ng p24/mL, preferably higher than 210 ng p24/mL, even more preferably higher than 300 ng p24/mL. More preferably, the physical titer of particles pseudotyped with an ERV syncytin such as HERV-W, produced at the end of step b) is higher than 300 ng p24/mL, preferably higher than 400 ng p24/mL.
- the physical titer of particles pseudotyped with an ERV syncytin such as HERV-FRD, produced at the end of step b) is higher than 210 ng p24/mL, preferably higher than 300 ng p24/mL.
- high physical titer it is also meant a titer of particles produced at the end of step c) (i.e. concentrated) higher than 1 ⁇ 10 5 ng p24/mL, preferably higher than 1.1 ⁇ 10 5 ng p24/mL, more preferably higher than 1.5 ⁇ 10 5 ng p24/mL More preferably, the physical titer of particles pseudotyped with an ERV syncytin such as HERV-W produced at the end of step c) is higher than 2.2 ⁇ 10 5 ng p24/mL, preferably higher than 3.0 ⁇ 10 5 ng p24/mL, even preferably higher than 4.0 ⁇ 10 5 ng p24/mL.
- the physical titer of particles pseudotyped with an ERV syncytin such as HERV-FRD produced at the end of step c) is higher than 1.1 ⁇ 10 5 ng p24/mL, preferably higher than 1.5 ⁇ 10 5 ng p24/mL.
- a physical titer higher than 1 ⁇ 10 5 ng p24/mL corresponds to a physical titer higher than 1.2 ⁇ 10 12 calculated physical particles (pp)/mL or higher than about 3 ⁇ 10 11 pp/mL, as measured by Nanosight counting.
- infectious titer it is meant the number of functional lentiviral particles.
- the infectious titer may be measured according to classical methods known in the art, for example by flow cytometry to calculate a transducing units titer (TU/mL) or by qPCR to measure infectious genomes (ig/mL), which are illustrated in the examples.
- TU/mL transducing units titer
- ig/mL infectious genomes
- infectious titer of the lentiviral particles of the invention is measured upon infection of a permissive cell line, preferably 293T cells, or another permissive cell such as A20 cells, more preferably using the titration method described herein into the experimental example section of the application.
- high infectious titer it is meant a titer of infectious particles produced at the end of step c), higher than 2 E+04 TU/ml, preferably higher than 1 E+05 TU/ml, more preferably higher than 1 E+06 TU/ml, even more preferably higher than 2 E+06 TU/ml. More preferably, the infectious titer of particles pseudotyped with HERV-W produced at the end of step c), is higher than 1.2 E+05 TU/ml, preferably higher than 2 E+05 TU/ml, more preferably higher than 1 E+06 TU/ml, even more preferably higher than 1.5 E+06 TU/ml.
- the infectious titer of particles pseudotyped with HERV-FRD produced at the end of step c) is higher than 2 E+04 TU/ml, preferably higher than 2 E+05 TU/ml, more preferably higher than 1 E+06 TU/ml, even more preferably higher than 2.5 E+06 TU/ml.
- such high infectious titers are measured using 293T cell infection and the titration method described in the example herein.
- the present invention also relates to stable lentiviral particles pseudotyped with HERV-W or HERV-FRD and packaging a heterologous gene of interest. That may be obtainable, or obtained, by the above method.
- stable it is meant that the infectious titer of the stable lentiviral particles pseudotyped with an ERV syncytin, such as an ERV syncytin as previously defined and more preferentially pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A and packaging a heterologous gene of interest of the invention, and having infected 293T cells or another permissive cell line for instance A20 cells, has been divided at most by 10 between two consecutive time points.
- the two consecutive time points may represent a duration of a few weeks, such as 1 to 3 weeks.
- the two consecutive time points may also represent a duration of a few months, such as 1, 2 or 3 months, or 6, 9, 10 months or even 12 or 18 months.
- the lentiviral pseudotyped particles according to the invention may be frozen, they keep their stability properties. They are indeed resistant to very low temperature treatments, such as freezing or cryopreservation. They may also be resistant to medium temperature treatments: as soon as they present the stability properties as indicated above, they correspond to the present invention.
- Such lentiviral pseudotyped particles can thus be centrifugated and/or frozen, while maintaining their fusogenic and infectious properties, as well as their ability to deliver the gene of interest to the target cells, particularly in vivo.
- the stable pseudotyped lentiviral particles packaging a heterologous gene of interest according to the invention present a high physical titer, as well as a high infectious titer.
- heterologous gene it is meant a gene, which comes from an organism different from the one of the retroviral rev, gag and pol genes.
- gene of interest it is meant a functional version of a gene.
- the functional version means the wild-type version of said gene, a variant gene belonging to the same family, or a truncated version, which preserves the functionality of the encoded protein.
- the gene of interest may be derived from a gene, which is deficient or non-functional in a patient, or a gene coding for an immunogenic protein (such as a viral protein, a bacterial protein or a tumor antigen).
- the heterologous gene of interest may also be a reporter gene (useful for diagnosis purpose, and for identifying ligands of a target protein), a suicide gene, or a gene coding for a therapeutic RNA (ie coding for an antisense RNA complementary to a target DNA or RNA sequence, or a gRNA, a RNAi such as shRNA).
- the gene of interest is able to produce the encoded protein, peptide or RNA.
- lentiviral particle comprising:
- the native viral envelope glycoprotein may be modified by mutation or by any other amino acid modification;
- Such a glycoprotein is a fusion protein between at least a part of the viral glycoprotein, and another sequence.
- step a) appropriate cell lines are transfected with at least one plasmid.
- the transfection is a transient transfection.
- appropriate cell lines are transfected with at least one, two, three or four plasmids.
- These cell types include any eukaryotic cell which support the lentivirus life cycle.
- the appropriate cell lines are stable cell lines or cell lines refractory to the catastrophic consequences of the fusogenic effects of syncytins, so as to continue growing while producing the particles.
- Said appropriate cell lines are mammalian cell lines, preferably human cell lines. Representative examples of such cells include Human Embryonic Kidney (HEK) 293 cells and derivatives thereof, HEK293 T cells, as well as subsets of cells selected for their ability to grow as adherent cells, or adapted to grow in suspension under serum-free conditions. Such cells are highly transfectable.
- HEK Human Embryonic Kidney
- the appropriate cell lines are already expressing at least one, and at most four of the five sequences which are the heterologous gene of interest, the retroviral rev, gag and pol genes, and the nucleic acid coding for an ERV syncytin such as HERV-W, HERV-FRD or murine syncytinA, preferably in inducible form.
- step a) comprises transfecting said cell line with at least one plasmid comprising at least one sequence which is not already expressed in said cell line.
- the plasmid mixture, or the single plasmid (if only one plasmid is used) is chosen such that, when transfected into said cell lines in step a), said cell lines express all five above sequences.
- the plasmid or mixture of plasmids to be transfected comprises the remaining sequences to be expressed, i.e. the heterologous gene of interest and the nucleic acid coding for an ERV syncytin such as HERV-W, HERV-FRD or murine syncytinA.
- heterologous gene of interest the heterologous gene of interest
- nucleic acid coding for an ERV syncytin as previously described and notably coding for HERV-W, HERV-FRD or the murine syncytinA.
- plasmid mixture When two or three plasmids are used (plasmid mixture), each of them comprises some of the sequences of interest listed in the previous paragraph, so that the plasmid mixture comprises all the above cited sequences of interest.
- the quadritransfection comprises the following:
- the first plasmid comprises the gene of interest
- the second plasmid comprises the rev gene
- the third plasmid comprises the gag and pol genes
- the fourth plasmid comprises a nucleic acid coding for an ERV syncytin as previously described and notably coding for HERV-W, HERV-FRD or the murine syncytin-A.
- Said quadritransfection is preferably performed with specific ratios between the four plasmids.
- the molar ratio between the different plasmids can be adapted for optimizing the scale-up of the production.
- the person skilled in the art is able to adapt this parameter to the specific plasmids he uses for producing the lentivirus of interest.
- the weight ratios of the first, second, third, fourth plasmids are preferably (0.8-1.2):(0.1-0.4); (0.5-0.8):(0.8-1.2), more preferably around 1:0.25; 0.65:1.
- the rev, gag and pol genes are retroviral, preferably lentiviral.
- they are HIV genes, preferably HIV-1 genes, but could be also EIAV (Equine Infectious Anemia Virus), SIV (Simian immunodeficiency Virus), Foamy Virus, or MLV (Murine Leukemia Virus) virus genes.
- the nucleic acid coding for the ERV syncytin is a DNA or cDNA sequence.
- it corresponds to the cDNA sequence respectively listed in SEQ ID NO:1, 2 or 40, or to a sequence presenting at least 80%, preferably at least 90%, more preferably at least 95%, more preferably at least 99% identity with such SEQ ID NO:1, 2, or 40 respectively.
- step a) comprises the transfection of at least the plasmid comprising, preferably consisting of, the cDNA sequence listed in SEQ ID NO:3 or 4.
- identity refers to the sequence similarity between two polypeptide molecules or between two nucleic acid molecule. When a position in both compared sequences is occupied by the same base or same amino acid residue, then the respective molecules are identical at that position.
- the percentage of identity between two sequences corresponds to the number of matching positions shared by the two sequences divided by the number of positions compared and multiplied by 100. Generally, a comparison is made when two sequences are aligned to give maximum identity.
- the identity may be calculated by alignment using, for example, the GCG (Genetics Computer Group, Program Manual for the GCG Package, Version 7, Madison, Wis.) pileup program, or any of sequence comparison algorithms such as BLAST, FASTA or CLUSTALW.
- the plasmids encoding the envelope glycoproteins which may be used are known to those skilled in the art such as the commercially available pCDNA3, backbone or any other plasmid cassette using a similar expression system, for instance using the CMV promoter such as the pKG plasmid described in Merten et al. (Hum Gene Ther., 2011).
- step a) various techniques known in the art may be employed for introducing nucleic acid molecules into cells.
- Such techniques include chemical-facilitated transfection using compounds such as calcium phosphate, cationic lipids, cationic polymers, liposome-mediated transfection, such as cationic liposome like Lipofectamine (Lipofectamine 2000 or 3000), polyethyleneimine (PEI), non-chemical methods such as electroporation, particle bombardment or microinjection.
- the transfection of step a) is carried out using calcium phosphate.
- step a) may be performed by transient transfection of 293T cells with 4 plasmids (quadritransfection), in the presence of calcium phosphate.
- the 4 plasmids are preferably: a pKL plasmid expressing the HIV-1 gag and pol genes, a pK plasmid expressing HIV-1 rev gene, a pCCL plasmid expressing the heterologous gene of interest under control of a cellular promoter such as the human phosphoglycerate kinase (PGK) promoter and a pCDNA3 plasmid expressing an ERV syncytin, such as an ERV syncytin as previously defined and more preferentially expressing HERV-W (Syncytin-1), HERV-FRD (Syncytin-2) or the murine syncytin-A glycoproteins from a CMV promoter.
- a cellular promoter such as the human phosphoglycerate
- the method according to the present invention comprises a step b) of incubating the transfected cells obtained in a), so that they produce, preferably in the supernatant, the lentiviral particles pseudotyped with an ERV syncytin, such as an ERV syncytin as previously defined and more preferentially pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A including the heterologous gene of interest.
- an ERV syncytin such as an ERV syncytin as previously defined and more preferentially pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A including the heterologous gene of interest.
- ERV syncytin such as an ERV syncytin as previously defined and more preferentially pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A and which include the heterologous gene of interest.
- the transfected cells are thus allowed to grow for a time which may be comprised between 20 and 72 hours post-transfection, in particular after 24 hours.
- the medium used for culturing the cells is a classical medium, such as DMEM, comprising a sugar, such as glucose.
- DMEM a classical medium
- the medium is a serum-free medium.
- Culture may be carried out in a number of culture devices such as multistack systems or bioreactors adapted to the culture of cells in suspension.
- the bioreactor may be a single-use (disposable) or reusable bioreactor.
- the bioreactor may for example be selected from culture vessels or bags and tank reactors.
- Non-limiting representative bioreactors include a glass bioreactor (e.g. B-DCU® 2L-10L, Sartorius), a single-use bioreactor utilizing rocking motion agitation such as wave bioreactor (e.g. Cultibag RM® 10L-25L, Sartorius), single use stirrer tank bioreactor (Cultibag STR® 50L, Sartorius), or stainless steel tank bioreactor.
- the obtained stable lentiviral particles are harvested and concentrated; this is step c).
- the stable lentiviral particles obtained in b) are harvested before fusion of the transfected cells, more preferably 24h post-transfection.
- the stable lentiviral particles present in the supernatant obtained in b) are centrifugated and/or purified. Said concentration step c) may be performed by any known method in the art, such as by centrifugation, ultrafiltration/diafiltration and/or chromatography.
- the supernatant is centrifugated at a speed comprised between 40000 and 60000 g, during 1 h to 3 h, at a temperature comprised between 1° C. and 5° C., so as to obtain a centrifugate of stable pseudotyped viral particles.
- the centrifugation is performed at a speed of 45000 to 55000 g, during 1 h30 to 2 h30, at a temperature of 2° C. to 5° C., preferably around 4° C.
- the particles are concentrated in the form of a centrifugate, which may be used.
- step c) is a chromatography, such as an anion exchange chromatography, or an affinity chromatography.
- the anion exchange chromatography may be preceded or followed by a step of ultrafiltration, in particular an ultrafiltration/diafiltration, including tangential flow filtration.
- the anion exchange chromatography is for example a weak anion exchange chromatography (including DEAE (D)—diethylaminoethyl, PI—polyethylenimine).
- This method allows obtaining lentiviral particles pseudotyped with an ERV syncytin, such as an ERV syncytin as previously defined and more preferentially pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A.
- Said particles are stable, because, thanks to the above method, they can be concentrated without being degraded, as shown in the examples.
- said particles comprise the heterologous gene of interest.
- the stable lentiviral particles pseudotyped with an ERV syncytin such as an ERV syncytin as previously defined and more preferentially pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A and packaging the gene of interest according to the invention, are suspended in a pharmaceutically acceptable carrier, so as to obtain a pharmaceutical composition.
- an ERV syncytin such as an ERV syncytin as previously defined and more preferentially pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A and packaging the gene of interest according to the invention
- a “pharmaceutically acceptable carrier” refers to a vehicle that does not produce an adverse, allergic or other untoward reaction when administered to a mammal, especially a human, as appropriate.
- a pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
- the pharmaceutical composition contains vehicles, which are pharmaceutically acceptable for a formulation capable of being injected.
- vehicles which are pharmaceutically acceptable for a formulation capable of being injected.
- These may be in particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and the like or mixtures of such salts), or dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or suspensions.
- the solution or suspension may comprise additives which are compatible with enveloped viruses and do not prevent virus entry into target cells.
- the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
- An example of an appropriate solution is a buffer, such as phosphate buffered saline (PBS).
- the stable pseudotyped lentiviral particles of the invention as they package the heterologous gene of interest, may be used as a medicament.
- a syncytin-pseudotyped lentiviral vector of the invention can be used in immunotherapy in humans and can functionally correct B cells in a human disease.
- the syncytin-pseudotyped vectors of the invention are able to target B cells in vivo.
- the data showed herein illustrated that these new tools are very well tolerated in vivo as gene transfer is observed for a long period of time.
- efficient transduction of the target cells (such as B cells) can be obtained without the need of vectofusin 1.
- the stable pseudotyped lentiviral particles may be used in gene therapy or immunotherapy or as a vaccine or in immunoprophylaxis.
- Gene therapy can be performed by gene transfer, gene editing, exon skipping, RNA-interference, trans-splicing or any other genetic modification of any coding or regulatory sequences in the cell, including those included in the nucleus, mitochondria or as commensal DNA (viral sequences contained in cells).
- the two main types of gene therapy are the following:
- the gene of interest may be a correct version of a gene which is deficient or mutated in a patient, as is the case for example in a genetic disease.
- the gene of interest will restore the expression of the deficient or mutated gene.
- deficient or mutated genes in patients exhibiting a disease which, once corrected in immune cells, preferably in B cells, T cells, monocytes or dendritic cells, more preferably in B cells, improve the patient's disease or symptoms. Examples of mutated genes in genetically defective B cells are the following:
- genes could be used as the gene of interest.
- mutated genes in genetic diseases of phagocyte function are the following: Wiskott Aldrich Syndrome (WAS gene), chronic granulomatous disease (CGD, CYBB or p47 genes), leukocyte adhesion deficiency (LAD), IL-12/23 deficiency (IL12 p40, p70, IL23 chains), bare lymphocyte syndrome due to absent HLA molecules, auto-inflammatory disorders such as familial Mediterranean fever (pyrin gene) or cryopyrin-related diseases (NALP3 mutations).
- WAS gene Wiskott Aldrich Syndrome
- CCD chronic granulomatous disease
- LAD leukocyte adhesion deficiency
- IL-12/23 deficiency IL12 p40, p70, IL23 chains
- bare lymphocyte syndrome due to absent HLA molecules
- auto-inflammatory disorders such as familial Mediterranean fever (pyrin gene) or cryopyrin-related diseases (NALP3 mutations).
- Replacement gene therapy could also be used to treat cancer.
- Genes of interest in cancer could regulate the cell cycle or the metabolism and migration of the tumor cells, or induce tumor cell death.
- inducible caspase-9 could be expressed in B cell leukemias or B cell lymphomas to trigger cell death, preferably in combination therapy to elicit durable anti-tumor immune responses.
- syncytin-1 or syncytin-2 could also be treated by gene transfer into these cells.
- gestational pathologies in which placental cells could be treated; cancer such as leukemias, lymphomas or solid tumor cells (including breast or lung tumor cells known to express ASCT2 or MFSD2a) in which the malignant cells could be treated; neurological conditions in which endothelial cells of the blood-brain-barrier could be treated; or any genetic or acquired condition implicating these cells.
- the stable pseudotyped lentiviral particles of the invention in therapy for immune cell engineering, preferably B cell engineering, by transducing said immune cells. It might be possible to generate regulatory B cells by expressing immunosuppressive proteins in B cells, for instance IL-10, or to induce the production of immunoregulatory proteins such as antibodies or fusion proteins.
- the heterologous gene of interest is chosen from gRNA, nucleases, DNA templates and RNAi components, such as shRNA.
- a specific example of gene editing would be the treatment of Waldenström macroglobulinemia: in such a disease, a point mutation (L265P) of (MYD88) has been observed in B cells of 80-88% of the patients and contributes to the survival and persistence of these tumor cells. Thus, by gene editing a correct version of this gene in afflicted patients, this may contribute to effective therapies against this disease.
- the stable pseudotyped lentiviral particles of the invention could be used together or sequentially to target the same cells through different receptors. This could be an advantage in strategies such as gene editing, in which multiple components of the gene editing platform need to be added to the cells.
- transduce immune cells preferably B cells
- stable pseudotyped lentiviral particles of the invention preferably B cells
- transduced B cells are able to produce the corresponding immunoglobulins.
- pathogens such as viruses (rabies, HIV, Ebola, Flu, CMV, Zika) or parasites ( T. cruzi, P. falciparum ) which could be used for prophylactic or therapeutic use or for diagnostic.
- the therapy may be an anti-inflammatory therapy, tolerance induction or a vaccination.
- the therapy may be for treating an autoimmune disease.
- the therapy may be as vaccine.
- recipient immature dendritic cells transduced with major or minor histocompatibility antigens specific of an allogeneic organ donor may be used to induce allogeneic organ transplant tolerance in the recipient.
- immunotherapy applications via genetic engineering of antigen-presenting cells such as human B cells, human myeloid dendritic cells or monocytes, may be found by introducing into these cells a recombinant gene expression cassette containing an antigenic sequence associated or not with immunommodulatory sequences, for antigenic presentation for the purpose of vaccination to protect against infectious diseases; for treating cancer; or for the purpose of inducing cell-specific or antigen-specific immune tolerance, in order to treat diseases with inflammatory immune components, such as diabetes or Alzheimer's disease, or to facilitate organ or bone marrow transplantation.
- inflammatory immune components such as diabetes or Alzheimer's disease, or to facilitate organ or bone marrow transplantation.
- the targeted tissue is not only immune cells, but could also be placenta as well as any tissue in which syncytin-mediated heterologous fusion occurs, or any tissue or any cell expressing the receptors for syncytin. Examples include possibilities of treating placenta to prevent pre-eclampsia. Pre-eclampsia is a leading cause of maternal mortality and some studies have detected in the pre-eclamptic placenta that differentially expressed microRNAs deregulate TGF- ⁇ 2 response (Zhou et al Sci Rep. 2016 Jan. 29; 6:19910. doi: 10.1038/srep19910.).
- syncytin-pseudotyped vectors may correct this problem.
- the target tissue could be skeletal muscle as it was recently shown that syncytins are expressed in myoblasts and may contribute to fusion between myoblasts (Frese et al., 2015).
- syncytin-pseudotyped vectors which may recognize receptor on skeletal muscle cells, may be used for muscle gene therapy.
- a patient denotes a mammal
- a patient according to the invention is a human.
- An immune cell is a cell involved in the immune system. It comprises notably B cells, T cells, NK cells, macrophages and dendritic cells.
- a B cell (or B lymphocyte) is an immune cell responsible for the production of antibodies, and involved in the humoral immune response.
- a dendritic cell is an immune cell, which is accessory: it is an antigen-presenting cell. Its main function is to process the antigen material and present it on its cell surface to the T cells.
- a T cell is an immune cell involved in cell-mediated immune response. It may be chosen from killer T cells, helper T cells and gamma delta T cells.
- the stable pseudotyped lentiviral particles may be used in immunotherapy or as a vaccine or in immunoprophylaxis.
- the heterologous gene of interest may code for an immunogenic protein, such as a viral protein, a bacterial protein or a tumor antigen. In such a case, the expression of the gene will stimulate immune responses, allowing immunization. This corresponds to a vaccine.
- the heterologous gene of interest may code for a protein which prevents B cell viral infection, such as EBV infection, which may cause malignant transformation in immunodeficient patients.
- the invention also relates to the use of stable lentiviral particles pseudotyped with an ERV syncytin, such as an ERV syncytin as previously defined and more preferentially pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A packaging a heterologous gene of interest, for therapy by transducing immune cells, preferably B cells.
- an ERV syncytin such as an ERV syncytin as previously defined and more preferentially pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A packaging a heterologous gene of interest, for therapy by transducing immune cells, preferably B cells.
- the invention also relates to the use of stable lentiviral particles pseudotyped with an ERV syncytin, such as an ERV syncytin as previously defined and more preferentially pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A packaging a heterologous gene of interest, for bioengineering in human B cells.
- an ERV syncytin such as an ERV syncytin as previously defined and more preferentially pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A packaging a heterologous gene of interest, for bioengineering in human B cells.
- vectored antibodies in B cells which consists of expressing by gene transfer in human B cells recombinant antibodies directed against toxins, pathogens (such as HIV-1) or parasites (such as Plasmodium) to facilitate the rapid recognition and neutralization of these pathogens.
- mice Examples of recombinant antibodies that are vectored in mice in a different system are described in “Balazs A B, et al. Nat Med. 2014 March; 20(3):296-300. doi: 10.1038/nm” or “Deal C et al. Proc Natl Acad Sci USA. 2014 Aug. 26; 111(34):12528-32. doi: 10.1073/pnas.1407362111”.
- Bioengineering in human B cells could also consist of using gene transfer to immortalize the antigen-responsive human B cells (for instance CD27+ germinal center B cells) with genes such as anti-apoptotic genes, or B cell oncogenes (such as Bcl6 or BclX), for the purpose of growing such cells responding to a pathogen and selecting their antibody sequences, as is described in “Kwakkenbos M J et al. Nat Med. 2010 January; 16(1):123-8. doi: 10.1038/nm.2071. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming”.
- Said lentiviral particles pseudotyped with an ERV syncytin such as an ERV syncytin as previously defined and more preferentially pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A, packaging a heterologous gene of interest, may be administered to a patient per se, for example by injection. In such a case, the transduction of immune cells will be made in vivo.
- a sample of immune cells, preferably B cells, or their precursors, of a patient is previously taken, then said lentiviral particles are injected into the immune cells or their precursors of the sample (i.e.
- the sample of immune cells or their precursors infected with said lentiviral particles, and thus comprising the heterologous gene of interest is the medicament.
- the invention also aims the use of a sample of immune cells or their precursors infected with said lentiviral particles in therapy, or for a diagnosis purpose (in case the heterologous gene of interest is a reporter gene).
- the invention also relates to the use of lentiviral particles pseudotyped with HERV-W or HERV-FRD including a heterologous gene of interest, for treating immune deficiencies, auto-immunities, infectious diseases or B cell-related cancers.
- immune deficiencies it is meant a condition leading to increased number or severity of microbial (bacterial, viral, parasitic) infections or reducing the anti-tumor surveillance and leading to increased frequency of cancers.
- the heterologous gene of interest may be a suicide gene, a “dominant-negative” gene, a gene coding for an antibody which would block target cell activation, a gene coding for a protein correcting the expression of an oncogene, or a gene coding for a protein reducing or altering the viral cycle of a transformant virus for B cells (such as EBV in case of Burkitt's syndrome).
- auto-immunities it is a meant autoimmune diseases. They correspond to conditions involving an abnormal immune response of the body against healthy cells of said body. Auto-immunities may be confined to an organ or a tissue. Autoimmune diseases, in particular autoimmune diseases susceptible to be treated by B cell-depleting strategies (i.e.
- rituximab and which could be treated by expressing a gene in the pathological B cells with the intention of killing them (such as caspase 9 or inducible caspase 9, thymidine kinase, or any other “suicide gene”), or with the intention of immunomodulating their function by expressing immunoregulatory genes such as IL-10, are for instance: rheumatoid arthritis, systemic lupus erythematosus, idiopathic thrombocytopenic purpura, anti-neutrophil cytoplasmic antibody associated vasculitis (ANCA vasculitis), Grave's disease, systemic sclerosis, autoimmune hemolytic anemia, pemphigus vulgaris, cold agglutinin disease, Sjogren's syndrome, thrombotic thrombocytopenic purpura, cryoglobulinemia, IgM mediated neuropathy, multiple sclerosis, neuromyelitis optica, idiopathic membranous nephropathy
- infectious diseases diseases which are caused by pathogenic microorganisms, such as bacteria, viruses, parasites or fungi; the diseases can be spread, directly or indirectly, from one person to another.
- Bacterial infections may be due to Streptococcus, Staphylococcus and E. coli.
- Viral infections may be due to Papillomaviridae, Polyomaviridae (BK virus, JC virus), Herpesviridae (Herpes simplex type 1 or 2, Varicella-zoster virus, Epstein-Barr virus, cytomegalovirus), Poxviridae (smallpox), Hepadnaviridae (hepatitis B), Parvoviridae (parvovirus B19), Caliciviridae (Norwalk virus), Picornaviridae (coxsakievirus, hepatitis A virus, poliovirus, rhinovirus), Coronoviridae (severe acute respiratory syndrome virus), Flaviviridae (hepatitis C virus, yellow fever virus, dengue virus, West Nile virus, TBE virus, Zika Virus), Retroviridae (HIV), Filoviridae (Ebola virus, Marburg virus), Orthomyxoviridae (Influenza virus), Paramyxoviridae (Mea
- Parasitic infections may be due to protozoan organisms (such as Plasmodium spp), helminths organisms or ectoparasites.
- Fungal infections may be due to Tinea versicolor, dermatophytes ( Microsporum, Trichophyton, Epidermophyton ) or Candida albicans.
- B cell-related cancer refers to the pathological condition in mammals that is typically characterized by unregulated cell growth of B cells.
- B cell malignancies may be acute lymphoid leukemia, chronic lymphocytic leukemia, multiple myeloma, Waldenström macroglobulinemia or any type of B cell lymphoma including opsoclonus myoclonus and any type of virus-induced B cell pathology such as those caused by Epstein-Barr-Virus, in which a therapeutic effect could be obtained by gene transfer of a cell cycle modulator or anti-oncogenic gene sequence (such as p53, antisense sequence to an oncogene, shRNA against an oncogene) or a suicide gene (such as icasp9, thymidine kinase) or anti-viral sequences, or any genetic sequence susceptible to arrest the growth, the spreading or the production of pathological molecules by the tumor cells, including sequences for gene editing when specific gene mutations are present, such as mutations in
- treating means reversing, alleviating or inhibiting the progress of the disorder or condition to which such term applies, or reversing, alleviating or inhibiting the progress of one or more symptoms of the disorder or condition to which such term applies.
- the present invention relates to an ex vivo process for obtaining immune cells modified to express a heterologous gene of interest, comprising a step of infecting immune cells with stable lentiviral particles pseudotyped with an ERV syncytin as previously described and notably pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A packaging a gene of interest, in the presence of a LAH4 peptide or a functional derivative thereof, preferably vectofusin-1.
- the immune cells are chosen from B cells, T cells, dendritic cells and macrophages.
- the immune cells are na ⁇ ve.
- the na ⁇ ve immune cells are not previously stimulated.
- the stimulation step is minimal and performed by incubating na ⁇ ve immune cells in a medium comprising IL-7 so as to preserve the survival of na ⁇ ve B cells.
- the ex vivo process for obtaining immune cells modified to express a heterologous gene of interest comprises a step of directly infecting na ⁇ ve immune cells, especially na ⁇ ve B cells, with stable lentiviral particles pseudotyped with an ERV syncytin as previously described and notably pseudotyped with HERV-W, HERV-FRD, or the murine syncytin-A packaging a heterologous gene of interest, in the presence of a LAH4 peptide or a functional derivative thereof.
- Said na ⁇ ve immune cells are not previously stimulated.
- the present invention also relates to the na ⁇ ve immune cells, preferably na ⁇ ve B cells, comprising the heterologous gene of interest obtainable by said ex vivo process.
- the ex vivo process for obtaining immune cells modified to express a heterologous gene of interest according to the invention may also comprise the following steps:
- na ⁇ ve immune cells optionally stimulating na ⁇ ve immune cells by incubating them in a medium comprising IL-7, and then
- the present invention also relates to the na ⁇ ve immune cells previously stimulated obtainable by said ex vivo process.
- the LAH4 peptide or functional derivative thereof, preferably vectofusin-1 is present notably at a concentration of 7 to 20 ⁇ g/ml, more preferably of 10 to 15 ⁇ g/ml.
- LAH4 peptide refers to the peptide with the amino acid sequence consisting of SEQ ID NO: 5.
- LAH4 functional derivative means any peptide whose sequence has been designed based on the primary structure of the LAH4 peptide and having the ability to improve the transduction efficiency of a virus or viral vector.
- a LAH4 functional derivative is a peptide having the ability to improve the transduction efficiency of a virus encapsidated with a an ERV syncytin as previously described and notably encapsidated with HERV-W, HERV-FRD or the murine syncytin-A envelope in eukaryotic cells, in particular human, mouse, rat, monkey, dog or hamster cells, in particular a human CD34+ cell.
- the LAH4 peptide or a functional derivative thereof may be selected among the sequences represented in SEQ ID NO: 5 to 31:
- LAH4 (SEQ ID NO: 5) KKALLALALHHLAHLALHLALALKKA LAH4-L1: (SEQ ID NO: 6) KKALLAHALHLLALLALHLAHALKKA LAH4-L1-dKC: (SEQ ID NO: 7) KKALLAHALHLLALLALHLAHALA LAH4-L1-R: (SEQ ID NO: 8) RRALLAHALHLLALLALHLAHALRRA LAH4-L0: (SEQ ID NO: 9) KKALLAHALAHLALLALHLALHLKKA LAH4-L2: (SEQ ID NO: 10) KKALLALALHHLALLALHLAHALKKA LAH4-L3: (SEQ ID NO: 11) KKALLALALHHLALLAHHLALALKKA LAH4-L4iso: (SEQ ID NO: 12) KKALLHLALLHAALLAHHLALALKKA LAH4-L5: (SEQ ID NO: 13) KKALLHLALLHAALLAHLAALHL
- LAH4-A4 which is also called vectofusin-1, and which has SEQ ID NO: 18.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising the stable pseudotyped lentiviral particles of the invention, or the immune cells transfected with said stable particles, in a pharmacologically acceptable medium.
- pharmacologically acceptable medium it is meant a vehicle compatible with an administration to the patient.
- the present invention also relates to the use of the stable lentiviral particles pseudotyped with an ERV syncytin as previously described and notably pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A including a heterologous gene of interest, preferably stable lentiviral particles pseudotyped with an ERV syncytin as previously described and notably pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A including a heterologous gene of interest, for generating animal models, particularly in mice (so as to obtain murine models). This may be useful for exploring disease mechanisms, particularly B cell diseases.
- FIG. 1 Transduction of BeWO Cells with Syncytin-Pseudotyped Vectors in the Presence of Various Transduction Additives
- BeWO cells were infected with GFP-encoding vectors, either with LV-VSVg (10 8 TU/mL) or with LV-Syn2 (10 5 TU/mL) in the absence or presence of additives protamine sulfate (PS), polybrene (PB) or Vectofusin-1 (VF1) and transgene expression was measured by FACS after 3 days. The percentages of live GFP+ cells in the gate are shown. Results from one experiment.
- PS protamine sulfate
- PB polybrene
- VF1 Vectofusin-1
- FIGS. 2 A-D Transduction of 293T Cells with Syncytin-Pseudotyped Vectors and Vectofusin-1 (VF-1)
- 293 T cells were cultured with GFP-encoding LV-Syn1 (A) or LV-Syn2 (B) using vector concentrations ranging from 10 4 to 10 5 TU/mL and in the absence or presence of VF1.
- GFP expression was measured by FACS after 3 days.
- C. The enhancing effect of VF1 is statistically-significant as shown in 5-6 experiments using a Mann-Whitney test.
- VCN vector copy number per cell
- FIG. 3 Transduction of Primary Blood Cell Subsets with Syncytin-Pseudotyped Vectors
- PBMC Human peripheral blood mononuclear cells
- GFP-encoding LV-Syn1 or LV-Syn2 vectors (10 5 TU/mL) in the absence or presence of VF1 and either immediately after isolation of the cells (no activation) or following an overnight culture of cells with IL-7 (10 ng/mL).
- IL-7 10 ng/mL
- GFP was measured by FACS in different subsets of live cells (CD3+ CD19 ⁇ CD11c ⁇ T cells; CD3 ⁇ CD19+ CD11c ⁇ B cells; CD3 ⁇ CD19 ⁇ CD11c+ myeloid dendritic cells) , naive (CD27 ⁇ ) or memory (CD27+) B cell subsets.
- FIG. 4 Dose-Dependent Effects of Syncytin-Pseudotyped Vectors on Blood Cell Subsets
- FIGS. 5 A-B Transduction of CD11c+ Blood Cells with Syncytin-Pseudotyped Vectors
- PBMC whole PBMC (2 donors tested in 2 separate experiments) or plastic-adherent PBMC (1 donor tested in another separate experiment) were transduced with GFP-encoding LV-Syn1 or LV-Syn2 (2 ⁇ 10 5 TU/mL) or LV-VSVg (10 8 TU/mL) vector in the absence of presence of VF1 (12 ⁇ g/mL).
- Cells were washed and further cultured in XVivo20+10% FCS+GM-CSF+IL-4 for 3 to 7 days.
- A Gating strategy for the analysis of CD11c+ HLD-DR+ myeloid cells.
- B Representative experiment out of 3 showing the transduction of CD11c+ HLD-DR+ cells obtained after 3 days in different conditions.
- FIGS. 6 A-C Expression of ASCT2 and MFSD2a Receptors on Blood Cells
- A Multicolor FACS analysis for ASCT2 and MFSD2a expression in CD19+ B cells, CD3+ T cells and CD11c+ myeloid dendritic cells in one representative experiment out of 3 (1 blood donor each).
- B Average and standard deviation of the percentage of cells expressing the indicated receptors in 5 experiments, after subtraction of the background obtained with the rabbit immunoglobulin control.
- C RT-PCR analysis of MFSD2a and ASCT2 mRNA on PBMC cell subsets averaging 2 experiments.
- FIGS. 7 A-B Phenotype of blood mononuclear cells of a SCIDX1 patient treated by gene therapy. Flow cytometry analysis was performed: (A) with a healthy donor PBMC and in comparison (B) after thawing the patient's peripheral blood mononuclear cells (PBMC) and in comparison.
- PBMC peripheral blood mononuclear cells
- FIGS. 8 A-C & 9 A-C Transduction of murine spleen cells ( FIG. 8 ) and of bone marrow cells ( FIG. 9 ) with LV-Syn A vectors.
- LV-SynA vector encoding dNGFR was added on red-blood cell-depleted spleen cells obtained from C57Bl/6 mice. After 3 days, the phenotype of cells and transgene expression were measured by flow cytometry.
- FIGS. 10 A-D In vivo delivery of the LucII transgene with LV-SynA.
- Bioluminescence detection of transgene expression was performed 16 days post IV injection of LVs. One of the anesthetized mice was opened to confirm bioluminescence of the spleen (D).
- Histograms represent the mean fluorescence intensity (MFI) of unstained negative control cells (293T: 5%; HCT116: 3%), cells stained with irrelevant IgG and the Alexa 647-conjugated secondary antibody (293T: and HCT116: 1%), cells stained with the anti-ASCT2 and secondary antibody (293T: 12%, HCT116: 4%) and cells stained with anti-MFSD2a and secondary antibody (293T: 99%, HCT116: 65%).
- MFI mean fluorescence intensity
- mice 7 week-old female NSG mice (Nod/Scid/gc ⁇ / ⁇ ) purchased from Charles River were injected in the retro-orbital sinus with 10 7 PBMC in 100 ⁇ L volume. After 24 hours, the mice were injected intravenously in the tail vein with 150 ⁇ L of undiluted LV-Syn1 vector. After 7 days, mice were sacrificed and spleens were collected, lysed with ACK and the red blood cell-depleted fraction was analyzed by FACS to measure GFP on the CD45+ human cell fraction. Results show the FACS plots of 2 mice in which human GFP+ cells were found.
- Spleen cells were obtained from 6 week-old female C57Bl/6 mice following red blood cell lysis with ACK.
- the cells were cultured in RPMI supplemented with 10% FCS and bet2 mercaptoethanol at the concentration of 10 6 cells/mL in 100 ⁇ L in the presence of LV-SYn1 or LV-Syn2 encoding ⁇ NGFR at 1 or 5 ⁇ 10 5 TU/mL and VF1 (12 ⁇ g/mL). After 3 days, expression of ⁇ NGFR was measured by FACS on live cells.
- A20 cells were transduced with different amounts of LV-SynA vector (0, 0.2, 0.6, 1.8, 3.2, 5.4 and 16.2 ⁇ L) with VF1 (red) and without VF1) To 12 ⁇ g/mL. The cells are cultured for 7 days in complete medium. Evaluation of the number of copies of syncytin A by qPCR.
- Human embryonic kidney 293T cells and human colorectal carcinoma HCT116 cells (CCL-247; ATCC, Manassas, Va.) were cultured at 37° C., 5% CO2 in Dulbecco's modified Eagle's medium (DMEM+glutamax) (Life Technologies, St-Aubin, France) supplemented with 10% of heat inactivated fetal calf serum (FCS) (Life Technologies).
- DMEM+glutamax Dulbecco's modified Eagle's medium
- FCS heat inactivated fetal calf serum
- Human choriocarcinoma BeWO cells (CCL-98; ATCC) were cultured in Ham's F12K medium (Life technologies) supplemented with 10% of FCS.
- Raji cells and Jurkat cells were infected in XVivo 20 medium.
- Plasmids pCDNA3-syncytin-1 and pCDNA3-syncytin-2 coding for human syncytin-1 (ERVW-1-001) or human syncytin-2 (ERVFRD-1) were constructed by cloning the respective synthesized DNA sequences (Gencust, Dudelange, Luxembourg) corresponding to Ensembl genome browser ENST00000493463 and ENSG00000244476 transcript sequences, into a pCDNA3 plasmid (Invitrogen, Carlsbad, Calif.) using NHeI et XhoI restriction enzymes. Plasmid sequences were verified by two strand sequencing.
- the syncytin-2 plasmid functionality was verified by immunoblotting protein extracts following transfection of 293T cells using the anti-HERV-FRD antibody (LS-BIO, Nanterre, France) detecting a 65-70 Kd protein expected to be syncytin-2. Plasmids were produced with endotoxin-free using DNA RNA purification Nucleobond kit (Macherey-Nagel, Duren, Germany) Lentiviral particles pseudotyped with either syncytin-1 or syncytin-2 were produced by transient transfection of 293T cells with 4 plasmids, using calcium phosphate.
- Each T175 cm 2 flask was transfected with 14.6 ⁇ g pKLgagpol expressing the HIV-1 gagpol gene, 5.6 ⁇ g pKRev expressing HIV-1 rev sequences, 22.5 ⁇ g of the gene transfer cassette (pCCL PGK GFP expressing enhanced green fluorescent protein (GFP) under control of the human phospho glycerate kinase (PGK) promoter (Charrier et al, 2011) or pCCL PGK delta-NGFR expressing a truncated form of the nerve growth factor receptor (NGFR) under control of the human PGK promoter) and 22 ⁇ g of either the pCDNA3-syncytin-1 or pCDNA3-syncytin-2 plasmid.
- PGK GFP enhanced green fluorescent protein
- PGK phospho glycerate kinase
- NGFR nerve growth factor receptor
- VF1 Vectofusin-1 peptides were synthetized by standard fluorenyl-methyloxy-carbonyl chloride solid-phase peptide synthesis, followed by HPLC and mass spectrometry purification (Gencust). Peptides were solubilized in H 2 O, aliquoted and stored at ⁇ 80° C. until used. When needed for transduction experiments, VF1 was thawed, resuspended in medium and added to vector and to cells at a final concentration of 12 ⁇ g/mL.
- Protamine sulfate (PS) (Sigma-Aldrich, St Louis, Mo.) and polybrene (PB) (Sigma-Aldrich) were also diluted extemporaneally with vector and cells and respectively used at final concentrations of 8 ⁇ g/mL and 6 ⁇ g/mL in the transduction culture.
- PS Protamine sulfate
- PB polybrene
- Peripheral blood collected with EDTA was purchased from the Etableau Francais du Sang (Evry, France).
- Peripheral blood mononuclear cells (PBMC) purified by Ficoll gradient centrifugation (Eurobio, les Ulis, France) were suspended in serum-free medium X-VIVO 20 (Lonza, Levallois-Perret, France) for transduction.
- cytokines IL-7 (10 ng/ ⁇ L) (Miltenyi Biotech, Bergisch Gladbach, Germany) was added to the medium overnight prior to transduction.
- LV-Syn1 or LV-Syn2 vectors (1.10 5 TU/mL), or LV-VSVg (1.10 8 TU/mL) were added to cells in the presence of VF1 (12 ⁇ g/mL). After 6 hours, medium was changed to XVivo20 supplemented with 10% FCS and IL-7 (10 ng/mL) and cells were cultured for up to 7 days.
- FCS 10% FCS
- IL-7 10 ng/mL
- CD40L (2 ⁇ g/mL) and IL-4 (20 ng/mL) was added to the medium and cells were cultured in these conditions for up to 2 weeks.
- hGM-CSF 50 ng/ml
- IL-4 (20 ng/ml) were added to medium.
- PBMC peripheral blood mononuclear cells
- PBMC of SCID-X1 patient treated by gene therapy were rapidly thawed at 37° C. and then washed twice with PBS. After trypan blue counting the cells are labeled with 2 ⁇ M CFSE (Molecular Probes, Cambridge, UK), transduced with Lv-Syn1 IL2rg vector and cultured (3.105/200 ⁇ L) in 96-well round bottomed plates in the absence or presence of CD40Ligand [2 ⁇ g/mL] (Miltenyi Biotec) and IL-21 [50 ng/mL] (Miltenyi Biotec).
- CD40Ligand [2 ⁇ g/mL]
- IL-21 50 ng/mL
- B cell transduction ie, NGFR or IL2Rg expression
- B cell proliferation ie, CFSE dilution
- the frequency of CD19+ CD27+ cells were determined by flow cytometry.
- Human IgG secretion in medium was determined by ELISA (Sigma-Aldrich, St Louis, Mo.).
- PBMCs were labeled with 2 ⁇ M CFSE (Molecular Probes, Cambridge, UK) and cultured (3.10 5 /200 ⁇ L) in 96-well round bottomed plates in the absence or presence of CD40Ligand [2 ⁇ g/mL] (Miltenyi Biotec) and IL-21 [50 ng/mL] (Miltenyi Biotec).
- B cell transduction ie, NGFR or IL2Rg expression
- B cell proliferation ie, CFSE dilution
- the frequency of CD19+ CD27++ plasmablasts were determined by flow cytometry.
- Human IgG secretion was determined by ELISA (Sigma-Aldrich, St Louis, Mo.).
- Antibodies used for flow cytometry were purchased from BD-Biosciences (Le Pont de Claix, France) and include PE conjugated anti-CD3 and anti-CD1a, Alexa-Fluor 700 conjugated anti-CD19, APC-H7 conjugated anti-CD45 and anti-IgD, CF594 conjugated anti-IgM, PeCy7 conjugated anti-CD27 and anti-HLA-DR, APC conjugated anti-CD14, V450 conjugated anti-CD11c. Prior to adding antibodies to cells, Fc receptors were blocked by incubating cells with gammaglobulin (1 mg/mL) (Sigma Aldrich) for 15 minutes, at 4° C. Saturating amounts of antibodies were then added for 30 minutes at 4° C.
- the detection of human IL2Rg was performed using PE conjugated anti-human CD132 antibody (BD bioscience).
- sequences of ASCT2 primers are (sense, 5′-GGCTTGGTAGTGTTTGCCAT-3′; antisense, 5′-GGGCAAAGAGTAAACCCACA-3′) and MFSD2A primers are (sense, 5′-CTCCTGGCCATCATGCTCTC-3′; antisense, 5′-GGCCACCAAGATGAGAAA-3′).
- TFIID Transcription Final II D
- mice 7 week-old female NSG mice (Nod/Scid/gc ⁇ / ⁇ ) purchased from Charles River were injected in the retro-orbital sinus with 10 7 PBMC in 100 ⁇ L volume. After 24 hours, the mice were injected intravenously in the tail vein with 150 ⁇ L of undiluted LV-Syn1 vector. After 7 days, mice were sacrificed and spleens were collected, lysed with ACK and the red blood cell-depleted fraction was analyzed by FACS
- Spleen cells were obtained from 6 week-old female C57Bl/6 mice following red blood cell lysis with ACK.
- the cells were cultured in RPMI supplemented with 10% FCS and bet2 mercaptoethanol at the concentration of 10 6 cells/mL in 100 ⁇ L in the presence of LV-SYn1 or LV-Syn2 encoding ⁇ NGFR at 1 or 5 ⁇ 10 5 TU/mL and VF1 (12 ⁇ g/mL). After 3 days, expression of ⁇ NGFR was measured by FACS on live cells.
- Syncytin-1 and Syncytin-2 Pseudotyped LVs can be Produced as Stable and Infectious Particles
- syncytin-1 and syncytin-2 Two human endogenous retroviral envelope glycoproteins, syncytin-1 and syncytin-2, were explored as possible new pseudotypes for recombinant HIV-1-derived LV.
- the full-length cDNAs of these glycoproteins were expressed in a transient LV production system in 293T cells.
- An optimization of the amount of syncytin-1 and syncytin-2 plasmids for the transfection step increased the production of LV particles based on p24 levels in medium (Supplementary Figure S1A). In the conditions defined (see Materials and Methods), it was possible to produce stable and infectious particles pseudotyped with either of these envelopes.
- Concentration was performed by ultracentrifugation (19500 rpm (50000 g) for 2 hours). Physical titers in p24 levels were measured by ELISA and infectious titers were measured as 293T cells transducing units (TU) in the presence of Vectofusin-1 using flow cytometry.
- the inventors first infected the human
- BeWo choriocarcinoma cell line known to express both the ASCT2 receptor for syncytin-1 and the more restricted MFSD2a receptor for syncytin-2 (Esnault et al, 2008). BeWo cells were not transduced effectively with LV-Syn1 or LV-Syn2 whereas they were well-transduced with VSVg-pseudotyped LV. However, adding cationic agents such as protamine sulfate (PS), polybrene (PB), or Vectofusin-1 (VF1) enhanced the transduction of BeWo cells as shown with LV-Syn2 ( FIG. 1 ). Of these agents, the greatest level of transduction enhancement was obtained with VF1.
- PS protamine sulfate
- PB polybrene
- VF1 Vectofusin-1
- Vectofusin-1 is a short histidine-rich amphipathic peptide which enhances the infectivity of lentiviral and y-retroviral vectors pseudotyped with various envelope glycoproteins including RD114-TR (Fenard et al, 2015 et Majdoul et al, 2015). The effects of Vectofusin-1 had not been tested before with syncytins, and this short peptide reveals the gene transfer potential of syncytin-pseudotyped LV particles.
- Syncytins are cellular proteins, which may be useful to derive immunologically-tolerated vectors for in vivo applications.
- PBMC peripheral blood mononuclear cell
- PBMCs peripheral blood mononuclear cell
- IL-7 naive lymphocytes
- the cells were preactivated with IL-7 or not as indicated, and were transduced with indicated LV in the presence or absence of Vectofusin-1 (VF1) additive.
- PBMC were obtained from different donors and the number of donors (n) tested is indicated. & p ⁇ 0.05 compared to “no vector” in a paired Student's t test
- PBMC contain multiple subsets of cells in different proportion. As shown in FIG. 3 and Table 2, transgene expression was found in a large proportion of CD19+ B lymphocytes and CD11c+ myeloid/dendritic cells (which are a minority in PBMC) whereas only a fraction of CD3+ T cells (which are more abundant in PBMC) were marked in agreement with the overall low results of transduction obtained in CD45+ cells. An average of 59% each of CD19+ cells or of CD11c+ cells were transduced by LV-Syn1 following a pre-activation with IL-7 (Table 2). As observed with 293T and BeWo cells, adding VF1 was necessary to achieve PBMC transduction as few cells were transduced in the absence of this additive. The VF1 peptide also enhanced the transduction of PBMC by LV-VSVg.
- Transduction results are expressed as the average percentage ⁇ SD of cells positive for GFP in CD3+ (T cells), CD19+ (B cells) or CD11c+ (dendritic myeloid cells) cells in culture, 3 days after infection. Data represent 3 separate experiments without VF1 and 8 to 9 separate experiments in the presence of VF1.
- CD19+ B cells have been characterized (Kaminski et al, 2012) including na ⁇ ve CD19+ CD27 ⁇ IgD+ cells (50-70% of the population); memory non-switched CD19+ CD27+ IgD+ cells (15-20% of the population); memory switched CD19+ CD27+ IgD ⁇ IgM ⁇ cells (2-5% of the population); memory switched IgM only CD19+ CD27+ IgD ⁇ IgM+ cells (2-5% of the population) and plasmablasts CD19+ CD27hi (1-2% of the population).
- the B cell transducing effects of LV-Syn1 and LV-Syn2 were found to be vector concentration dependent ( FIG. 4 ) and transgene independent. Almost all peripheral blood CD19+ cells could be transduced using 10 6 TU/mL of LV-Syn1 or LV-Syn2 vectors encoding either GFP or ⁇ NGFR thereby providing a very effective system to express various types of heterologous proteins in these cells.
- the inventor verified proviral integration in cells treated with the vector and cultured over time. Following addition of the vector to the cells, the inventors added CD40L and IL-4 to activate and expand the culture for 8-14 days. In such cultures, the inventors detected vector copies specifically when vectors were added together with Vectofusin-1 (Table 4) even though conditions were not optimal to ensure the survival of all cells.
- B cell-activation signals such as CD40 ligand (CD40L) and IL-21 previously reported to be essential for the development of memory B cells (Recher et al 2011)
- the inventors confirmed that transduced B cells could be activated efficiently (Table 5).
- the inventors confirmed the marking of cells capable of responding to CD40L and IL-21 and with activated B cell, including plasmablast, phenotype (Table 5).
- the inventors used EBV to transform PBMC immediately after they had been infected with the LV-Syn1 vector and obtained lymphoblastic cells containing stably integrated vector sequences (Table 4). These results confirm that the syncytin vectors can stably transduce primary B cells that retain functional ability to proliferate and be expanded.
- PBMCs were labeled with 2 ⁇ M CFSE, transduced with Lv-Syn1-2 NGFR, and cultured in the absence or presence of CD40Ligand [2 ⁇ g/mL] and IL-21 [50 ng/mL]. After 3 and 6 days culture, B cell transduction (ie, NGFR expression), B cell proliferation (ie, CFSE dilution) and the frequency of CD19+ CD27++ plasmablasts were determined by flow cytometry.
- B cell transduction ie, NGFR expression
- B cell proliferation ie, CFSE dilution
- CD19+ CD27++ plasmablasts were determined by flow cytometry.
- Freshly-isolated murine spleen cells were cultured with LV-Syn1 or LV-SYn2 vectors encoding ⁇ NGFR for 3 days. As shown in Supplementary Figure S7 this resulted in a very efficient transduction of CD19+ B cells. In these cultures, much fewer CD19 ⁇ cells were transduced in proportion, thus confirming the particular tropism of the syncytin-pseudotyped vectors for B cells in mice as in humans. The data also show that the syncytin-1 and syncytin-2 glycoproteins recognize murine counterparts and these findings will facilitate future preclinical studies with these vectors.
- CD19 ⁇ CD3 ⁇ CD11c+ cells was transduced with LV-Syn1 and LV-Syn2 from PBMC without prior activation and in the presence of Vectofusin-1. Further phenotyping showed that such CD11c cells also expressed high levels of HLA-DR and were transduced effectively with the syncytin-pseudotyped vectors ( FIG. 5 ). The cells were grown in GM-CSF+IL-4, expressed CD1a, CD80, CD86 and lacked CD14, suggesting that they were immature dendritic cells (Supplementary Figure S3A).
- CD14+ HLA-DR+ cells which have the phenotype of monocytic cells are also transduced (Supplementary Figure S3B).
- both LV-Syn1 and LV-Syn2 can be used effectively to express a transgene in antigen presenting cells.
- LV-Syn1 and LV-Syn2 Vectors do not Efficiently Transduce Primary Human T Cells
- Peripheral blood T cells were not efficiently transduced by the syncytin-pseudotyped LV, although some cells could be transduced upon activation. Following prior activation with IL-7, a small proportion of peripheral blood T cells was transduced with LV-Syn1 or LV-Syn2 vectors but these effects were not consistent from experiment to experiment ( FIG. 3 and Table 2). Without prior activation, transduction levels were always low.
- ASCT2 and MFSD2a which are respectively the entry receptors for syncytin-1 and syncytin-2 were detected on the cell surface of blood cell subsets using and indirect immunofluorescence detection ( FIG. 6 A ).
- the highest percentage of cells expressing these markers were CD19+ and CD11c+ cells, whereas T cells expressed lower levels of these receptors ( FIG. 6 B ).
- FIG. 6 B T cells expressed lower levels of these receptors
- qRT-PCR which show for the first time that human B cells express MFSD2a and ASCT2 ( FIG. 6 -C).
- Expression of ASCT2 and MFSD2a was also found on 293T cells whereas it was at a much lower level of HCT116 cells which are not transduced with the vectors (Supplementary Figure S4).
- the expression of the receptors correlated well with the transduction levels that were achieved.
- the inventors attempted to transduce a panel of human cell lines.
- the Burkitt's lymphoma Raji B cells and Jurkat T cells were tested.
- Raji B cells could be transduced with the Syncytin-pseudotyped vectors (Supplementary Figure S5).
- the highest levels obtained in Raji cells using 2 ⁇ 10 6 TU/mL of LV-Syn2 vector reached 16% (as opposed to >90% reached with 10 6 TU/mL in primary B cells as seen in FIG. 4 ).
- the inventors verified that Raji cells were permissive for transduction with LV because 88% transduction of Raji cells were transduced with 10 8 TU/mL LV-VSVg (control of Supplementary Figure S5, not shown).
- transduced Raji cells were sorted by flow cytometry and cultured for 49 days, demonstrating the stable integration of the transgene for prolonged periods of time (Supplementary Table S2).
- Jurkat T cells were partially transduced with syncytin-pseudotyped vectors (Supplementary Figure S5).
- syncytin-pseudotyped LV can be used as gene transfer tools for some cell lines.
- B cells transduction appears to be more effective in primary cells than with established B cell lines.
- GFP GFP-specific protein kinase
- LV-Syn1 5% with LV-Syn2, and 100% withLV-VSVg vector.
- cells expressing GFP GFP (GFP+) or not (GFP ⁇ ) were sorted by flow cytometry and these sorted cells were cultured until day 49 to measure GFP expression by FACS and the average vector copy number per cell (VCN) by qPCR.
- Severe combined immunodeficiency type-1 is an X-linked primary immunodeficiency which is caused by mutations in the interleukin 2-receptor gamma chain (IL2Rg) gene. Allogeneic bone marrow transplantation can cure the disease but some patients remain incompletely corrected with only partial chimerism in B cells (Recher et al 2011). Patients with less than 5% B cell chimerism remain incapable of maturing and producing immunoglobulins. Their B cells remain incapable of becoming mature memory IgG secreting B cells. Indeed, it was found recently that IL2Rg is also the receptor for IL-21 providing essential signals for the maturation of B cells (Recher et al 2011).
- IL2Rg is also the receptor for IL-21 providing essential signals for the maturation of B cells (Recher et al 2011).
- the patient blood mononuclear cells were found to contain CD3+ IL2Rg+ T cells but contrary to healthy individuals, the patient blood CD19+ B cells did not express the maturation marker CD27, did not express IL2Rg ( FIG. 7 A and B) and did not produce IgG (Table 6).
- LV-syncytin1 vectors encoding the IL2Rg
- patients cells were able to respond to CD40L+IL-21 by producing IgG in medium, even though activation markers were not detected on the cells, probably due to the high level of mortality of these fragile cells in culture.
- mice were first engrafted with 10 7 PBMC per mouse and the next day received a single bolus of LV-Syn1 intravenously. After 7 days, mice were sacrificed and different tissues were examined In 2 mice out of 3, the inventors found the presence of CD45+ CD19+ human B cells in the spleen in which a small proportion (3-15%) expressed GFP suggesting that they had been transduced in vivo (Supplementary Figure S6). These preliminary results suggest the possibility of using syncytin-pseudotyped vectors to target human B cells in vivo.
- the plasmid was verified by sequencing (Beckman Coulter Genomics, Takeley, UK).
- HEK293T cells plated in T175 cm2 flasks in DMEM+10% fetal calf serum (FCS) were co-transfected with the following 4 plasmids (quantities per flask): pKLgagpol (14.6 ⁇ g), pKRev (5.6 ⁇ g), pcDNA3.1-SynA (20 ⁇ g), and transfer plasmid either PRRL-SFFV LucII or pRRL-SFFV-LucII-2A- ⁇ NGFR-WPRE (22.5 ⁇ g). After 24 hours, the cells are washed and fresh fmedium is added.
- FCS fetal calf serum
- medium is harvested, clarified by centrifugation 1500 rpm for 5 min and filtered 0.45 ⁇ m, then concentrated by ultracentrifugation 50000 g for 2 h at 12° C. and stored at ⁇ 80° C. until used.
- Infectious titer was determined as infectious genome titer (IG/mL) using the murine lymphoma cell line A20. Serial dilutions of vector are added to A20 cells in the presence of Vectofusin-1® (12 ⁇ g/uL) for 6 hours.
- LV-SynA encoding LucII vector was produced and 5 ⁇ 10 5 TU of vector were injected intravenously into albinos C57Bl/6 mice. Controls included LV-VSVg encoding LucII and PBS.
- mice were anesthetized with ketamine (100 mg/kg)/xylasine (10 mg/kg), and 100 ⁇ L of 150 ⁇ g/mL D-luciferin was administered intra-peritoneally and imaged 10 min later with a CCD camera ISO14N4191 (IVIS Lumina, Xenogen, MA, USA).
- a 3 min bioluminescent image was obtained using 15 cm filed-of-view, binning (resolution) factor 4, 1/f stop and open filter.
- Region of interest (ROIs) were defined manually (using a standard area in each case), signal intensities were calculated using the living image 3.0 software (Xenogen) and expressed as photons per second. Background photon flux was defined from an ROI drawn over the control mice or control muscle where no vector had been administered.
- Syncytin A is non-orthologue but functionally similar murine counterpart to human Syncytins-1 and -2 (Dupressoir et al 2005).
- SyncytinA can successfully pseudotype rHIV-derived LV.
- LV-Syn A were very efficient at transducing the murine A20 B lymphoma cell line in the presence of VF1 ( Figure S8) (Supplementary table S4).
- SynA was as efficient as its human counterparts to transduce primary non-activated murine B cells in vitro.
- LV-SynA were capable of transducing without pre-treatment murine B cells from spleen ( FIG. 8 ) and from bone marrow ( FIG. 9 ).
- These experiments also show that murine T cells can be transduced as well. The transduction of B220 low cells suggests that immature B cells were transduced and can be targeted for biological applications.
- FIG. 10 shows the bioluminescent detection of the transgene 16 days after injection of a LV-SynA vector encoding LucII.
- the vector was injected through the mice tail vein and the inventors did not use vectofusin for this.
- the presence of vector in the spleen CD45+ CD19+ cells was confirmed by purifying spleen cells by flow cytometry cell sorting and measuring the levels of transduction by q-PCR (supplementary table S3).
- Syncytins are unique tools to mediate entry into human and murine B cells in vitro and in vivo.
- CD19+ cells were incubated in the indicated conditions, using various preparations of LV pseudotyped with syncytin A, or syncytin 1 and expressing different transgenes.
- LV HIV-1-derived lentiviral vectors
- S1 syncytin-1
- S2 syncytin-2
- SA syncytin A
- VSVg VSVg
- ⁇ NGFR nerve growth factor receptor
- GFP green fluorescent protein
- the methods consisted either of (a) an ELISA measuring the p24 concentration in the sample followed by a calculation of the titer as physical particles (pp) assuming that 1 fg of p24 corresponds to 12 pp of LV (Farson et al, 2001) or (b) using the NS300 Nanosight particle counter from Malvern Instruments (UK) which directly measures the particle concentration in the sample using automated microscopy.
- Retrovirology 2 19.
- Vectofusin-1 a new viral entry enhancer, strongly promotes lentiviral transduction of human hematopoietic stem cells.
- the envelope glycoprotein of human endogenous retrovirus type W uses a divergent family of amino acid transporters/cell surface receptors. Journal of virology 76: 6442-6452.
- Placental syncytins Genetic disjunction between the fusogenic and immunosuppressive activity of retroviral envelope proteins. Proceedings of the National Academy of Sciences of the United States of America 104: 20534-20539.
- Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature 509: 503-506.
- IL-21 is the primary common gamma chain-binding cytokine required for human B-cell differentiation in vivo. Blood 118: 6824-6835.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a method for obtaining stable pseudotyped lentiviral particles including a heterologous gene of interest, comprising the following steps:
-
- a) transfecting at least one plasmid in appropriate cell lines, wherein said at least one plasmid comprises the gene of interest, the rev, gag and pol genes, and a sequence coding for an ERV syncytin, wherein the rev, gag and pol genes are retroviral genes;
- b) incubating the transfected cells obtained in a), so that they produce the stable pseudotyped lentiviral particles in the supernatant; and
- c) harvesting and concentrating the stable lentiviral particles obtained in b).
The present invention also relates to a method to transduce immune cells using lentiviral vectors pseudotyped with an ERV syncytin glycoprotein. The method can be performed on non-stimulated blood cells or on cells stimulated briefly with IL7, and the cells can be expanded.
The stable pseudotyped lentiviral particles obtained are particularly useful in gene therapy.
Description
- The present invention relates to stable pseudotyped lentiviral particles and uses thereof, particularly in therapy. The invention also refers to a method for preparing such stable pseudotyped lentiviral particles. The invention also relates to an in vitro method to transduce human peripheral blood naive B cells and monocytic cells, preferably with minimal or no pre-activation, using such pseudotyped lentiviral particles, in the presence of vectofusin.
- Gene therapy approaches are often hampered by low transduction efficiencies of target cells by recombinant viral vectors. Retroviral vectors, and in particular human immunodeficiency virus 1 (HIV-1)-based lentiviral vectors (LVs) are promising vehicles for gene therapy. These vectors are used currently in clinical applications to treat various diseases such as immune deficiencies, neurodegenerative or neurological diseases, anemias or HIV infection.
- Some of the applications of retroviral vectors rely on the transduction of specific target cells ex vivo such as lymphocytes or hematopoietic stem/progenitor cells expressing the CD34 marker. LVs are used to transduce T lymphocytes to generate long-lived CAR-T cells for the treatment of cancers such as refractory chronic lymphocytic leukemia (CLL) (Porter et al, Science Transl. Med. 7: 303ra139 2015). LV are used to transduce CD34+ cells for autologous gene therapy of a variety of immune, blood, metabolic or neurodegenerative disorders of genetic origin (Wagemaker G. Hum Gene Ther. 2014 October; 25(10):862-5. doi: 10.1089/hum.2014). Lentiviral vectors are versatile tools that can be pseudotyped with various viral envelope glycoproteins, thereby conferring specific cellular tropism characteristics to the particles (Buchholz et al. Trends Biotechnol. 2015 December; 33(12):777-90. doi: 10.1016/j.tibtech.2015.09.008.).
- A limiting factor with the use of recombinant lentiviral particles is the capacity to obtain highly infectious titers during production of recombinant lentiviral particles. One way to circumvent this limitation is to concentrate the viral supernatant during the purification steps. However, purification protocols are difficult to establish for some LVs, depending on the envelope glycoproteins used to pseudotype viral particles. Therefore, many lentiviral vector preparations have low titer and transduction efficacy is limited.
- Another limiting factor is that it is difficult to transduce primary cells, thus they must often be activated to be transduced, thereby losing their naive status.
- Finally, another limiting factor is the ability of the lentiviral vector itself to infect target cells. Several envelope glycoproteins such as VSV-G or RD114TR can be used to pseudotype lentiviral vectors and have variable infectivity on target cells such as CD34+ cells and primary blood cells.
- Syncytins are endogenous retroviral virus (ERV syncytins) envelope glycoproteins which have fusogenic properties (Dupressoir et al., 2005; Lavialle et al., 2013).
- Human endogenous retroviral envelope glycoprotein encoded by the ERVW-1 gene (ENSG00000242950; also known as syncytin-1 or HERV-W) has been described for its fusogenic properties in patent application EP2385058. Said application describes its use in cancer treatment, by the formation of syncytia.
- Some studies have shown the possibility of pseudotyping HIV-1 virions, but not MLV-particles, with the HERV-W envelope to obtain an infectious virus capable of transducing 293T cells. However, such HERV-W particles were not stable as concentration, freezing and thawing considerably reduced titers (An et al, Journal of Virology, April 2001, p. 3488-3489). A deletion of the R intracytoplasmic region was used to increase the fusion and the pseudotype titer of HIV-1-derived gene transfer vectors (Lavillette et al 2002). The glycoprotein encoded by the ERVFRD-1 gene (ENSG00000244476; also known as syncytin-2, or HERV-FRD) was used to pseudotype SIV vectors and reportedly works as HIV or MLV pseudotype but at very low titers precluding functional studies and little information is available on the HERV-FRD HIV pseudotype (Blaise et al, Journal of Virology, January 2004, p. 1050-1054).
- There is thus a need for means for improving the transduction efficiency of a virus or viral vector, particularly a stable virus or viral vector, for example for improving delivery of a gene into specific target cells. Specifically, there is a need for a virus or viral vector, which would be stable, and could thus be obtained at an industrial scale. There is also a need for a stable vector which could be used in vitro, or in vivo, as a tool presenting new biological properties.
- There is also a need for a process for selectively transducing cells with a virus or viral vector, so as to target in vitro, or in vivo, specific cells only. Such a virus or viral vector would have to be fully-tolerized, specific for targeted cells, and adequate for multiple administrations.
- Surprisingly, the inventors have elaborated a process for obtaining lentiviral particles pseudotyped with a specific envelope glycoprotein, which are stable and which may be frozen. Said lentiviral pseudotyped particles also improve the transduction of selected target cells, in particular immune cells; this broadens the therapeutic scope of said particles. Said pseudotyped lentiviral particles are indeed efficient for transducing immune cells, and particularly B cells, T cells and dendritic cells and allow functional correction of cell deficiency. Moreover, these lentiviral pseudotyped vectors can be administered in vivo where they lead to detectable, stable and well-tolerated gene transfer in spleen and bone marrow with evidence of CD19+ spleen B cell transduction.
- Thus, the use of said pseudotyped lentiviral particles is a promising strategy for patients suffering from placental dysfunction, cancers, infectious diseases, immune deficiencies, auto-immunity or for gene therapy or as vaccines or as biotechnology engineering tool.
- The invention relates to a method for obtaining stable pseudotyped lentiviral particles including a heterologous gene of interest, comprising the following steps:
-
- a) transfecting at least one plasmid in appropriate cell lines, wherein said at least one plasmid comprises the heterologous gene of interest, the retroviral rev, gag and pol genes, and a nucleic acid coding for an ERV syncytin;
- b) incubating the transfected cells obtained in a), so that they produce the stable lentiviral particles pseudotyped with an ERV syncytin, respectively, and packaging the heterologous gene of interest; and
- c) harvesting and concentrating the stable lentiviral particles obtained in b).
- The method according to the invention allows obtaining high physical titers, as well as high infectious titers, of stable pseudotyped lentiviral particles including a heterologous gene of interest.
- Also provided are stable lentiviral particles pseudotyped with an ERV syncytin and packaging a heterologous gene of interest. They may be obtainable or obtained by the method described in the above paragraph. Said stable pseudotyped lentiviral particles may be useful as a medicament. Particularly, said stable pseudotyped lentiviral particles may be useful in gene therapy or in immunotherapy, particularly as a vaccine or in immunoprophylaxis.
- The present invention also relates to lentiviral particles pseudotyped with an ERV syncytin including a heterologous gene of interest, preferably stable lentiviral particles pseudotyped with an ERV syncytin including a heterologous gene of interest, for use for therapy by transducing cells which express the cognate receptors such as for example ASCT2, ASCT1 or MFSD2a respectively for syncytin-1 (HERV-W) and syncytin-2 (HERV-1-RD), such as human choriocarcinoma cells, human epithelial cells, or human immune cells such as B cells, T cells, or CD11c+ cells such as myeloid cells (e.g.: granulocytes, monocytes and their progenitor cells). The invention also relates to the ability to use the lentiviral particles pseudotyped with an ERV syncytin to efficiently transduce murine B cells and T cells.
- The present invention also relates to lentiviral particles pseudotyped with an ERV syncytin including a gene of interest, preferably stable lentiviral particles pseudotyped with an ERV syncytin including a heterologous gene of interest, for use for treating immune deficiencies, auto-immunities, infectious diseases, placental dysfunction (such as pre-eclampsia), diseases involving the blood-brain barrier, or cancers including B cell-related cancers, or to make models of these diseases in mice.
- The stable lentiviral particles pseudotyped with an ERV syncytin including a heterologous gene of interest may also be useful for the in vitro transduction of immune cells, preferably B cells or CD11c+ cells such as myeloid cells (e.g.: granulocytes, monocytes and their progenitor cells).
- The transduction of immune cells, preferably B cells, may find applications in biotechnology engineering, for example in the production of immunoglobulins, or in immune cell, preferably B cell engineering.
- The present invention also relates to an ex vivo process for obtaining immune cells modified to express a heterologous gene of interest, comprising a step of infecting immune cells with lentiviral particles pseudotyped with an ERV syncytin including a heterologous gene of interest, preferably stable lentiviral particles pseudotyped with an ERV syncytin including a heterologous gene of interest, preferably in the presence of a LAH4 peptide or a functional derivative thereof.
- The present invention also relates to the use of the stable lentiviral particles pseudotyped with an ERV syncytin including a heterologous gene of interest, preferably stable lentiviral particles pseudotyped with an ERV syncytin including a heterologous gene of interest, for biotechnology engineering. Particularly, they may be used for generating cell lines, preferably B cell lines, in order to produce a specific product, such as immunoglobulins. The stable particles of the present invention may also be used to generate models of study, particularly in mice (so as to obtain murine models). This may be useful for exploring disease mechanisms, particularly B cell diseases or B cell-mediated diseases, generating dendritic cells and/or myeloid cells expressing a product for the purpose of vaccination, or producing products with specific therapeutic effects.
- According to the invention, the ERV syncytin is selected from the group consisting of HERV-W, HERV-FRD, murine syncytin-A, murine syncytin-B, syncytin-Ory1, syncytin-Car1 and syncytin-Rum1 and their functional orthologs, preferably the ERV syncytin is selected from the group consisting of HERV-W, HERV-FRD and murine syncytin-A and even more preferably the ERV syncytin is HERV-W or HERV-FRD.
- The inventors have surprisingly discovered that ERV syncytins which have high fusogenic properties, such as the human syncytin-1 (HERV-W), the human syncytin-2 (HERV-FRD) and the murine syncytin A, may be used for obtaining pseudotypes for recombinant HIV-1 derived lentivirus. As clearly demonstrated in the examples, the results show that it is possible to produce stable and infectious lentiviral particles comprising a gene of interest, which have selective tropism on cell lines. Surprisingly syncytin-pseudotyped lentiviral particles are able to efficiently transduce human primary B lymphocytes and CD11c+ myeloid and/or dendritic cells notably in the presence of Vectofusin-1, a cationic transduction additive.
- Thus, the inventors have elaborated a method for obtaining lentiviral particles pseudotyped with an ERV syncytin, which are stable, infectious and which may be frozen. The lentiviral pseudotyped particles improve the transduction of selected target cells, in particular immune cells, and particularly B cells, T cells and dendritic cells.
- The detailed embodiments of the invention are described below.
- The present invention relates to a method for obtaining stable pseudotyped lentiviral particles including a heterologous gene of interest, comprising the following steps:
-
- a) transfecting at least one plasmid in appropriate cell lines, wherein said at least one plasmid comprises the heterologous gene of interest, the retroviral rev, gag and pol genes, and a nucleic acid coding for an ERV syncytin;
- b) incubating the transfected cells obtained in a), so that they produce the lentiviral particles pseudotyped with an ERV syncytin, respectively, and packaging the heterologous gene of interest; and
- c) harvesting and concentrating the stable lentiviral particles obtained in b).
- Preferably, step c) of the method according to the invention comprises harvesting, concentrating and/or purifying the stable lentiviral particles produced in step b), from the supernatant. Thus, preferably, the concentration of step c) comprises centrifugating and/or purifying the harvested stable lentiviral particles obtained in b). Said harvest may be performed according to well-known methods in the art. Preferably, the lentiviral vectors are harvested before fusion of the transfected cells, more preferably between 20 hours and 72 hours post-transfection, preferably after 24 hours. Preferably, the harvesting step consists of a single lentivirus harvest, preferably implemented between 20 and 72 hours post-transfection, preferably between 20 and 30 hours post-transfection, more preferably after 24 hours.
- ERV syncytins according to the invention refer to highly fusogenic envelope glycoproteins from eutherian mammals, which belong to the family of Endogenous Retroviruses (ERVs). These proteins are encoded by genes, which display a preferential expression in placenta and induce syncytium formation when introduced into cultured cells (Lavialle et al., 2013).
- ERVs syncytins according to the invention can be selected from human syncytins (e.g.: HERV-W and HERV-FRD), murine syncytins (e.g.: syncytin-A and syncytin-B), syncytin-Ory1, syncytin-Car1, syncytin-Rum1 or their functional orthologs (Dupressoir et al., 2005; Lavialle et al., 2013).
- By functional orthologs it is intended orthologs proteins encoded by orthologs genes and that exhibit fusogenic properties. Fusogenic properties may be assessed in fusion assays as described in Dupressoir et al. (PNAS 2005). Briefly, cells are transfected for example by using Lipofectamine (Invitrogen) and about 1-2 μg of DNA for 5×105 cells or calcium phosphate precipitation (Invitrogen, 5-20 μg of DNA for 5×105 cells). Plates are generally inspected for cell fusion 24-48 h after transfection. Syncytia can be visualized by using May-Grünwald and Giemsa staining (Sigma) and the fusion index calculated as [(N−S)/T]×100, where N is the number of nuclei in the syncytia, S is the number of syncytia, and T is the total number of nuclei counted.
- Human syncytins encompasses HERV-W and HERV-FRD. Functional orthologs of these proteins can be found in Hominidae. HERV-W refers to a highly fusogenic membrane glycoprotein belonging to the family of Human Endogenous Retroviruses (HERVs). HERV-W is an envelope glycoprotein; it is also called Syncytin-1. It has the sequence indicated in Ensembl database, corresponding to Transcript ERVW-1-001, ENST00000493463. The corresponding cDNA has the sequence listed in SEQ ID NO: 1. HERV-FRD also refers to a highly fusogenic membrane glycoprotein belonging to the family of Human Endogenous Retroviruses (HERVs). HERV-FRD is an envelope glycoprotein, also called Syncytin-2. It has the sequence indicated in Ensembl database, corresponding to Transcript ERVFRD-1, ENSG00000244476. The corresponding cDNA has the sequence listed in SEQ ID NO:2.
- Murine syncytins encompasses murine syncytin-A (i.e.: mus musculus syncytin-A, synA) and murine syncytin-B (i.e.: mus musculus syncytin-B, synB). Functional orthologs of these proteins can be found in the Muridae family. Murine syncytin-A is encoded by the syncytin-A gene. Syncytin-A has the sequence indicated in Ensembl database Syna ENSMUSG00000085957. The corresponding cDNA has the sequence listed in SEQ ID NO:40. Murine syncytin-B is encoded by the syncytin-B gene. Syncytin-B has the sequence indicated in Ensembl databaseSynb ENSMUSG00000047977. The corresponding cDNA has the sequence listed in SEQ ID NO:41.
- The syncytin-Ory1 is encoded by the syncytin-Ory1 gene. Functional orthologs of syncytin-Ory1 can be found in the Leporidae family (typically rabbit and hare).
- The syncytin-Car1 is encoded by the syncytin-Car1 gene. Functional orthologs of syncytin-Car1 can be found in carnivores mammals from the Laurasiatheria superorder (Cornelis et al., 2012; Lavialle et al., 2013).
- The syncytin-Rum1 is encoded by the syncytin-Rum1 gene. Functional orthologs of syncytin Rum-1 can be found in ruminant mammals.
- In the various embodiments of the present invention, the ERV syncytin according to the invention can be typically selected from the group consisting of HERV-W, HERV-FRD, syncytin-A, syncytin-B, syncytin-Ory1, syncytin-Car1 and syncytin-Rum1 and their functional orthologs; preferably the ERV syncytin is selected from the group consisting of HERV-W, HERV-FRD, murine syncytin-A and their functional orthologs, more preferably the ERV syncytin is selected from the group consisting of HERV-W, HERV-FRD and murine syncytin-A and even more preferably the ERV syncytin is HERV-W or HERV-FRD.
- The method according to the invention allows obtaining high physical titers, as well as high infectious titers, of stable pseudotyped lentiviral particles including a heterologous gene of interest. Indeed, the stable pseudotyped lentiviral particles including a heterologous gene of interest are obtained at a high physical titer thanks to the method of the invention, and are infectious, thus efficient, particularly for transducing B cells, or myeloid cells.
- By “physical titer”, it is meant the number of lentiviral particles which are produced. The physical titer may be measured according to classical methods known in the art, and which are commonly used to quantify lentiviral particles, for example by p24 ELISA, which is illustrated in the examples, by direct particle counting with an automated counter such as the Nanosight NS300 instrument from Malvern using the manufacturer's instructions, by RT (reverse transcriptase) ELISA (as described in Ciré et al, Plosone, July 2014, Vol. 9,
Issue 7, Immunization of mice with lentiviral vectors targeted to MHC class II+ cells is due to preferential transduction of dendritic cells in vivo) or by viral RNA RT-qPCR. - By “high physical titer”, it is meant a titer of particles produced at the end of step b) higher than 200 ng p24/mL, preferably higher than 210 ng p24/mL, even more preferably higher than 300 ng p24/mL. More preferably, the physical titer of particles pseudotyped with an ERV syncytin such as HERV-W, produced at the end of step b) is higher than 300 ng p24/mL, preferably higher than 400 ng p24/mL. More preferably, the physical titer of particles pseudotyped with an ERV syncytin such as HERV-FRD, produced at the end of step b) is higher than 210 ng p24/mL, preferably higher than 300 ng p24/mL.
- By “high physical titer”, it is also meant a titer of particles produced at the end of step c) (i.e. concentrated) higher than 1×105 ng p24/mL, preferably higher than 1.1×105 ng p24/mL, more preferably higher than 1.5×105 ng p24/mL More preferably, the physical titer of particles pseudotyped with an ERV syncytin such as HERV-W produced at the end of step c) is higher than 2.2×105 ng p24/mL, preferably higher than 3.0×105 ng p24/mL, even preferably higher than 4.0×105 ng p24/mL. More preferably, the physical titer of particles pseudotyped with an ERV syncytin such as HERV-FRD produced at the end of step c) is higher than 1.1×105 ng p24/mL, preferably higher than 1.5×105 ng p24/mL.
- According to Farson et al., (Hum. Gene Ther. 2001) one can assume that 1 femtogram (fg) of p24 corresponds to 12 physical particles (pp) of lentivirus. Without wishing to be bound by theory, the inventors believe that this calculated number of physical particles obtained based on p24 is slightly overestimated as compared to a value obtained by direct particle counting with an automated counter (such as the Nanosight NS300 instrument), because p24 alone is also taken into account. Generally it can be estimated that there is on average about 4 times more particles calculated with p24 ELISA than particles measured with the automated counter (see Supplementary Table S6 in Example 3 below). Thus a physical titer higher than 1×105 ng p24/mL corresponds to a physical titer higher than 1.2×1012 calculated physical particles (pp)/mL or higher than about 3×1011 pp/mL, as measured by Nanosight counting.
- By “infectious titer”, it is meant the number of functional lentiviral particles. The infectious titer may be measured according to classical methods known in the art, for example by flow cytometry to calculate a transducing units titer (TU/mL) or by qPCR to measure infectious genomes (ig/mL), which are illustrated in the examples. A publication describing such a method is Kutner R H, Zhang X Y, Reiser J (2009). Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nature protocols 4: 495-505. The infectious titer of the lentiviral particles of the invention is measured upon infection of a permissive cell line, preferably 293T cells, or another permissive cell such as A20 cells, more preferably using the titration method described herein into the experimental example section of the application.
- By “high infectious titer”, it is meant a titer of infectious particles produced at the end of step c), higher than 2 E+04 TU/ml, preferably higher than 1 E+05 TU/ml, more preferably higher than 1 E+06 TU/ml, even more preferably higher than 2 E+06 TU/ml. More preferably, the infectious titer of particles pseudotyped with HERV-W produced at the end of step c), is higher than 1.2 E+05 TU/ml, preferably higher than 2 E+05 TU/ml, more preferably higher than 1 E+06 TU/ml, even more preferably higher than 1.5 E+06 TU/ml. More preferably, the infectious titer of particles pseudotyped with HERV-FRD produced at the end of step c), is higher than 2 E+04 TU/ml, preferably higher than 2 E+05 TU/ml, more preferably higher than 1 E+06 TU/ml, even more preferably higher than 2.5 E+06 TU/ml. Preferably such high infectious titers are measured using 293T cell infection and the titration method described in the example herein.
- The present invention also relates to stable lentiviral particles pseudotyped with HERV-W or HERV-FRD and packaging a heterologous gene of interest. That may be obtainable, or obtained, by the above method.
- By “stable”, it is meant that the infectious titer of the stable lentiviral particles pseudotyped with an ERV syncytin, such as an ERV syncytin as previously defined and more preferentially pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A and packaging a heterologous gene of interest of the invention, and having infected 293T cells or another permissive cell line for instance A20 cells, has been divided at most by 10 between two consecutive time points. The two consecutive time points may represent a duration of a few weeks, such as 1 to 3 weeks. The two consecutive time points may also represent a duration of a few months, such as 1, 2 or 3 months, or 6, 9, 10 months or even 12 or 18 months. The lentiviral pseudotyped particles according to the invention may be frozen, they keep their stability properties. They are indeed resistant to very low temperature treatments, such as freezing or cryopreservation. They may also be resistant to medium temperature treatments: as soon as they present the stability properties as indicated above, they correspond to the present invention.
- Such lentiviral pseudotyped particles can thus be centrifugated and/or frozen, while maintaining their fusogenic and infectious properties, as well as their ability to deliver the gene of interest to the target cells, particularly in vivo. Again, the stable pseudotyped lentiviral particles packaging a heterologous gene of interest according to the invention present a high physical titer, as well as a high infectious titer.
- By “heterologous” gene, it is meant a gene, which comes from an organism different from the one of the retroviral rev, gag and pol genes.
- By “gene of interest”, it is meant a functional version of a gene. The functional version means the wild-type version of said gene, a variant gene belonging to the same family, or a truncated version, which preserves the functionality of the encoded protein.
- The gene of interest may be derived from a gene, which is deficient or non-functional in a patient, or a gene coding for an immunogenic protein (such as a viral protein, a bacterial protein or a tumor antigen). The heterologous gene of interest may also be a reporter gene (useful for diagnosis purpose, and for identifying ligands of a target protein), a suicide gene, or a gene coding for a therapeutic RNA (ie coding for an antisense RNA complementary to a target DNA or RNA sequence, or a gRNA, a RNAi such as shRNA). The gene of interest is able to produce the encoded protein, peptide or RNA.
- By «pseudotype», it is meant a lentiviral particle comprising:
- an envelope glycoprotein derived from a virus, said virus being different from the one from which said lentiviral particle is derived;
- a modified envelope glycoprotein. In such a case, the native viral envelope glycoprotein may be modified by mutation or by any other amino acid modification; or
- a chimeric glycoprotein. Such a glycoprotein is a fusion protein between at least a part of the viral glycoprotein, and another sequence.
- In step a), appropriate cell lines are transfected with at least one plasmid. Preferably, the transfection is a transient transfection.
- Preferably, appropriate cell lines are transfected with at least one, two, three or four plasmids. These cell types include any eukaryotic cell which support the lentivirus life cycle.
- Preferably, the appropriate cell lines are stable cell lines or cell lines refractory to the catastrophic consequences of the fusogenic effects of syncytins, so as to continue growing while producing the particles. Said appropriate cell lines are mammalian cell lines, preferably human cell lines. Representative examples of such cells include Human Embryonic Kidney (HEK) 293 cells and derivatives thereof, HEK293 T cells, as well as subsets of cells selected for their ability to grow as adherent cells, or adapted to grow in suspension under serum-free conditions. Such cells are highly transfectable.
- In one embodiment, the appropriate cell lines are already expressing at least one, and at most four of the five sequences which are the heterologous gene of interest, the retroviral rev, gag and pol genes, and the nucleic acid coding for an ERV syncytin such as HERV-W, HERV-FRD or murine syncytinA, preferably in inducible form. In such a case, step a) comprises transfecting said cell line with at least one plasmid comprising at least one sequence which is not already expressed in said cell line. The plasmid mixture, or the single plasmid (if only one plasmid is used) is chosen such that, when transfected into said cell lines in step a), said cell lines express all five above sequences.
- For example, if the appropriate cell line expresses the retroviral rev, gag and pol genes, then the plasmid or mixture of plasmids to be transfected comprises the remaining sequences to be expressed, i.e. the heterologous gene of interest and the nucleic acid coding for an ERV syncytin such as HERV-W, HERV-FRD or murine syncytinA.
- When one single plasmid is used, it comprises all the 5 sequences of interest, i.e.:
- the heterologous gene of interest,
- the rev, gag and pol genes, and
- a nucleic acid coding for an ERV syncytin as previously described and notably coding for HERV-W, HERV-FRD or the murine syncytinA.
- When two or three plasmids are used (plasmid mixture), each of them comprises some of the sequences of interest listed in the previous paragraph, so that the plasmid mixture comprises all the above cited sequences of interest.
- Preferably four plasmids are used, and the quadritransfection comprises the following:
- the first plasmid comprises the gene of interest,
- the second plasmid comprises the rev gene,
- the third plasmid comprises the gag and pol genes, and
- the fourth plasmid comprises a nucleic acid coding for an ERV syncytin as previously described and notably coding for HERV-W, HERV-FRD or the murine syncytin-A.
- Said quadritransfection is preferably performed with specific ratios between the four plasmids. The molar ratio between the different plasmids can be adapted for optimizing the scale-up of the production. The person skilled in the art is able to adapt this parameter to the specific plasmids he uses for producing the lentivirus of interest. In particular, the weight ratios of the first, second, third, fourth plasmids are preferably (0.8-1.2):(0.1-0.4); (0.5-0.8):(0.8-1.2), more preferably around 1:0.25; 0.65:1.
- The rev, gag and pol genes are retroviral, preferably lentiviral. Preferably, they are HIV genes, preferably HIV-1 genes, but could be also EIAV (Equine Infectious Anemia Virus), SIV (Simian immunodeficiency Virus), Foamy Virus, or MLV (Murine Leukemia Virus) virus genes.
- The nucleic acid coding for the ERV syncytin, such as an ERV syncytin as previously defined and more preferentially coding for HERV-W, HERV-FRD or the murine syncytin-A is a DNA or cDNA sequence. Preferably, it corresponds to the cDNA sequence respectively listed in SEQ ID NO:1, 2 or 40, or to a sequence presenting at least 80%, preferably at least 90%, more preferably at least 95%, more preferably at least 99% identity with such SEQ ID NO:1, 2, or 40 respectively. Preferably, step a) comprises the transfection of at least the plasmid comprising, preferably consisting of, the cDNA sequence listed in SEQ ID NO:3 or 4.
- The term “identity” refers to the sequence similarity between two polypeptide molecules or between two nucleic acid molecule. When a position in both compared sequences is occupied by the same base or same amino acid residue, then the respective molecules are identical at that position. The percentage of identity between two sequences corresponds to the number of matching positions shared by the two sequences divided by the number of positions compared and multiplied by 100. Generally, a comparison is made when two sequences are aligned to give maximum identity. The identity may be calculated by alignment using, for example, the GCG (Genetics Computer Group, Program Manual for the GCG Package,
Version 7, Madison, Wis.) pileup program, or any of sequence comparison algorithms such as BLAST, FASTA or CLUSTALW. - The plasmids encoding the envelope glycoproteins which may be used are known to those skilled in the art such as the commercially available pCDNA3, backbone or any other plasmid cassette using a similar expression system, for instance using the CMV promoter such as the pKG plasmid described in Merten et al. (Hum Gene Ther., 2011).
- According to step a), various techniques known in the art may be employed for introducing nucleic acid molecules into cells. Such techniques include chemical-facilitated transfection using compounds such as calcium phosphate, cationic lipids, cationic polymers, liposome-mediated transfection, such as cationic liposome like Lipofectamine (Lipofectamine 2000 or 3000), polyethyleneimine (PEI), non-chemical methods such as electroporation, particle bombardment or microinjection.
- According to a preferred embodiment of the invention, the transfection of step a) is carried out using calcium phosphate.
- Typically, step a) may be performed by transient transfection of 293T cells with 4 plasmids (quadritransfection), in the presence of calcium phosphate. The 4 plasmids are preferably: a pKL plasmid expressing the HIV-1 gag and pol genes, a pK plasmid expressing HIV-1 rev gene, a pCCL plasmid expressing the heterologous gene of interest under control of a cellular promoter such as the human phosphoglycerate kinase (PGK) promoter and a pCDNA3 plasmid expressing an ERV syncytin, such as an ERV syncytin as previously defined and more preferentially expressing HERV-W (Syncytin-1), HERV-FRD (Syncytin-2) or the murine syncytin-A glycoproteins from a CMV promoter.
- Then, after step a), the method according to the present invention comprises a step b) of incubating the transfected cells obtained in a), so that they produce, preferably in the supernatant, the lentiviral particles pseudotyped with an ERV syncytin, such as an ERV syncytin as previously defined and more preferentially pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A including the heterologous gene of interest. Indeed, once step a) is performed, incubation of the obtained cells is performed. This leads to the production in the supernatant of the stable lentiviral particles, which are pseudotyped with an ERV syncytin, such as an ERV syncytin as previously defined and more preferentially pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A and which include the heterologous gene of interest.
- After transfection, the transfected cells are thus allowed to grow for a time which may be comprised between 20 and 72 hours post-transfection, in particular after 24 hours.
- In a particular embodiment, the medium used for culturing the cells is a classical medium, such as DMEM, comprising a sugar, such as glucose. Preferably, the medium is a serum-free medium. Culture may be carried out in a number of culture devices such as multistack systems or bioreactors adapted to the culture of cells in suspension. The bioreactor may be a single-use (disposable) or reusable bioreactor. The bioreactor may for example be selected from culture vessels or bags and tank reactors. Non-limiting representative bioreactors include a glass bioreactor (e.g. B-DCU® 2L-10L, Sartorius), a single-use bioreactor utilizing rocking motion agitation such as wave bioreactor (e.g. Cultibag RM® 10L-25L, Sartorius), single use stirrer tank bioreactor (Cultibag STR® 50L, Sartorius), or stainless steel tank bioreactor.
- After incubation, the obtained stable lentiviral particles are harvested and concentrated; this is step c). Preferably, the stable lentiviral particles obtained in b) are harvested before fusion of the transfected cells, more preferably 24h post-transfection. Preferably, the stable lentiviral particles present in the supernatant obtained in b) are centrifugated and/or purified. Said concentration step c) may be performed by any known method in the art, such as by centrifugation, ultrafiltration/diafiltration and/or chromatography.
- According to one embodiment, the supernatant is centrifugated at a speed comprised between 40000 and 60000 g, during 1 h to 3 h, at a temperature comprised between 1° C. and 5° C., so as to obtain a centrifugate of stable pseudotyped viral particles.
- Preferably, the centrifugation is performed at a speed of 45000 to 55000 g, during 1 h30 to 2 h30, at a temperature of 2° C. to 5° C., preferably around 4° C. At the end of this step, the particles are concentrated in the form of a centrifugate, which may be used.
- According to another embodiment, step c) is a chromatography, such as an anion exchange chromatography, or an affinity chromatography. The anion exchange chromatography may be preceded or followed by a step of ultrafiltration, in particular an ultrafiltration/diafiltration, including tangential flow filtration. The anion exchange chromatography is for example a weak anion exchange chromatography (including DEAE (D)—diethylaminoethyl, PI—polyethylenimine).
- This method allows obtaining lentiviral particles pseudotyped with an ERV syncytin, such as an ERV syncytin as previously defined and more preferentially pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A. Said particles are stable, because, thanks to the above method, they can be concentrated without being degraded, as shown in the examples. Moreover, said particles comprise the heterologous gene of interest.
- Preferably, the stable lentiviral particles pseudotyped with an ERV syncytin, such as an ERV syncytin as previously defined and more preferentially pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A and packaging the gene of interest according to the invention, are suspended in a pharmaceutically acceptable carrier, so as to obtain a pharmaceutical composition.
- A “pharmaceutically acceptable carrier” refers to a vehicle that does not produce an adverse, allergic or other untoward reaction when administered to a mammal, especially a human, as appropriate. A pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
- Preferably, the pharmaceutical composition contains vehicles, which are pharmaceutically acceptable for a formulation capable of being injected. These may be in particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and the like or mixtures of such salts), or dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions.
- The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or suspensions. The solution or suspension may comprise additives which are compatible with enveloped viruses and do not prevent virus entry into target cells. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. An example of an appropriate solution is a buffer, such as phosphate buffered saline (PBS).
- The stable pseudotyped lentiviral particles of the invention, as they package the heterologous gene of interest, may be used as a medicament.
- Indeed, the results provided in the present application clearly demonstrate that a syncytin-pseudotyped lentiviral vector of the invention can be used in immunotherapy in humans and can functionally correct B cells in a human disease. Furthermore, the syncytin-pseudotyped vectors of the invention are able to target B cells in vivo. The data showed herein illustrated that these new tools are very well tolerated in vivo as gene transfer is observed for a long period of time. For in vivo applications, efficient transduction of the target cells (such as B cells) can be obtained without the need of
vectofusin 1. - Thus, the stable pseudotyped lentiviral particles may be used in gene therapy or immunotherapy or as a vaccine or in immunoprophylaxis.
- Gene therapy can be performed by gene transfer, gene editing, exon skipping, RNA-interference, trans-splicing or any other genetic modification of any coding or regulatory sequences in the cell, including those included in the nucleus, mitochondria or as commensal DNA (viral sequences contained in cells).
- The two main types of gene therapy are the following:
-
- a therapy aiming the replacement of a deficient/abnormal gene: this is replacement gene therapy;
- a therapy aiming gene editing: in such a case, the purpose is to provide to a cell the necessary tools so that the gene of interest is expressed: this is gene editing therapy.
- In replacement gene therapy, the gene of interest may be a correct version of a gene which is deficient or mutated in a patient, as is the case for example in a genetic disease. In such a case, the gene of interest will restore the expression of the deficient or mutated gene. Of particular interest are deficient or mutated genes in patients exhibiting a disease which, once corrected in immune cells, preferably in B cells, T cells, monocytes or dendritic cells, more preferably in B cells, improve the patient's disease or symptoms. Examples of mutated genes in genetically defective B cells are the following:
-
- the gene coding the gamma chain in X-linked severe combined immunodeficiency disease (SCID-X1) (the patients have a T-NK-B+ phenotype), or for SCID-X1 patients already treated by gene therapy but in whom B cell correction was not induced;
- the gene TNFRSF13B encoding the TACI (transmembrane activator and calcium-modulator and cyclophilin-ligand interactor) which is mutated in common variable immunodeficiency (CVID);
- the CD19 or BAFFR gene which may be mutated in common variable immunodeficiency (CVID);
- any of the genes responsible for hyper-immunoglobulin M, notably caused by mutations in the gene coding for CD40;
- the WAS gene which is mutated in Wiskott-Aldrich syndrome, including WAS patients already treated by stem cell-based gene therapy and in whom B cell correction is incomplete;
- the Fanc genes, which are mutated in either of the Fanconi anemia subtype, for instance FancA or FancC;
- any of the genes responsible for hyperimmunoglobulin E.
- Thus, these genes could be used as the gene of interest.
- Examples of mutated genes in genetic diseases of phagocyte function, in particular those which lead to the production of non-functional or abnormal monocytes or dendritic cells and which could be treated by expressing or correcting the causal gene in said monocytes or dendritic cells, are the following: Wiskott Aldrich Syndrome (WAS gene), chronic granulomatous disease (CGD, CYBB or p47 genes), leukocyte adhesion deficiency (LAD), IL-12/23 deficiency (IL12 p40, p70, IL23 chains), bare lymphocyte syndrome due to absent HLA molecules, auto-inflammatory disorders such as familial Mediterranean fever (pyrin gene) or cryopyrin-related diseases (NALP3 mutations).
- Replacement gene therapy could also be used to treat cancer. Genes of interest in cancer could regulate the cell cycle or the metabolism and migration of the tumor cells, or induce tumor cell death. For instance, inducible caspase-9 could be expressed in B cell leukemias or B cell lymphomas to trigger cell death, preferably in combination therapy to elicit durable anti-tumor immune responses.
- Diseases involving cells expressing the receptors for ERV syncytin such as syncytin-1 or syncytin-2 could also be treated by gene transfer into these cells. For example, one can quote gestational pathologies in which placental cells could be treated; cancer such as leukemias, lymphomas or solid tumor cells (including breast or lung tumor cells known to express ASCT2 or MFSD2a) in which the malignant cells could be treated; neurological conditions in which endothelial cells of the blood-brain-barrier could be treated; or any genetic or acquired condition implicating these cells.
- In gene therapy, it might be possible to use the stable pseudotyped lentiviral particles of the invention in therapy for immune cell engineering, preferably B cell engineering, by transducing said immune cells. It might be possible to generate regulatory B cells by expressing immunosuppressive proteins in B cells, for instance IL-10, or to induce the production of immunoregulatory proteins such as antibodies or fusion proteins.
- It could also be possible to insert sequences favoring gene splicing, expression or regulation or gene editing. Tools such as CRISPR/Cas9 may be used for this purpose. This could be used to modify gene expression in B cells, in the case of auto-immunity or cancer, or to perturb the cycle of viruses in B cells. In such cases, preferably, the heterologous gene of interest is chosen from gRNA, nucleases, DNA templates and RNAi components, such as shRNA.
- A specific example of gene editing would be the treatment of Waldenström macroglobulinemia: in such a disease, a point mutation (L265P) of (MYD88) has been observed in B cells of 80-88% of the patients and contributes to the survival and persistence of these tumor cells. Thus, by gene editing a correct version of this gene in afflicted patients, this may contribute to effective therapies against this disease.
- The stable pseudotyped lentiviral particles of the invention could be used together or sequentially to target the same cells through different receptors. This could be an advantage in strategies such as gene editing, in which multiple components of the gene editing platform need to be added to the cells.
- In gene editing therapy, it might also be possible to transduce immune cells, preferably B cells, with the stable pseudotyped lentiviral particles of the invention. Preferably then, if the heterologous gene of interest codes for an immunoglobulin, then transduced B cells are able to produce the corresponding immunoglobulins. An example would be to engineer a known sequence of variable immunoglobulin regions which confers specific recognition of pathogens such as viruses (rabies, HIV, Ebola, Flu, CMV, Zika) or parasites (T. cruzi, P. falciparum) which could be used for prophylactic or therapeutic use or for diagnostic.
- When the transduced immune cells are macrophages, then the therapy may be an anti-inflammatory therapy, tolerance induction or a vaccination.
- When the transduced immune cells are B cells, then the therapy may be for treating an autoimmune disease.
- When the transduced immune cells are dendritic cells, then the therapy may be as vaccine.
- For example, recipient immature dendritic cells transduced with major or minor histocompatibility antigens specific of an allogeneic organ donor may be used to induce allogeneic organ transplant tolerance in the recipient.
- Again, immunotherapy applications via genetic engineering of antigen-presenting cells such as human B cells, human myeloid dendritic cells or monocytes, may be found by introducing into these cells a recombinant gene expression cassette containing an antigenic sequence associated or not with immunommodulatory sequences, for antigenic presentation for the purpose of vaccination to protect against infectious diseases; for treating cancer; or for the purpose of inducing cell-specific or antigen-specific immune tolerance, in order to treat diseases with inflammatory immune components, such as diabetes or Alzheimer's disease, or to facilitate organ or bone marrow transplantation.
- In gene therapy, the targeted tissue is not only immune cells, but could also be placenta as well as any tissue in which syncytin-mediated heterologous fusion occurs, or any tissue or any cell expressing the receptors for syncytin. Examples include possibilities of treating placenta to prevent pre-eclampsia. Pre-eclampsia is a leading cause of maternal mortality and some studies have detected in the pre-eclamptic placenta that differentially expressed microRNAs deregulate TGF-β2 response (Zhou et al Sci Rep. 2016 Jan. 29; 6:19910. doi: 10.1038/srep19910.). Possibly, gene transfer or gene editing in placental cells through the use of syncytin-pseudotyped vectors may correct this problem. Possibly the target tissue could be skeletal muscle as it was recently shown that syncytins are expressed in myoblasts and may contribute to fusion between myoblasts (Frese et al., 2015). Possibly, syncytin-pseudotyped vectors which may recognize receptor on skeletal muscle cells, may be used for muscle gene therapy.
- As used herein, the term “patient” denotes a mammal Preferably, a patient according to the invention is a human.
- An immune cell is a cell involved in the immune system. It comprises notably B cells, T cells, NK cells, macrophages and dendritic cells.
- A B cell (or B lymphocyte) is an immune cell responsible for the production of antibodies, and involved in the humoral immune response.
- A dendritic cell is an immune cell, which is accessory: it is an antigen-presenting cell. Its main function is to process the antigen material and present it on its cell surface to the T cells.
- A T cell (or T lymphocyte) is an immune cell involved in cell-mediated immune response. It may be chosen from killer T cells, helper T cells and gamma delta T cells.
- The stable pseudotyped lentiviral particles may be used in immunotherapy or as a vaccine or in immunoprophylaxis. In such a case, the heterologous gene of interest may code for an immunogenic protein, such as a viral protein, a bacterial protein or a tumor antigen. In such a case, the expression of the gene will stimulate immune responses, allowing immunization. This corresponds to a vaccine. In immunoprophylaxis, the heterologous gene of interest may code for a protein which prevents B cell viral infection, such as EBV infection, which may cause malignant transformation in immunodeficient patients.
- Thus, the invention also relates to the use of stable lentiviral particles pseudotyped with an ERV syncytin, such as an ERV syncytin as previously defined and more preferentially pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A packaging a heterologous gene of interest, for therapy by transducing immune cells, preferably B cells.
- The invention also relates to the use of stable lentiviral particles pseudotyped with an ERV syncytin, such as an ERV syncytin as previously defined and more preferentially pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A packaging a heterologous gene of interest, for bioengineering in human B cells. For instance, one can quote the production of vectored antibodies in B cells which consists of expressing by gene transfer in human B cells recombinant antibodies directed against toxins, pathogens (such as HIV-1) or parasites (such as Plasmodium) to facilitate the rapid recognition and neutralization of these pathogens. Examples of recombinant antibodies that are vectored in mice in a different system are described in “Balazs A B, et al. Nat Med. 2014 March; 20(3):296-300. doi: 10.1038/nm” or “Deal C et al. Proc Natl Acad Sci USA. 2014 Aug. 26; 111(34):12528-32. doi: 10.1073/pnas.1407362111”.
- Bioengineering in human B cells could also consist of using gene transfer to immortalize the antigen-responsive human B cells (for instance CD27+ germinal center B cells) with genes such as anti-apoptotic genes, or B cell oncogenes (such as Bcl6 or BclX), for the purpose of growing such cells responding to a pathogen and selecting their antibody sequences, as is described in “Kwakkenbos M J et al. Nat Med. 2010 January; 16(1):123-8. doi: 10.1038/nm.2071. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming”.
- Said lentiviral particles pseudotyped with an ERV syncytin, such as an ERV syncytin as previously defined and more preferentially pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A, packaging a heterologous gene of interest, may be administered to a patient per se, for example by injection. In such a case, the transduction of immune cells will be made in vivo. In another alternative, a sample of immune cells, preferably B cells, or their precursors, of a patient is previously taken, then said lentiviral particles are injected into the immune cells or their precursors of the sample (i.e. thus in vitro), and the treated sample is finally re-administered to the patient. In this latter case, the sample of immune cells or their precursors infected with said lentiviral particles, and thus comprising the heterologous gene of interest, is the medicament. Thus, the invention also aims the use of a sample of immune cells or their precursors infected with said lentiviral particles in therapy, or for a diagnosis purpose (in case the heterologous gene of interest is a reporter gene).
- The invention also relates to the use of lentiviral particles pseudotyped with HERV-W or HERV-FRD including a heterologous gene of interest, for treating immune deficiencies, auto-immunities, infectious diseases or B cell-related cancers.
- By “immune deficiencies”, it is meant a condition leading to increased number or severity of microbial (bacterial, viral, parasitic) infections or reducing the anti-tumor surveillance and leading to increased frequency of cancers.
- For this purpose, the heterologous gene of interest may be a suicide gene, a “dominant-negative” gene, a gene coding for an antibody which would block target cell activation, a gene coding for a protein correcting the expression of an oncogene, or a gene coding for a protein reducing or altering the viral cycle of a transformant virus for B cells (such as EBV in case of Burkitt's syndrome).
- By “auto-immunities”, it is a meant autoimmune diseases. They correspond to conditions involving an abnormal immune response of the body against healthy cells of said body. Auto-immunities may be confined to an organ or a tissue. Autoimmune diseases, in particular autoimmune diseases susceptible to be treated by B cell-depleting strategies (i.e. rituximab) and which could be treated by expressing a gene in the pathological B cells with the intention of killing them (such as caspase 9 or inducible caspase 9, thymidine kinase, or any other “suicide gene”), or with the intention of immunomodulating their function by expressing immunoregulatory genes such as IL-10, are for instance: rheumatoid arthritis, systemic lupus erythematosus, idiopathic thrombocytopenic purpura, anti-neutrophil cytoplasmic antibody associated vasculitis (ANCA vasculitis), Grave's disease, systemic sclerosis, autoimmune hemolytic anemia, pemphigus vulgaris, cold agglutinin disease, Sjogren's syndrome, thrombotic thrombocytopenic purpura, cryoglobulinemia, IgM mediated neuropathy, multiple sclerosis, neuromyelitis optica, idiopathic membranous nephropathy, dermatomyositis, autoimmune neurological disorders, hemophilia A, or organ transplantation (kidney) complications by organ rejection or bone marrow transplantation complications caused by graft versus host disease.
- By “infectious diseases”, it is meant diseases which are caused by pathogenic microorganisms, such as bacteria, viruses, parasites or fungi; the diseases can be spread, directly or indirectly, from one person to another. Bacterial infections may be due to Streptococcus, Staphylococcus and E. coli. Viral infections may be due to Papillomaviridae, Polyomaviridae (BK virus, JC virus), Herpesviridae (
Herpes simplex type - As used herein, the term “B cell-related cancer” refers to the pathological condition in mammals that is typically characterized by unregulated cell growth of B cells. B cell malignancies may be acute lymphoid leukemia, chronic lymphocytic leukemia, multiple myeloma, Waldenström macroglobulinemia or any type of B cell lymphoma including opsoclonus myoclonus and any type of virus-induced B cell pathology such as those caused by Epstein-Barr-Virus, in which a therapeutic effect could be obtained by gene transfer of a cell cycle modulator or anti-oncogenic gene sequence (such as p53, antisense sequence to an oncogene, shRNA against an oncogene) or a suicide gene (such as icasp9, thymidine kinase) or anti-viral sequences, or any genetic sequence susceptible to arrest the growth, the spreading or the production of pathological molecules by the tumor cells, including sequences for gene editing when specific gene mutations are present, such as mutations in MyD88 in the case of Waldenström hyperglobulinemia, or sequences to edit critical viral life cycle genes, or sequences that will activate an anti-tumor immune response or any combination of these approaches.
- In the context of the invention, the term “treating” or “treatment”, as used herein, means reversing, alleviating or inhibiting the progress of the disorder or condition to which such term applies, or reversing, alleviating or inhibiting the progress of one or more symptoms of the disorder or condition to which such term applies.
- Finally, the present invention relates to an ex vivo process for obtaining immune cells modified to express a heterologous gene of interest, comprising a step of infecting immune cells with stable lentiviral particles pseudotyped with an ERV syncytin as previously described and notably pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A packaging a gene of interest, in the presence of a LAH4 peptide or a functional derivative thereof, preferably vectofusin-1.
- Preferably, the immune cells are chosen from B cells, T cells, dendritic cells and macrophages.
- Preferably, the immune cells are naïve. According to the preferred embodiment, the naïve immune cells are not previously stimulated.
- According to another embodiment, when stimulation is used, the stimulation step is minimal and performed by incubating naïve immune cells in a medium comprising IL-7 so as to preserve the survival of naïve B cells.
- Thus, preferably, the ex vivo process for obtaining immune cells modified to express a heterologous gene of interest according to the invention, comprises a step of directly infecting naïve immune cells, especially naïve B cells, with stable lentiviral particles pseudotyped with an ERV syncytin as previously described and notably pseudotyped with HERV-W, HERV-FRD, or the murine syncytin-A packaging a heterologous gene of interest, in the presence of a LAH4 peptide or a functional derivative thereof. Said naïve immune cells are not previously stimulated. The present invention also relates to the naïve immune cells, preferably naïve B cells, comprising the heterologous gene of interest obtainable by said ex vivo process.
- According to another embodiment, the ex vivo process for obtaining immune cells modified to express a heterologous gene of interest according to the invention, may also comprise the following steps:
- optionally stimulating naïve immune cells by incubating them in a medium comprising IL-7, and then
- infecting the naïve immune cells, stimulated or not, with lentiviral particles pseudotyped with an ERV syncytin as previously described and notably pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A including a gene of interest, in the presence of a LAH4 peptide or a functional derivative thereof. The present invention also relates to the naïve immune cells previously stimulated obtainable by said ex vivo process.
- Preferably, the LAH4 peptide or functional derivative thereof, preferably vectofusin-1, is present notably at a concentration of 7 to 20 μg/ml, more preferably of 10 to 15 μg/ml.
- In the context of the present invention, the “LAH4 peptide” refers to the peptide with the amino acid sequence consisting of SEQ ID NO: 5. As used herein, the term “LAH4 functional derivative” means any peptide whose sequence has been designed based on the primary structure of the LAH4 peptide and having the ability to improve the transduction efficiency of a virus or viral vector. In particular embodiment, a LAH4 functional derivative is a peptide having the ability to improve the transduction efficiency of a virus encapsidated with a an ERV syncytin as previously described and notably encapsidated with HERV-W, HERV-FRD or the murine syncytin-A envelope in eukaryotic cells, in particular human, mouse, rat, monkey, dog or hamster cells, in particular a human CD34+ cell.
- The LAH4 peptide or a functional derivative thereof may be selected among the sequences represented in SEQ ID NO: 5 to 31:
-
LAH4: (SEQ ID NO: 5) KKALLALALHHLAHLALHLALALKKA LAH4-L1: (SEQ ID NO: 6) KKALLAHALHLLALLALHLAHALKKA LAH4-L1-dKC: (SEQ ID NO: 7) KKALLAHALHLLALLALHLAHALA LAH4-L1-R: (SEQ ID NO: 8) RRALLAHALHLLALLALHLAHALRRA LAH4-L0: (SEQ ID NO: 9) KKALLAHALAHLALLALHLALHLKKA LAH4-L2: (SEQ ID NO: 10) KKALLALALHHLALLALHLAHALKKA LAH4-L3: (SEQ ID NO: 11) KKALLALALHHLALLAHHLALALKKA LAH4-L4iso: (SEQ ID NO: 12) KKALLHLALLHAALLAHHLALALKKA LAH4-L5: (SEQ ID NO: 13) KKALLHLALLHAALLAHLAALHLKKA LAH4-L6iso: (SEQ ID NO: 14) KKALLHLALLLAALHAHLAALHLKKA LAH4-A1: (SEQ ID NO: 15) KKALLAHALHLLAALALHLAHLLKKA LAH4-A2: (SEQ ID NO: 16) KKALLLAALHHLAALALHLAHLLKKA LAH4-A3: (SEQ ID NO: 17) KKALLLAALHHLLALAHHLAALLKKA LAH4-A4 (also called vectofusin-1): (SEQ ID NO 18) KKALLHAALAHLLALAHHLLALLKKA LAH4-A5: (SEQ ID NO : 19) KKALLHALLAHLAALLHALLAHLKKA LAH4-A6iso: (SEQ ID NO: 20) KKALLHALLAALLAHLHALLAHLKKA LAH4-A4-K1N: (SEQ ID NO: 21) KALLHAALAHLLALAHHLLALLKKA LAH4-A4-K3N: (SEQ ID NO: 22) KKKLLHAALAHLLALAHHLLALLKKA LAH4-A4-dKC: (SEQ ID NO: 23) KKALLHAALAHLLALAHHLLALLA LAH4-A4-d1aa: (SEQ ID NO: 24) KKALLHAALAHLLALAHHLLALLK LAH4-A4-d2aa: (SEQ ID NO: 25) KKLLHAALAHLLALAHHLLALLK LAH4-A4-d2Caa: (SEQ ID NO: 26) KKALLHAALAHLLALAHHLLALK LAH4-A4-d3aa: (SEQ ID NO: 27) KKLHAALAHLLALAHHLLALLK LAH4-A4-d5aa: (SEQ ID NO: 28) KKLHAALAHLLALAHHLLAK LAH2-A6: (SEQ ID NO: 29) KKALLHAALAHLLALAAALLALLKKA K2-L10A12-K2: (SEQ ID NO: 30) KKALLAAALAALLALAAALLALLKKA LAH4-A4-Leu: (SEQ ID NO: 31) KKLLLHALLAHLLALLHHLLALLKKL. - Preferably, one uses a functional derivative of the LAH4 peptide. Preferably, said functional derivative is LAH4-A4, which is also called vectofusin-1, and which has SEQ ID NO: 18.
- The present invention also relates to a pharmaceutical composition comprising the stable pseudotyped lentiviral particles of the invention, or the immune cells transfected with said stable particles, in a pharmacologically acceptable medium. By “pharmacologically acceptable medium”, it is meant a vehicle compatible with an administration to the patient.
- The present invention also relates to the use of the stable lentiviral particles pseudotyped with an ERV syncytin as previously described and notably pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A including a heterologous gene of interest, preferably stable lentiviral particles pseudotyped with an ERV syncytin as previously described and notably pseudotyped with HERV-W, HERV-FRD or the murine syncytin-A including a heterologous gene of interest, for generating animal models, particularly in mice (so as to obtain murine models). This may be useful for exploring disease mechanisms, particularly B cell diseases.
- The invention will now be exemplified with the following examples, which are not limitative.
-
FIG. 1 : Transduction of BeWO Cells with Syncytin-Pseudotyped Vectors in the Presence of Various Transduction Additives - BeWO cells were infected with GFP-encoding vectors, either with LV-VSVg (108 TU/mL) or with LV-Syn2 (105 TU/mL) in the absence or presence of additives protamine sulfate (PS), polybrene (PB) or Vectofusin-1 (VF1) and transgene expression was measured by FACS after 3 days. The percentages of live GFP+ cells in the gate are shown. Results from one experiment.
-
FIGS. 2A-D : Transduction of 293T Cells with Syncytin-Pseudotyped Vectors and Vectofusin-1 (VF-1) - A. B. One representative experiment out of 3 showing the dose-dependent effects of syncytin-pseudotyped vectors in the presence of VF1. 293 T cells were cultured with GFP-encoding LV-Syn1 (A) or LV-Syn2 (B) using vector concentrations ranging from 104 to 105 TU/mL and in the absence or presence of VF1. GFP expression was measured by FACS after 3 days. C. The enhancing effect of VF1 is statistically-significant as shown in 5-6 experiments using a Mann-Whitney test. D. Correlation between expression of GFP as measured by FACS and vector copy number per cell (VCN) as measured by qPCR was obtained from 3 separate experiments testing different vector concentrations.
-
FIG. 3 : Transduction of Primary Blood Cell Subsets with Syncytin-Pseudotyped Vectors - Human peripheral blood mononuclear cells (PBMC) (4 to 9 separate blood donors) were infected with GFP-encoding LV-Syn1 or LV-Syn2 vectors (105 TU/mL) in the absence or presence of VF1 and either immediately after isolation of the cells (no activation) or following an overnight culture of cells with IL-7 (10 ng/mL). After 3 days, GFP was measured by FACS in different subsets of live cells (CD3+ CD19− CD11c− T cells; CD3− CD19+ CD11c− B cells; CD3− CD19− CD11c+ myeloid dendritic cells) , naive (CD27−) or memory (CD27+) B cell subsets.
-
FIG. 4 : Dose-Dependent Effects of Syncytin-Pseudotyped Vectors on Blood Cell Subsets - Representative results of 3 donors of PBMC incubated with IL-7 overnight, then transduced with ΔNGFR-encoding LV-Syn1 and LV-Syn2 at
concentrations -
FIGS. 5A-B : Transduction of CD11c+ Blood Cells with Syncytin-Pseudotyped Vectors - Whole PBMC (2 donors tested in 2 separate experiments) or plastic-adherent PBMC (1 donor tested in another separate experiment) were transduced with GFP-encoding LV-Syn1 or LV-Syn2 (2×105 TU/mL) or LV-VSVg (108 TU/mL) vector in the absence of presence of VF1 (12 μg/mL). Cells were washed and further cultured in XVivo20+10% FCS+GM-CSF+IL-4 for 3 to 7 days. A. Gating strategy for the analysis of CD11c+ HLD-DR+ myeloid cells. B. Representative experiment out of 3 showing the transduction of CD11c+ HLD-DR+ cells obtained after 3 days in different conditions.
-
FIGS. 6A-C : Expression of ASCT2 and MFSD2a Receptors on Blood Cells - A. Multicolor FACS analysis for ASCT2 and MFSD2a expression in CD19+ B cells, CD3+ T cells and CD11c+ myeloid dendritic cells in one representative experiment out of 3 (1 blood donor each). B. Average and standard deviation of the percentage of cells expressing the indicated receptors in 5 experiments, after subtraction of the background obtained with the rabbit immunoglobulin control. C. RT-PCR analysis of MFSD2a and ASCT2 mRNA on PBMC cell subsets averaging 2 experiments.
-
FIGS. 7A-B : Phenotype of blood mononuclear cells of a SCIDX1 patient treated by gene therapy. Flow cytometry analysis was performed: (A) with a healthy donor PBMC and in comparison (B) after thawing the patient's peripheral blood mononuclear cells (PBMC) and in comparison. -
FIGS. 8A-C & 9A-C: Transduction of murine spleen cells (FIG. 8 ) and of bone marrow cells (FIG. 9 ) with LV-Syn A vectors. LV-SynA vector encoding dNGFR was added on red-blood cell-depleted spleen cells obtained from C57Bl/6 mice. After 3 days, the phenotype of cells and transgene expression were measured by flow cytometry. -
FIGS. 10A-D : In vivo delivery of the LucII transgene with LV-SynA. A single bolus of LV-SYn A encoding LucII (C, n=7, flux: 1,8.108 photons/sec) was injected intravenously into albinos C57Bl/6 mice (5×105 TU/mouse n=3). As control a LV-VSVg encoding the same transgene was used (B, n=4, flux:7.108 photons/sec), as well as PBS (A, n=7, flux: 1,5.104 photons/sec). Bioluminescence detection of transgene expression was performed 16 days post IV injection of LVs. One of the anesthetized mice was opened to confirm bioluminescence of the spleen (D). - Supplementary Figures S1A-D
-
- A. Optimization of plasmid ratio for LV production by transient transfection in HEK293T cells. Production of LV-Syn2 vector coding for GFP using various amounts of pcDNA3Syn2 plasmid in each T175 cm2 flask as indicated on the X axis. Medium was collected 24 h after transfection and p24 was measured by ELISA. Results of average±SD of 4 measures.
- B. Dose-dependent increase in transduction and stability of transduction over time. HEK293T cells were transduced with increasing concentrations of LV-Syn1 encoding GFP. Cells were cultured for the indicated times (d=days) at which GFP expression was measured by FACS. Results are expressed as percentage of GFP+ cells in the culture. Results of 1 experiment representative of 4.
- C. Comparative transduction of different cell lines with syncytin-pseudotyped LV. HEK293T cells, BeWO cells or HCT116 cells were transduced with LV-Syn1 (105 TU/mL), LV-Syn2 (105 TU/mL) or LV-VSVg (106 TU/mL) vectors encoding GFP. Expression of GFP was measured by FACS after 3 days. Results obtained with LV-Syn1 and LV-Syn1 respectively on 5 and 6 separate experiments on 293 T cells; 1 and 3 experiments on BeWO cells and 2 and 4 experiments on HCT116 cells.
- Supplementary Figures S2A-B
-
- A. Treatment schema of PBMC with vectors
- B. FACS gating strategy to analyse the transduction of various B cell subpopulations
- Supplementary Figures S3A-B
-
- A. FACS gating strategy to analyze the transduction of dendritic cells which are CD3− CD19−, HLA-DR+, CD1a+ and express or not GFP and CD86 or CD80. Transduction of PBMC with LV-Syn1, LV-Syn2 or LV-VSVG vectors in the same conditions as in
FIG. 5 and expression of CD80 and CD86 (percentages indicated in quadrants) on the subset of CD3−CD19−CD14−CD1a+GFP+ cells after 7 days. - B. Same as A. and expression of GFP (percentages indicated in histogram) on the subset of CD3−CD19−CD14+HLA-DR+ cells after 7 days.
- A. FACS gating strategy to analyze the transduction of dendritic cells which are CD3− CD19−, HLA-DR+, CD1a+ and express or not GFP and CD86 or CD80. Transduction of PBMC with LV-Syn1, LV-Syn2 or LV-VSVG vectors in the same conditions as in
- Supplementary Figure S4: Immunostaining for ASCT2 and MFSD2a on HEK293T Cells and HCT116 Cells
- Histograms represent the mean fluorescence intensity (MFI) of unstained negative control cells (293T: 5%; HCT116: 3%), cells stained with irrelevant IgG and the Alexa 647-conjugated secondary antibody (293T: and HCT116: 1%), cells stained with the anti-ASCT2 and secondary antibody (293T: 12%, HCT116: 4%) and cells stained with anti-MFSD2a and secondary antibody (293T: 99%, HCT116: 65%).
- Supplementary Figure S5: Transduction of Raji and Jurkat Cells with LV-Syn1 and LV-Syn2 Vectors Encoding GFP Using 106 TU/mL Vector
- Cells were analyzed by
FACS 8 days after infection. - Supplementary Figure S6: In Vivo Transduction with LV-Syn1 Vector
- 7 week-old female NSG mice (Nod/Scid/gc−/−) purchased from Charles River were injected in the retro-orbital sinus with 107 PBMC in 100 μL volume. After 24 hours, the mice were injected intravenously in the tail vein with 150 μL of undiluted LV-Syn1 vector. After 7 days, mice were sacrificed and spleens were collected, lysed with ACK and the red blood cell-depleted fraction was analyzed by FACS to measure GFP on the CD45+ human cell fraction. Results show the FACS plots of 2 mice in which human GFP+ cells were found.
- Supplementary Figure S7: Ex Vivo Transduction of Murine Cells with the LV-Syn1 or LV-Syn2 Vectors
- Spleen cells were obtained from 6 week-old female C57Bl/6 mice following red blood cell lysis with ACK. The cells were cultured in RPMI supplemented with 10% FCS and bet2 mercaptoethanol at the concentration of 106 cells/mL in 100 μL in the presence of LV-SYn1 or LV-Syn2 encoding ΔNGFR at 1 or 5×105 TU/mL and VF1 (12 μg/mL). After 3 days, expression of ΔNGFR was measured by FACS on live cells.
- Supplementary Figure S8: Infectious Titration of LV-SynA on the Murine B Cell Lymphoma Cell Line A20
- A20 cells were transduced with different amounts of LV-SynA vector (0, 0.2, 0.6, 1.8, 3.2, 5.4 and 16.2 μL) with VF1 (red) and without VF1) To 12 μg/mL. The cells are cultured for 7 days in complete medium. Evaluation of the number of copies of syncytin A by qPCR.
- Materials and Methods
- Cell Lines
- Human
embryonic kidney 293T cells and human colorectal carcinoma HCT116 cells (CCL-247; ATCC, Manassas, Va.) were cultured at 37° C., 5% CO2 in Dulbecco's modified Eagle's medium (DMEM+glutamax) (Life Technologies, St-Aubin, France) supplemented with 10% of heat inactivated fetal calf serum (FCS) (Life Technologies). Human choriocarcinoma BeWO cells (CCL-98; ATCC) were cultured in Ham's F12K medium (Life technologies) supplemented with 10% of FCS. Raji cells and Jurkat cells were infected inXVivo 20 medium. - Cloning of Syncytin-Expressing Plasmids and Production of Vectors
- Plasmids pCDNA3-syncytin-1 and pCDNA3-syncytin-2 coding for human syncytin-1 (ERVW-1-001) or human syncytin-2 (ERVFRD-1) were constructed by cloning the respective synthesized DNA sequences (Gencust, Dudelange, Luxembourg) corresponding to Ensembl genome browser ENST00000493463 and ENSG00000244476 transcript sequences, into a pCDNA3 plasmid (Invitrogen, Carlsbad, Calif.) using NHeI et XhoI restriction enzymes. Plasmid sequences were verified by two strand sequencing. The syncytin-2 plasmid functionality was verified by immunoblotting protein extracts following transfection of 293T cells using the anti-HERV-FRD antibody (LS-BIO, Nanterre, France) detecting a 65-70 Kd protein expected to be syncytin-2. Plasmids were produced with endotoxin-free using DNA RNA purification Nucleobond kit (Macherey-Nagel, Duren, Germany) Lentiviral particles pseudotyped with either syncytin-1 or syncytin-2 were produced by transient transfection of 293T cells with 4 plasmids, using calcium phosphate. Each T175 cm2 flask was transfected with 14.6 μg pKLgagpol expressing the HIV-1 gagpol gene, 5.6 μg pKRev expressing HIV-1 rev sequences, 22.5 μg of the gene transfer cassette (pCCL PGK GFP expressing enhanced green fluorescent protein (GFP) under control of the human phospho glycerate kinase (PGK) promoter (Charrier et al, 2011) or pCCL PGK delta-NGFR expressing a truncated form of the nerve growth factor receptor (NGFR) under control of the human PGK promoter) and 22 μg of either the pCDNA3-syncytin-1 or pCDNA3-syncytin-2 plasmid. Medium was changed the following day and replaced by DMEM 4.5 g/L glucose supplemented with penicillin and streptomycin and 10% FCS. After 24 hours, medium containing viral particles was collected, centrifuged at low speed, sterile-filtered (0.22 μm) and concentrated by
ultracentrifugation 50 000 g (19500 RPM using a Beckman ultracentrifuge with rotor SW28) for 2 h at 4° C. The pellet was resuspended in PBS, aliquoted and stored at −80° C. VSVg-pseudotype particles were produced also by transient transfection as reported (Merten et al, 2011). - Transduction Additives
- Vectofusin-1 (VF1) peptides were synthetized by standard fluorenyl-methyloxy-carbonyl chloride solid-phase peptide synthesis, followed by HPLC and mass spectrometry purification (Gencust). Peptides were solubilized in H2O, aliquoted and stored at −80° C. until used. When needed for transduction experiments, VF1 was thawed, resuspended in medium and added to vector and to cells at a final concentration of 12 μg/mL. Protamine sulfate (PS) (Sigma-Aldrich, St Louis, Mo.) and polybrene (PB) (Sigma-Aldrich) were also diluted extemporaneally with vector and cells and respectively used at final concentrations of 8 μg/mL and 6 μg/mL in the transduction culture.
- Titration of Vectors
- Concentrated and cryopreserved vector was titered before use. Physical particle titer was determined by p24 ELISA (Alliance© HIV-1 Elisa kit, Perkin-Elmer, Villebon/Yvette, France) as previously reported (Charrier et al, 2011). Infectious titer was determined by adding serial dilutions of vector to HEK293T cells in the presence of 12 μg/mL VF1 and after 3 days, 293T cells were analyzed by flow cytometry to calculate a transducing units titer (TU/mL) or by qPCR to measure infectious genomes (ig/mL) using standard calculations (Kutner et al, 2009).
- Culture and Transduction of Peripheral Blood Mononuclear Cells
- Peripheral blood collected with EDTA was purchased from the Etablissement Francais du Sang (Evry, France). Peripheral blood mononuclear cells (PBMC) purified by Ficoll gradient centrifugation (Eurobio, les Ulis, France) were suspended in serum-free medium X-VIVO 20 (Lonza, Levallois-Perret, France) for transduction. In some experiments, cytokines IL-7 (10 ng/μL) (Miltenyi Biotech, Bergisch Gladbach, Germany) was added to the medium overnight prior to transduction. For transduction, LV-Syn1 or LV-Syn2 vectors (1.105 TU/mL), or LV-VSVg (1.108 TU/mL) were added to cells in the presence of VF1 (12 μg/mL). After 6 hours, medium was changed to XVivo20 supplemented with 10% FCS and IL-7 (10 ng/mL) and cells were cultured for up to 7 days. To expand transduced B cells, CD40L (2 μg/mL) and IL-4 (20 ng/mL) was added to the medium and cells were cultured in these conditions for up to 2 weeks. To expand myeloid dendritic cells, hGM-CSF (50 ng/ml) and IL-4 (20 ng/ml) were added to medium.
- EBV Immortalization
- PBMC were cultured overnight with IL-7, then infected with vectors. After 6 hours, the cells were washed and cultured in the presence of B95.8 marmoset cell supernatant with cyclosporin using standard procedures for EBV immortalization. Medium was changed twice weekly.
- Transduction of a SCID-X1 Patient Cells
- PBMC of SCID-X1 patient treated by gene therapy were rapidly thawed at 37° C. and then washed twice with PBS. After trypan blue counting the cells are labeled with 2 μM CFSE (Molecular Probes, Cambridge, UK), transduced with Lv-Syn1 IL2rg vector and cultured (3.105/200 μL) in 96-well round bottomed plates in the absence or presence of CD40Ligand [2 μg/mL] (Miltenyi Biotec) and IL-21 [50 ng/mL] (Miltenyi Biotec). After 3, 6 and 7 days culture, B cell transduction (ie, NGFR or IL2Rg expression), B cell proliferation (ie, CFSE dilution) and the frequency of CD19+ CD27+ cells were determined by flow cytometry. Human IgG secretion in medium was determined by ELISA (Sigma-Aldrich, St Louis, Mo.).
- In Vitro B Cells Activation
- PBMCs were labeled with 2 μM CFSE (Molecular Probes, Cambridge, UK) and cultured (3.105/200 μL) in 96-well round bottomed plates in the absence or presence of CD40Ligand [2 μg/mL] (Miltenyi Biotec) and IL-21 [50 ng/mL] (Miltenyi Biotec). After 3, 6 and 7 days culture, B cell transduction (ie, NGFR or IL2Rg expression), B cell proliferation (ie, CFSE dilution) and the frequency of CD19+ CD27++ plasmablasts were determined by flow cytometry. Human IgG secretion was determined by ELISA (Sigma-Aldrich, St Louis, Mo.).
- Flow Cytometry
- Antibodies used for flow cytometry were purchased from BD-Biosciences (Le Pont de Claix, France) and include PE conjugated anti-CD3 and anti-CD1a, Alexa-
Fluor 700 conjugated anti-CD19, APC-H7 conjugated anti-CD45 and anti-IgD, CF594 conjugated anti-IgM, PeCy7 conjugated anti-CD27 and anti-HLA-DR, APC conjugated anti-CD14, V450 conjugated anti-CD11c. Prior to adding antibodies to cells, Fc receptors were blocked by incubating cells with gammaglobulin (1 mg/mL) (Sigma Aldrich) for 15 minutes, at 4° C. Saturating amounts of antibodies were then added for 30 minutes at 4° C. in PBS with 0.1% bovine serum albumin (BSA) (Sigma Aldrich) and cells were washed twice. At the end of the procedure, 7-amino-actinomycin D (0.3 mg/mL) (Sigma-Aldrich) was added to exclude dead cells. For receptor studies, rabbit polyclonal anti-SLC1A5 (ASCT2) (Abcam, Paris, France), anti-MFSD2a (Origene, Rockville, Md.) or rabbit immunoglobulin controls (Origene) were used and revealed by Alexa 647-conjugated goat anti-rabbit antibodies (Thermo Fisher Scientific, Waltham, Md.). Acquisitions were performed on a LSRII using Diva software (BD-Biosciences) and analyses were carried out with Kaluza software (Beckman-Coulter, Villepinte, France). - The detection of human IL2Rg was performed using PE conjugated anti-human CD132 antibody (BD bioscience).
- Measure of ASCT2 and MFSD2A Expression by RT-qPCR
- Total RNA was extracted from purified cells using SV total RNA isolation (Promega, Charbonniére les bains, France). Residual DNA was removed from the samples using the free DNA kit (Ambion, Courtaboeuf, France). cDNA was synthesized from 1 μg of RNA using random hexamers according to the protocol Superscript II first strand synthesis system for reverse transcription-PCR (Invitrogen). Real time PCR was performed using LightCycler 480 system (Roche, Bâle, Switzerland) with 0.1 μM of each primer according to the protocol Sybr Green PCR Master Mix (Applied Biosystem, Foster city, Calif., USA). The primer pairs used for amplification of either ASCT2 or MFSD2A were described previously (Cornelis et al, PNAS, 2008 and Toufailly et al, placenta, 2013). Sequences of ASCT2 primers are (sense, 5′-GGCTTGGTAGTGTTTGCCAT-3′; antisense, 5′-GGGCAAAGAGTAAACCCACA-3′) and MFSD2A primers are (sense, 5′-CTCCTGGCCATCATGCTCTC-3′; antisense, 5′-GGCCACCAAGATGAGAAA-3′). We also used TFIID (Transcription Final II D) primers as normalization. TFIID primers sequences are (sense, 5′-ACGGACAACTGCGTTGATTTT-3′; antisens, 5′-ACTTAGCTGGGAAGCCCAAC-3′). Results are expressed in fold change using the formula: relative abundance=2{circumflex over ( )}−ΔΔCt with ΔCt=Ct ASCT2 or MFSD2A−Ct TFIID and ΔΔCt=ΔCtsample−ΔCtcalibrator.
- In Vivo Transduction with LV-Syn1 Vector
- 7 week-old female NSG mice (Nod/Scid/gc−/−) purchased from Charles River were injected in the retro-orbital sinus with 107 PBMC in 100 μL volume. After 24 hours, the mice were injected intravenously in the tail vein with 150 μL of undiluted LV-Syn1 vector. After 7 days, mice were sacrificed and spleens were collected, lysed with ACK and the red blood cell-depleted fraction was analyzed by FACS
- Ex Vivo Transduction of Murine Cells with the LV-Syn1 or LV-Syn2 Vectors
- Spleen cells were obtained from 6 week-old female C57Bl/6 mice following red blood cell lysis with ACK. The cells were cultured in RPMI supplemented with 10% FCS and bet2 mercaptoethanol at the concentration of 106 cells/mL in 100 μL in the presence of LV-SYn1 or LV-Syn2 encoding ΔNGFR at 1 or 5×105 TU/mL and VF1 (12 μg/mL). After 3 days, expression of ΔNGFR was measured by FACS on live cells.
- Statistical Analysis
- Statistical significance was assessed by one-way ANOVA analysis, Mann-Whitney or Student's t test, as specified, using GraphPad Prism software (GraphPad Inc, La Jolla, Calif.).
- Results
- Syncytin-1 and Syncytin-2 Pseudotyped LVs can be Produced as Stable and Infectious Particles
- Two human endogenous retroviral envelope glycoproteins, syncytin-1 and syncytin-2, were explored as possible new pseudotypes for recombinant HIV-1-derived LV. The full-length cDNAs of these glycoproteins were expressed in a transient LV production system in 293T cells. An optimization of the amount of syncytin-1 and syncytin-2 plasmids for the transfection step increased the production of LV particles based on p24 levels in medium (Supplementary Figure S1A). In the conditions defined (see Materials and Methods), it was possible to produce stable and infectious particles pseudotyped with either of these envelopes. Using different transgenes (GFP and dNGFR), harvested raw stocks of LV-Syn-1 titered on average 705 ng p24/mL (n=7 productions) and LV-Syn-2 titered on average 496 ng p24/mL (n=4 productions) (Table 1). Lentiviral particles pseudotyped with either of these envelopes could be successfully concentrated by ultracentrifugation using the same conditions as used for VSVg-pseudotyped particles (Charrier et al, 2011). The concentrated stocks were cryopreserved at −80° C. and were stable for several months. Upon thawing of the LV stocks, titers of 4.1±1.7 E+05 ng p24/mL were obtained for LV-Syn1 (n=6 productions) and 1.7±0.6 E+05 ng p24/mL for LV-Syn2 (n=6 productions) and vectors could be produced to code different transgenes (GFP or ΔNGFR) (Table 1).
-
TABLE 1 Titers of syncytin 1- and 2-pseudotyped LVs Titer harvest Titer concentrate Vector Transgene ng p24/mL n ng p24/mL × 105 293T TU/mL × 106 n LV-Syn1 GFP 794 ± 217 5 4.1 ± 1.7 2.8 ± 6.0 6 LV-Syn2 GFP 366 ± 165 4 1.7 ± 0.6 2.7 ± 6.0 6 LV-Syn1 ANGFR 485 ± 64 2 4.5 ± 3.4 6.3 ± 7.5 3 LV-Syn2 ANGFR 671 ± 141 3 6.4 ± 4.2 4.4 ± 1.5 2 Legend: Separate batches of LV with the indicated envelope and transgene (n = number of batches tested) were produced by transient transfection, clarified, sterile-filtered, concentrated or not, cryopreserved, thawed and titered. Concentration was performed by ultracentrifugation (19500 rpm (50000 g) for 2 hours). Physical titers in p24 levels were measured by ELISA and infectious titers were measured as 293T cells transducing units (TU) in the presence of Vectofusin-1 using flow cytometry. - To determine the infectious properties of these particles, the inventors first infected the human
- BeWo choriocarcinoma cell line known to express both the ASCT2 receptor for syncytin-1 and the more restricted MFSD2a receptor for syncytin-2 (Esnault et al, 2008). BeWo cells were not transduced effectively with LV-Syn1 or LV-Syn2 whereas they were well-transduced with VSVg-pseudotyped LV. However, adding cationic agents such as protamine sulfate (PS), polybrene (PB), or Vectofusin-1 (VF1) enhanced the transduction of BeWo cells as shown with LV-Syn2 (
FIG. 1 ). Of these agents, the greatest level of transduction enhancement was obtained with VF1. Vectofusin-1 is a short histidine-rich amphipathic peptide which enhances the infectivity of lentiviral and y-retroviral vectors pseudotyped with various envelope glycoproteins including RD114-TR (Fenard et al, 2015 et Majdoul et al, 2015). The effects of Vectofusin-1 had not been tested before with syncytins, and this short peptide reveals the gene transfer potential of syncytin-pseudotyped LV particles. - In the presence of VF1, it was possible to transduce 293 T cells with either of the syncytins-pseudotyped vectors in a dose-dependent manner and reaching levels comparable to those obtained in BeWo cells (
FIG. 2A ,B). In contrast, only about 1 to 2% of 293T cells were transduced without this additive. The enhancing effects of VF1 were statistically-significant over repeated experiments in 293T cells using LV-Syn1 or LV-Syn2 (FIG. 2C ). The transduction of 293T cells with syncytin-pseudotyped vectors led to a stable genomic integration of the transgene over time as examined in continuous cultures lasting 2 weeks (Supplementary Figure S1B). The level of gene expression was coherent with the number of copies per cell, showing no evidence of transgene silencing over time (FIG. 2D ). - The discovery of the enhancing effects of the VF1 peptide on LV-Syn1 and LV-Syn2 infectivity enabled the development of a robust infectious titration assay using 293T cells. The choice of the 293T cell line was prompted by failure to transduce HCT116 colon carcinoma cells which are routinely used to titer VSVg-pseudotyped LV in the laboratory. HCT116 could not be transduced with LV-Syn1 or LV-Syn2 at any concentration tested and even in the presence of Vectofusin-1 (Supplementary Figure S1C). In addition, 293 T cells were preferred over BeWo cells for this infectious titer assay because of more consistent growth patterns and a trend to higher transduction levels in repeat experiments (Supplementary Figure S1C). In the conditions defined for the assay (see Materials and Methods), the infectious titer of concentrated and cryopreserved batches of GFP-encoding LV-Syn1 and LV-Syn2 were respectively 2.8±6×E+06 TU/mL (n=6 batches) and 2.7±6×E+06 TU/mL (n=6 batches) for GFP transgene and 6.3±7.5×E+06 TU/mL (n=3 batches) and 4.4±1.5×E+06 TU/mL (n=2 batches) for dNGFR transgene (Table 1). Thus syncytin-1 and syncytin-2 glycoproteins can pseudotype rHIV vectors to obtain stable particles that are infectious and useful for stable gene transfer. Their infectivity requires co-factors and is selective at the cellular level.
- LV-Syn1 and LV-Syn2 Vectors Efficiently Transduce Naive Blood Cells
- Syncytins are cellular proteins, which may be useful to derive immunologically-tolerated vectors for in vivo applications. Thus, to evaluate if syncytin-pseudotyped vectors would interact with blood cells, the inventors added the vectors to peripheral blood mononuclear cell (PBMC) in vitro. PBMCs were infected either immediately after their in vitro isolation, or following an overnight culture in the presence of IL-7 aiming at maintaining the viability of naive lymphocytes (Supplementary Figure S2A). After the infection step, cells were cultured in the presence of IL-7 to support cell viability for at least 3 days. Globally, transgene expression was low on the total nucleated cell population expressing CD45 (Supplementary Table S1). However, significantly higher amounts of cells were transduced in the presence of VF1 compared to mock controls without vector (Supplementary Table S1). The effects of LV-Syn1 were comparable to those of VSVg. Cells that had been preactivated with IL-7 were better transduced than cells infected immediately upon isolation.
-
SUPPLEMENTARY TABLE S1 Transduction of whole PBMC with LV-Syn1 and LV-Syn2 in the presence of Vectofusin-1 No vector LV-Syn1 LV-Syn2 LV-VSVg VF1 − + − + − + − + Prior activation with IL-7 Average ± SD 0.1 ± 0.1 0.3 ± 0.2 1.0 ± 0.1 12.7 ± 14.6& 1.7 ± 1 4.5 ± 2.7& 5.9 ± 7.8& 5.4 ± 1& n 9 7 3 9 3 7 9 6 Non-activated PBMC Average ± SD 0.2 ± 0.2 0.7 ± 0.7 2.7 ± 3.3 5.7 ± 6.7& 1.4 ± 1.6 0.8 ± 0.5 4.0 ± 2.0& 6.0 ± 2.5& n 6 6 2 6 2 6 6 6 Legend: Average percentage ± SD of total nucleated cells (CD45+) expressing GFP, 3 days after infection of PBMC. The cells were preactivated with IL-7 or not as indicated, and were transduced with indicated LV in the presence or absence of Vectofusin-1 (VF1) additive. PBMC were obtained from different donors and the number of donors (n) tested is indicated. &p < 0.05 compared to “no vector” in a paired Student's t test - PBMC contain multiple subsets of cells in different proportion. As shown in
FIG. 3 and Table 2, transgene expression was found in a large proportion of CD19+ B lymphocytes and CD11c+ myeloid/dendritic cells (which are a minority in PBMC) whereas only a fraction of CD3+ T cells (which are more abundant in PBMC) were marked in agreement with the overall low results of transduction obtained in CD45+ cells. An average of 59% each of CD19+ cells or of CD11c+ cells were transduced by LV-Syn1 following a pre-activation with IL-7 (Table 2). As observed with 293T and BeWo cells, adding VF1 was necessary to achieve PBMC transduction as few cells were transduced in the absence of this additive. The VF1 peptide also enhanced the transduction of PBMC by LV-VSVg. -
TABLE 2 Transduction of human peripheral blood cell subsets with the syncytin-pseudotyped LV CD19+ CD3+ CD11c+ B cells T cells myeloid cells no activation PBS 0.0 ± 0 0.1 ± 0.1 0.2 ± 0.3 LV-Syn1 2.3 ± 4.3 1.3 ± 2.6 5.5 ± 6.3 LV-Syn2 0.6 ± 0.4 0.4 ± 1.0 0.2 ± 8.2 LV-VSVg 3.6 ± 5.0 2.8 ± 2.9 11.5 ± 3.5 VF1 3.3 ± 4.0 0.24 ± 0.2 7.8 ± 8.4 LV-Syn1 + VF1 35.7 ± 24 3.61 ± 3.6 57.7 ± 11 LV-Syn2 + VF1 22.2 ± 26 1.49 ± 1.9 35.5 ± 34 LV-VSVg + VF1 27.6 ± 17 0.97 ± 0.6 45.2 ± 16 IL-7 activation PBS 0.3 ± 0.4 0.5 ± 0.4 0.8 ± 0.6 LV-Syn1 2.1 ± 2.6 0.8 ± 0.3 4.1 ± 6.0 LV-Syn2 1.8 ± 1.5 1.5 ± 1.0 2.2 ± 2.2 LV-VSVg 2.6 ± 1.6 1.3 ± 0.6 2.4 ± 0.8 VF1 0.8 ± 0.5 0.18 ± 0.2 0.25 ± 0.5 LV-Syn1 + VF1 59.3 ± 23 11.2 ± 19 59.2 ± 18 LV-Syn2 + VF1 44.0 ± 24 6.1 ± 10 40.1 ± 15 LV-VSVg + VF1 32.1 ± 18 3.5 ± 1.4 35.1 ± 10 Legend: Human PBMC were transduced with the indicated vectors and with or without Vectofusin-1 (VF1) in steady-state conditions (no activation) or following a short overnight pre-activation with IL-7, the subsequently cultured with IL-7 for 3 days. Transduction results are expressed as the average percentage ± SD of cells positive for GFP in CD3+ (T cells), CD19+ (B cells) or CD11c+ (dendritic myeloid cells) cells in culture, 3 days after infection. Data represent 3 separate experiments without VF1 and 8 to 9 separate experiments in the presence of VF1. - Remarkably, it was possible to transduce non-activated CD19+ cells suggesting that truly naïve cells can be targeted by syncytins. Various subsets of CD19+ B cells have been characterized (Kaminski et al, 2012) including naïve CD19+ CD27− IgD+ cells (50-70% of the population); memory non-switched CD19+ CD27+ IgD+ cells (15-20% of the population); memory switched CD19+ CD27+ IgD− IgM− cells (2-5% of the population); memory switched IgM only CD19+ CD27+ IgD−IgM+ cells (2-5% of the population) and plasmablasts CD19+ CD27hi (1-2% of the population). The FACS gating strategies following infection of PBMC are shown in Supplementary Figure S2B. Overall, both naïve and memory B cell subsets were effectively transduced with the syncytin-pseudotyped vectors regardless of prior activation (
FIG. 3 ). In greater detail, all memory B cell subsets were found to be transduced in the absence of prior activation (Table 3). In such non-activated conditions, syncytin-pseudotyped vectors transduced B cells more effectively than LV-VSVg suggesting a specific tropism of the syncytins for these cells. The B cell transducing effects of LV-Syn1 and LV-Syn2 were found to be vector concentration dependent (FIG. 4 ) and transgene independent. Almost all peripheral blood CD19+ cells could be transduced using 106 TU/mL of LV-Syn1 or LV-Syn2 vectors encoding either GFP or ΔNGFR thereby providing a very effective system to express various types of heterologous proteins in these cells. -
TABLE 3 Percentage of transduction of B cells subsets Memory Memory Memory Naive non-switch IgM only switched Plasmablasts PBS 0.2 ± 0.3 0.0 ± 0 0.3 ± 0.5 0.5 ± 1 0.3 ± 0.6 VF1 0.6 ± 0.5 1 ± 0.1 0 ± 0 0.3 ± 0.5 0.3 ± 0.6 LV-Syn1 0.4 ± 1.1 1 ± 0.9 0.2 ± 0.3 0 ± 0 0.3 ± 0.6 LV-Syn1 + VF1 62 ± 26 23 ± 3.3 16 ± 13 41 ± 11 32 ± 13 LV- Syn2 1 ± 0.1 4 ± 5.2 5 ± 6 4 ± 5.3 1.00 ± 1.4 LV-Syn2 + VF1 52 ± 29 29 ± 15 27 ± 34 26 ± 30 29 ± 8.5 LV-VSVg 0.1 ± 0.1 9 ± 8.4 4 ± 4 10 ± 16 2 ± 1.1 LV-VSVg + VF1 14 ± 14 18 ± 16 12 ± 11 20 ± 11 nd Legend: Human PBMC were transduced in steady-state conditions with LV-Syn1 or LV-Syn2 (1E105 TU/mL) or LV-VSVg (1E107 TU/mL). Results are the average percentage ± SD of cells positive for GFP in the indicated populations defined as naive B cells (CD3−, CD19+, CD27−, IgM+, IgD+ cells); memory non-switch B cells (CD3−, CD19+, CD27+, IgM+, IgD+ cells); memory IgM only B cells (CD3−, CD19+, CD27+, IgM+, IgD− cells); memory switched B cells (CD3−, CD19+, CD27+, IgM−, IgD−) and plasmablasts (CD3−, CD19+, CD27high), 3 days after infection. Data represent 2 to 3 separate experiments with 1 to 2 different donor per experiment. nd = not determined because too few cells to analyze in the gate. - Functional B Cells are Stably Transduced with Syncytin-Pseudotyped Vectors
- To exclude that the observed effects were non-specific, caused by pseudo-transduction or by artefactual auto-fluorescence of Vectofusin-1 which can occur upon aggregation (Fenard et al 2013) the inventor verified proviral integration in cells treated with the vector and cultured over time. Following addition of the vector to the cells, the inventors added CD40L and IL-4 to activate and expand the culture for 8-14 days. In such cultures, the inventors detected vector copies specifically when vectors were added together with Vectofusin-1 (Table 4) even though conditions were not optimal to ensure the survival of all cells. In addition, using B cell-activation signals such as CD40 ligand (CD40L) and IL-21 previously reported to be essential for the development of memory B cells (Recher et al 2011), the inventors confirmed that transduced B cells could be activated efficiently (Table 5). Using CFSE marking and flow cytometry to detect B cell division and transgene expression, the inventors confirmed the marking of cells capable of responding to CD40L and IL-21 and with activated B cell, including plasmablast, phenotype (Table 5). To further confirm the transduction of functional B cells, the inventors used EBV to transform PBMC immediately after they had been infected with the LV-Syn1 vector and obtained lymphoblastic cells containing stably integrated vector sequences (Table 4). These results confirm that the syncytin vectors can stably transduce primary B cells that retain functional ability to proliferate and be expanded.
-
TABLE 4 Functional B cells are stably transduced by syncytin-pseudotyped LV VCN Experiment 1 Experiment 2CD40L + IL-4 (Day 13) (Day 7) PBMC 0.0 0.0 PBMC + VF1 0.0 0.0 PBMC + LV-Syn1 + VF1 3.8 0.4 PBMC + LV-Syn2 + VF1 0.3 0.0 PBMC + LV-VSVg 0.2 0.1 PBMC + LV-VSVg + VF1 0.2 0.0 VCN Experiment 1 Experiment 2EBV (Day 14) (Day 14) PBMC 0 0; 0; 0 PBMC + VF1 0 not done PBMC + LV-Syn1 + VF1 0.5 0.02; 0.06; 0.2 PBMC + LV-Syn2 + VF1 not done 0.02; 0.02; 0.2 PBMC + LV-VSVg 0.05 not done Legend: PBMC were activated with IL-7 and transduced in the indicated conditions, then cultured for 6-13 days in the presence of CD40L and IL4 (top table) or incubated with EBV and cyclosporin A for immortalization using standard procedures and cultured for 2 weeks (bottom table). At the indicated times, genomic DNA was extracted from the culture and the average number of integrated vector copy per cell (VCN) was measured by qPCR. In experiment 2 of EBV transformation, results are shown with 3 different blood donors. -
TABLE 5 In vitro activation of transduced primary CD19+ B cells Day 3 Day 6IL-21 IL-21 + CD40L IL-21 IL-21 + CD40L LV- LV- LV- LV- LV- LV- LV- LV- Syn1 Syn2 Syn1 Syn2 Syn1 Syn2 Syn1 Syn2 % NGFR+ 37.2 ± 5.3 60.2 ± 8 26.8 ± 9.4 45.8 ± 11.5 39.8 ± 9.4 45.3 ± 6.9 17.3 ± 2.7 23.3 ± 6.8 B cells % NGFR+ 25.2 ± 15.7 16.7 ± 6 77.5 ± 16.4 82.3 ± 10 28.8 ± 12.8 28.7 ± 14.1 93.2 ± 3.4 93.5 ± 4 B cells in CFSE division % NGFR− 35.3 ± 16.7 34.2 ± 17 85.8 ± 7.4 91.0 ± 4.4 40.5 ± 18.9 31.7 ± 8.6 94.8 ± 1.2 95.2 ± 1.5 B cells in CFSE division % plasmablast 4.4 ± 1.8 5.7 ± 2.7 13.6 ± 4.8 14.1 ± 5.2 17.8 ± 13.1 18.2 ± 11.2 29.8 ± 13.1 28.9 ± 12.2 on NGFR+ B cells % plasmablast 4.7 ± 1.2 6.0 ± 3.0 15.8 ± 5.7 14.5 ± 5.6 20.8 ± 14.1 16.3 ± 12 32.7 ± 15 30.2 ± 10.9 on NGFR− B cells n = 6 different healthy donors Legend. PBMCs were labeled with 2 μM CFSE, transduced with Lv-Syn1-2 NGFR, and cultured in the absence or presence of CD40Ligand [2 μg/mL] and IL-21 [50 ng/mL]. After 3 and 6 days culture, B cell transduction (ie, NGFR expression), B cell proliferation (ie, CFSE dilution) and the frequency of CD19+ CD27++ plasmablasts were determined by flow cytometry. - Transduction of Murine Primary B Cells
- Freshly-isolated murine spleen cells were cultured with LV-Syn1 or LV-SYn2 vectors encoding ΔNGFR for 3 days. As shown in Supplementary Figure S7 this resulted in a very efficient transduction of CD19+ B cells. In these cultures, much fewer CD19− cells were transduced in proportion, thus confirming the particular tropism of the syncytin-pseudotyped vectors for B cells in mice as in humans. The data also show that the syncytin-1 and syncytin-2 glycoproteins recognize murine counterparts and these findings will facilitate future preclinical studies with these vectors.
- Transduction of CD11c+ Cells
- As seen in
FIG. 3 , a large proposition of CD19− CD3− CD11c+ cells was transduced with LV-Syn1 and LV-Syn2 from PBMC without prior activation and in the presence of Vectofusin-1. Further phenotyping showed that such CD11c cells also expressed high levels of HLA-DR and were transduced effectively with the syncytin-pseudotyped vectors (FIG. 5 ). The cells were grown in GM-CSF+IL-4, expressed CD1a, CD80, CD86 and lacked CD14, suggesting that they were immature dendritic cells (Supplementary Figure S3A). In addition, CD14+ HLA-DR+ cells which have the phenotype of monocytic cells are also transduced (Supplementary Figure S3B). Thus, both LV-Syn1 and LV-Syn2 can be used effectively to express a transgene in antigen presenting cells. - LV-Syn1 and LV-Syn2 Vectors do not Efficiently Transduce Primary Human T Cells
- Peripheral blood T cells were not efficiently transduced by the syncytin-pseudotyped LV, although some cells could be transduced upon activation. Following prior activation with IL-7, a small proportion of peripheral blood T cells was transduced with LV-Syn1 or LV-Syn2 vectors but these effects were not consistent from experiment to experiment (
FIG. 3 and Table 2). Without prior activation, transduction levels were always low. - Thus, differential transduction of blood cell subsets is observed with syncytin-pseudotyped vectors.
- Expression of the ASCT2 and MFSD2a Receptors on Blood Cell Subsets and Cell Lines
- ASCT2 and MFSD2a which are respectively the entry receptors for syncytin-1 and syncytin-2 were detected on the cell surface of blood cell subsets using and indirect immunofluorescence detection (
FIG. 6A ). The highest percentage of cells expressing these markers were CD19+ and CD11c+ cells, whereas T cells expressed lower levels of these receptors (FIG. 6B ). These results were confirmed by qRT-PCR, which show for the first time that human B cells express MFSD2a and ASCT2 (FIG. 6 -C). Expression of ASCT2 and MFSD2a was also found on 293T cells whereas it was at a much lower level of HCT116 cells which are not transduced with the vectors (Supplementary Figure S4). On cells tested, the expression of the receptors correlated well with the transduction levels that were achieved. - Human B and T Cell Lines are Transduced with Syncytin-Pseudotyped Vectors
- To extend the results obtained on primary cells and to further assess the cellular specificity of the syncytin-pseudotyped vectors, the inventors attempted to transduce a panel of human cell lines. The Burkitt's lymphoma Raji B cells and Jurkat T cells were tested. Raji B cells could be transduced with the Syncytin-pseudotyped vectors (Supplementary Figure S5). The highest levels obtained in Raji cells using 2×106 TU/mL of LV-Syn2 vector reached 16% (as opposed to >90% reached with 106 TU/mL in primary B cells as seen in
FIG. 4 ). The inventors verified that Raji cells were permissive for transduction with LV because 88% transduction of Raji cells were transduced with 108 TU/mL LV-VSVg (control of Supplementary Figure S5, not shown). In one experiment, transduced Raji cells were sorted by flow cytometry and cultured for 49 days, demonstrating the stable integration of the transgene for prolonged periods of time (Supplementary Table S2). Jurkat T cells were partially transduced with syncytin-pseudotyped vectors (Supplementary Figure S5). Thus syncytin-pseudotyped LV can be used as gene transfer tools for some cell lines. In B cells, transduction appears to be more effective in primary cells than with established B cell lines. -
SUPPLEMENTARY TABLE S2 Stable transduction of Raji cells with Syncytin-pseudotyped vectors % GFP+ cells VCN Sorted GFP− Sorted GFP+ Sorted GFP− Sorted GFP+ Vector cells cells cells cells LV- Syn1 0 72.8 0 1.003 LV- Syn2 0 93.8 0.001 1.017 LV-VSVg 0.3 86.3 0.116 6.177 Legend: Three different GFP-encoding vectors were used at the concentration of 1.2 105 TU/mL to infect Raji cells in the presence of Vectofusin-1 (12 μg/mL). After 2 weeks, the expression of GFP was 2.5% with LV-Syn1, 5% with LV-Syn2, and 100% withLV-VSVg vector. After 30 days, cells expressing GFP (GFP+) or not (GFP−) were sorted by flow cytometry and these sorted cells were cultured until day 49 to measure GFP expression by FACS and the average vector copy number per cell (VCN) by qPCR. - Functional Correction in a Primary Immune Deficit
- Severe combined immunodeficiency type-1 (SCIDX1) is an X-linked primary immunodeficiency which is caused by mutations in the interleukin 2-receptor gamma chain (IL2Rg) gene. Allogeneic bone marrow transplantation can cure the disease but some patients remain incompletely corrected with only partial chimerism in B cells (Recher et al 2011). Patients with less than 5% B cell chimerism remain incapable of maturing and producing immunoglobulins. Their B cells remain incapable of becoming mature memory IgG secreting B cells. Indeed, it was found recently that IL2Rg is also the receptor for IL-21 providing essential signals for the maturation of B cells (Recher et al 2011). Several gene therapy trials have been attempted to treat this disease using IL2Rg gene transfer in hematopoietic stem and progenitor cells. However, without conditioning of the patient, the gene-corrected cells only produce corrected T cells and B cells remain uncorrected as shown in the most recent gene therapy trial (Hacein-Bey-Abina et al 2014). As a result, such patients B cells are non-functional and patients remain dependent upon immunoglobulin infusion to prevent infections. This prompted the inventors to ask if syncytin-pseudotyped vectors could be used to transfer IL2Rg to peripheral B cells in patients who have been incompletely corrected by gene therapy. Cells from a patient were obtained. The patient blood mononuclear cells were found to contain CD3+ IL2Rg+ T cells but contrary to healthy individuals, the patient blood CD19+ B cells did not express the maturation marker CD27, did not express IL2Rg (
FIG. 7A and B) and did not produce IgG (Table 6). Upon gene transfer with LV-syncytin1 vectors encoding the IL2Rg, patients cells were able to respond to CD40L+IL-21 by producing IgG in medium, even though activation markers were not detected on the cells, probably due to the high level of mortality of these fragile cells in culture. These results demonstrate that peripheral blood B cells can be targeted by gene transfer to provide some functional correction in SCIDX1 and that syncytin-pseudotyped LV are useful tools for this application. - In Vivo Experiments
- The efficient transduction of primary human B cells by LV-Syn1 prompted to test if this vector functioned in vivo Immunodeficient NSG mice were first engrafted with 107 PBMC per mouse and the next day received a single bolus of LV-Syn1 intravenously. After 7 days, mice were sacrificed and different tissues were examined In 2 mice out of 3, the inventors found the presence of CD45+ CD19+ human B cells in the spleen in which a small proportion (3-15%) expressed GFP suggesting that they had been transduced in vivo (Supplementary Figure S6). These preliminary results suggest the possibility of using syncytin-pseudotyped vectors to target human B cells in vivo.
- Production of Stable and Infectious LV-SynA Particles
- Materials and Methods (See Also Materials and Methods for Example 1)
- Cloning of Syncytin A and Production of LV-Syn A.
- a. Generation of a Plasmid Expressing Murine Syncytin-A.
- The cloning of the murine syncytin-A cDNA into the HindIII and XbaI sites of the pcDNA3.1 eukaryotic expression plasmid was performed by inserting a PCR-amplified fragment from the pUC-SynA plasmid generated by Genecust (Ellange, Luxembourg) and which contains the Syn-A murine gene full-length cDNA (Ensembl reference ENSMUSG00000085957) using the following primers forward 5′
AGCAAGCTTATGGTTCGTCCTTGG 3′ (SEQ ID NO:32) (Tm=69.8° C.; % GC=50%; Sigma, Saint-Louis, USA) and reverse 5′AGCTCTAGACTAGACGGCATCCTC 3′ (SEQ ID NO:33) (Tm=65° C.; % GC=54%; Sigma) and ligation. The plasmid was verified by sequencing (Beckman Coulter Genomics, Takeley, UK). - b. Production of Syn-A-Pseudotyped Lentiviral Vectors.
- HEK293T cells plated in T175 cm2 flasks in DMEM+10% fetal calf serum (FCS) were co-transfected with the following 4 plasmids (quantities per flask): pKLgagpol (14.6 μg), pKRev (5.6 μg), pcDNA3.1-SynA (20 μg), and transfer plasmid either PRRL-SFFV LucII or pRRL-SFFV-LucII-2A-ΔNGFR-WPRE (22.5 μg). After 24 hours, the cells are washed and fresh fmedium is added. The following day, medium is harvested, clarified by centrifugation 1500 rpm for 5 min and filtered 0.45 μm, then concentrated by ultracentrifugation 50000 g for 2 h at 12° C. and stored at −80° C. until used.
- c. Titration of Syncytin-A-Pseudoptyped LV.
- Physical titer was determined by p24 ELISA as for other types of LV. Infectious titer was determined as infectious genome titer (IG/mL) using the murine lymphoma cell line A20. Serial dilutions of vector are added to A20 cells in the presence of Vectofusin-1® (12 μg/uL) for 6 hours. Medium is renewed and cells are incubated for 7 days and genomic DNA is obtained to measure vector copy number per cells using duplex qPCR on iCycler 7900HT (Applied Biosystems) with the primers: PSI forward 5′CAGGACTCGGCTTGCTGAAG3′ (SEQ ID NO:34),
PSI reverse 5′ TCCCCCGCTTAATACTGACG3′ (SEQ ID NO:35), and a PSI probe labeled with FAM (6-carboxyfluoresceine) 5′CGCACGGCAAGAGGCGAGG3′ (SEQ ID NO:36), Titin forward 5′ AAAACGAGCAGTGACGTGAGC3′ (SEQ ID NO:37), Titin reverse 5′TTCAGTCATGCTGCTAGCGC3′ (SEQ ID NO:38) and a Titin probe labeled withVIC 5′TGCACGGAAGCGTCTCGTCTCAGTC3′ (SEQ ID NO:39). - In Vivo Bioluminescent Gene Transfer in Mice.
- LV-SynA encoding LucII vector was produced and 5×105 TU of vector were injected intravenously into albinos C57Bl/6 mice. Controls included LV-VSVg encoding LucII and PBS. For the detection of bioluminescence, mice were anesthetized with ketamine (100 mg/kg)/xylasine (10 mg/kg), and 100 μL of 150 μg/mL D-luciferin was administered intra-peritoneally and imaged 10 min later with a CCD camera ISO14N4191 (IVIS Lumina, Xenogen, MA, USA). A 3 min bioluminescent image was obtained using 15 cm filed-of-view, binning (resolution)
factor - Results
- Murine Syncytins were explored for in vivo applications. Syncytin A is non-orthologue but functionally similar murine counterpart to human Syncytins-1 and -2 (Dupressoir et al 2005). We cloned the murine SynA into an expression plasmid and used it to produce lentiviral vector particles. We found that SyncytinA can successfully pseudotype rHIV-derived LV. We used the same conditions already defined for the production of human syncytin-pseudotype LV (22 Ug DNA per plate, one harvest only) to generate stable LV-SynA. LV-Syn A were very efficient at transducing the murine A20 B lymphoma cell line in the presence of VF1 (Figure S8) (Supplementary table S4). We found that SynA was as efficient as its human counterparts to transduce primary non-activated murine B cells in vitro. As seen in
FIG. 8 andFIG. 9 LV-SynA were capable of transducing without pre-treatment murine B cells from spleen (FIG. 8 ) and from bone marrow (FIG. 9 ). These experiments also show that murine T cells can be transduced as well. The transduction of B220 low cells suggests that immature B cells were transduced and can be targeted for biological applications. - Interestingly, it was possible to transduce human CD19+ B cells with LV pseudotyped with the murine syncytin A (supplementary table S5)
- LV-Syn A proved to be efficient for gene delivery in vivo in mice.
FIG. 10 shows the bioluminescent detection of thetransgene 16 days after injection of a LV-SynA vector encoding LucII. The vector was injected through the mice tail vein and the inventors did not use vectofusin for this. The presence of vector in the spleen CD45+ CD19+ cells was confirmed by purifying spleen cells by flow cytometry cell sorting and measuring the levels of transduction by q-PCR (supplementary table S3). Thus, Syncytins are unique tools to mediate entry into human and murine B cells in vitro and in vivo. -
SUPPLEMENTARY TABLE S3 In vivo delivery of the LucII transgene with LV-SynA. Vector copy number Whole spleen Spleen CD45 cells Spleen CD45+ 19+ cells 0.039 0.002 0.039 Legend: the table shows the vector copy number obtained on cell subpopulations obtained by flowcytometry cell sorting of spleen cells using CD45 and CD19 antibodies. CD45− cells represent stromal cells of non-hematopoietic origin. CD45+ CD19+ cells are B cells. -
SUPPLEMENTARY TABLE S4 Infectious titration of Lv-SynA on the murine B lymphoma cell line A20. Titer ng Titer Titer n P24/mL TU/mL GI/ mL SynA 10 1.74 · 105 7.1 · 106 1.3 · 106 10 2.3 · 105 1.98 · 107 4.72 · 106 LV- VSVg 1 5.23 · 105 2.1 · 107 — Legend: different LV-SynA and LV-VSVg productions and titers obtained in physical particles (ng p24/mL) and infectious particles (TU/mL and GI/ML). TU: transduction unit, GI: infectious genome. -
SUPPLEMENTARY TABLE S5 Transduction of human CD19+ B cells with syncytin-A-pseudotyped LV. CD19+ B ells Conditions nb copies donor 1Non transduced 0.04 LV-SA LucII 9.4 LV-S1 NGFR 3.6 donor 2Non transduced 0.1 LV-SA LucII 1.9 LV-S1 NGFR 1.1 donor 3Non transduced 0.05 LV-SA LucII 3.7 LV-S1 NGFR 2.0 Legend: Human peripheral blood CD19+ B cells were obtained from 3 separate blood donors, and were prepared by Ficoll separation of the mononuclear cells followed by positive selection of CD19+ B cells using magnetic beads and the Miltenyi AutoMacs system. CD19+ cells were incubated in the indicated conditions, using various preparations of LV pseudotyped with syncytin A, or syncytin 1 and expressing different transgenes. We used 2 μL of concentrated vector on the cells in the presence of Vectofusin-1 (12 μg/mL). Cells were washed after 6 hours and cultured for 4 days before measuring the number of integrated vector copies per cell using a duplex qPCR as described in (Merten et al. 2011). - Physical titers were determined by 2 different methods for HIV-1-derived lentiviral vectors (LV) pseudotyped with syncytin-1 (S1), syncytin-2 (S2), syncytin A (SA) or with VSVg, and encoding either the truncated form of the nerve growth factor receptor (ΔNGFR) or the green fluorescent protein (GFP). The LV were produced by transient transfection, concentrated by ultracentrifugation and cryopreserved a −80° C. before titration.
- The methods consisted either of (a) an ELISA measuring the p24 concentration in the sample followed by a calculation of the titer as physical particles (pp) assuming that 1 fg of p24 corresponds to 12 pp of LV (Farson et al, 2001) or (b) using the NS300 Nanosight particle counter from Malvern Instruments (UK) which directly measures the particle concentration in the sample using automated microscopy.
-
SUPPLEMENTARY TABLE S6 Titer pp/mL Titer pp/mL Vectors ELISA P24 Nanosight LV-S1-DNGFR 9.6 · 1012 7.1 · 1011 LV-S2- DNGFR 6 · 1012 1.4 · 1012 LV-SA Luc2-2A-DNGFR 2.8 · 1012 9.9 · 1011 LV-SA-DNGFR 2.4 · 1012 7.7 · 1011 LV-S2-DNGFR 9.4 1011 5 × 1011 LV-S1-DNGFR 1.6 × 1011 1.8 × 1011 LV-SA-Luc2 4.4 × 1011 3.1 × 1011 LV-VSVg-DNGFR 1.6 · 1012 8.9 · 1011 On average, a conversion factor between the titer pp/mL (ELISA P24) and the titer pp/mL (Nanosight) obtained as a [(mean titer ELISA P24)/(mean titer Nanosight)] is about 3.7, i.e. about 4. - An D S, Xie Y, Chen I S (2001). Envelope gene of the human endogenous retrovirus HERV-W encodes a functional retrovirus envelope. Journal of virology 75: 3488-3489.
- Antony J M, Ellestad K K, Hammond R, Imaizumi K, Mallet F, Warren K G et al (2007). The human endogenous retrovirus envelope glycoprotein, syncytin-1, regulates neuroinflammation and its receptor expression in multiple sclerosis: a role for endoplasmic reticulum chaperones in astrocytes. Journal of immunology 179: 1210-1224.
- Biffi A (2015). Gene therapy for lysosomal storage disorders: a good start. Human molecular genetics.
- Blaise S, de Parseval N, Benit L, Heidmann T (2003). Genomewide screening for fusogenic human endogenous retrovirus envelopes identifies
syncytin 2, a gene conserved on primate evolution. Proceedings of the National Academy of Sciences of the United States of America 100: 13013-13018. - Blaise S, Ruggieri A, Dewannieux M, Cosset F L, Heidmann T (2004). Identification of an envelope protein from the FRD family of human endogenous retroviruses (HERV-FRD) conferring infectivity and functional conservation among simians. Journal of virology 78: 1050-1054.
- Blaise S, de Parseval N, Heidmann T (2005). Functional characterization of two newly identified Human Endogenous Retrovirus coding envelope genes. Retrovirology 2: 19.
- Blond J L, Lavillette D, Cheynet V, Bouton O, Oriol G, Chapel-Fernandes S et al (2000). An envelope glycoprotein of the human endogenous retrovirus HERV-W is expressed in the human placenta and fuses cells expressing the type D mammalian retrovirus receptor. Journal of virology 74: 3321-3329.
- Charrier S, Ferrand M, Zerbato M, Precigout G, Viornery A, Bucher-Laurent S et al (2011). Quantification of lentiviral vector copy numbers in individual hematopoietic colony-forming cells shows vector dose-dependent effects on the frequency and level of transduction. Gene therapy 18: 479-487.
- Cheynet V, Ruggieri A, Oriol G, Blond J L, Boson B, Vachot L et al (2005). Synthesis, assembly, and processing of the Env ERVWEl/syncytin human endogenous retroviral envelope. Journal of virology 79: 5585-5593.
- Cire S, Da Rocha S, Yao R, Fisson S, Buchholz C J, Collins M K et al (2014) Immunization of mice with lentiviral vectors targeted to MHC class II+ cells is due to preferential transduction of dendritic cells in vivo. PloS one 9: e101644.
- Cornelis G, Heidmann O, Degrelle S A, Vernochet C, Lavialle C, Letzelter C, et al (2013). Captured retroviral envelope syncytin gene associated with the unique placental structure of higher ruminants PNAS 110(9): E828-E837.
- Dewannieux M, Blaise S, Heidmann T (2005). Identification of a functional envelope protein from the HERV-K family of human endogenous retroviruses. Journal of virology 79: 15573-15577.
- Dewannieux M, Heidmann T (2013). Endogenous retroviruses: acquisition, amplification and taming of genome invaders. Current opinion in virology 3: 646-656.
- Dupressoir A, Marceau G, Vernochet C, Benit L, Kanellopoulos C, Sapin V et al (2005). Syncytin-A and syncytin-B, two fusogenic placenta-specific murine envelope genes of retroviral origin conserved in Muridae. Proceedings of the National Academy of Sciences of the United States of America 102: 725-730.
- Esnault C, Priet S, Ribet D, Vernochet C, Bruls T, Lavialle C et al (2008). A placenta-specific receptor for the fusogenic, endogenous retrovirus-derived, human syncytin-2. Proceedings of the National Academy of Sciences of the United States of America 105: 17532-17537.
- Farson D, Witt R, McGuinness R, Dull T, Kelly M, Song et al (2001) A new-generation stable inducible packaging cell line for lentiviral vectors. Hum Gene Ther. 20;12(8):981-97.
- Fenard D, Ingrao D, Seye A, Buisset J, Genries S, Martin S et al (2013). Vectofusin-1, a new viral entry enhancer, strongly promotes lentiviral transduction of human hematopoietic stem cells. Molecular therapy Nucleic acids 2: e90.
- Fischer A, Hacein-Bey Abina S, Touzot F, Cavazzana M (2015). Gene therapy for primary immunodeficiencies. Clinical genetics 88: 507-515.
- Frecha C, Costa C, Levy C, Negre D, Russell S J, Maisner A et al (2009). Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. Blood 114: 3173-3180.
- Frese S, Ruebner M, Suhr F, Konou T M, Tappe K A, Toigo M et al (2015). Long-Term Endurance Exercise in Humans Stimulates Cell Fusion of Myoblasts along with Fusogenic Endogenous Retroviral Genes In Vivo. PloS one 10: e0132099.
- Funke S, Maisner A, Muhlebach M D, Koehl U, Grez M, Cattaneo R et al (2008). Targeted cell entry of lentiviral vectors. Molecular therapy: the journal of the American Society of Gene Therapy 16: 1427-1436.
- Ghosh S, Thrasher A J, Gaspar H B (2015). Gene therapy for monogenic disorders of the bone marrow. British journal of haematology.
- Girard-Gagnepain A, Amirache F, Costa C, Levy C, Frecha C, Fusil F et al (2014). Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs. Blood 124: 1221-1231.
- Hacein-Bey-Abina S, Pai S Y, Gaspar H B, Armant M, Berry C C, Blanche S et al (2014). A modified gamma-retrovirus vector for X-linked severe combined immunodeficiency. The New England journal of medicine 371: 1407-1417.
- Hacein-Bey Abina S, Gaspar H B, Blondeau J, Caccavelli L, Charrier S, Buckland K et al (2015). Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. Jama 313: 1550-1563.
- Hummel J, Kammerer U, Muller N, Avota E, Schneider-Schaulies S (2015). Human endogenous retrovirus envelope proteins target dendritic cells to suppress T-cell activation. European journal of immunology 45: 1748-1759.
- Imakawa K, Nakagawa S, Miyazawa T (2015). Baton pass hypothesis: successive incorporation of unconserved endogenous retroviral genes for placentation during mammalian evolution. Genes to cells: devoted to molecular & cellular mechanisms 20: 771-788.
- Ingrao D, Majdoul S, Seye A K, Galy A, Fenard D (2014). Concurrent measures of fusion and transduction efficiency of primary CD34+ cells with human immunodeficiency virus 1-based lentiviral vectors reveal different effects of transduction enhancers. Human gene therapy methods 25: 48-56.
- Kaminski D A, Wei C, Qian Y, Rosenberg A F, Sanz I (2012). Advances in human B cell phenotypic profiling. Frontiers in immunology 3: 302.
- Kichler A, Mason A J, Marquette A, Bechinger B (2013). Histidine-rich cationic amphipathic peptides for plasmid DNA and siRNA delivery. Methods in molecular biology 948: 85-103.
- Kneissl S, Zhou Q, Schwenkert M, Cosset F L, Verhoeyen E, Buchholz C J (2013). CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes. PloS one 8: e79047.
- Kutner R H, Zhang X Y, Reiser J (2009). Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nature protocols 4: 495-505.
- Lavillette D, Marin M, Ruggieri A, Mallet F, Cosset F L, Kabat D (2002). The envelope glycoprotein of human endogenous retrovirus type W uses a divergent family of amino acid transporters/cell surface receptors. Journal of virology 76: 6442-6452.
- Majdoul S, Seye A K, Kichler A, Holic N, Galy A, Bechinger B et al (2015). Molecular determinants of Vectofusin-1 and its derivatives for the enhancement of lentiviral-mediated gene transfer into hematopoietic stem/progenitor cells. The Journal of biological chemistry.
- Malassine A, Blaise S, Handschuh K, Lalucque H, Dupressoir A, Evain-Brion D et al (2007). Expression of the fusogenic HERV-FRD Env glycoprotein (syncytin 2) in human placenta is restricted to villous cytotrophoblastic cells. Placenta 28: 185-191.
- Mangeney M, Renard M, Schlecht-Louf G, Bouallaga I, Heidmann O, Letzelter C et al (2007). Placental syncytins: Genetic disjunction between the fusogenic and immunosuppressive activity of retroviral envelope proteins. Proceedings of the National Academy of Sciences of the United States of America 104: 20534-20539.
- Merten O W, Charrier S, Laroudie N, Fauchille S, Dugue C, Jenny C et al (2011). Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Human gene therapy 22: 343-356.
- Nguyen L N, Ma D, Shui G, Wong P, Cazenave-Gassiot A, Zhang X et al (2014). Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature 509: 503-506.
- Oburoglu L, Tardito S, Fritz V, de Barros S C, Merida P, Craveiro M et al (2014). Glucose and glutamine metabolism regulate human hematopoietic stem cell lineage specification. Cell stem cell 15: 169-184.
- Pochini L, Scalise M, Galluccio M, Indiveri C (2014). Membrane transporters for the special amino acid glutamine structure/function relationships and relevance to human health. Frontiers in chemistry 2: 61.
- Porter C D, Collins M K, Tailor C S, Parkar M H, Cosset F L, Weiss R A et al (1996). Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors. Human gene therapy 7: 913-919.
- Porter D L, Hwang W T, Frey N V, Lacey S F, Shaw P A, Loren A W et al (2015). Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science translational medicine 7: 303ra139.
- Recher M, Berglund U, Avery D T, Cowan M J, Gennery A R, Smart J et al (2011). IL-21 is the primary common gamma chain-binding cytokine required for human B-cell differentiation in vivo. Blood 118: 6824-6835.
- Renard M, Varela P F, Letzelter C, Duquerroy S, Rey F A, Heidmann T (2005). Crystal structure of a pivotal domain of human syncytin-2, a 40 million years old endogenous retrovirus fusogenic envelope gene captured by primates. Journal of molecular biology 352: 1029-1034.
- Tolosa J M, Schjenken J E, Clifton V L, Vargas A, Barbeau B, Lowry P et al (2012). The endogenous retroviral envelope protein syncytin-1 inhibits LPS/PHA-stimulated cytokine responses in human blood and is sorted into placental exosomes. Placenta 33: 933-941.
Claims (15)
1. Stable lentiviral particles pseudotyped with an endogenous retroviral syncytin (ERV syncytin) and packaging a heterologous gene of interest, presenting a high physical and/or infectious titer(s).
2. A method for obtaining the stable pseudotyped lentiviral particles of claim 1 , comprising the following steps:
a) transfecting at least one plasmid in appropriate cell lines, wherein said at least one plasmid comprises the gene of interest, the retroviral rev, gag and pol genes, and a sequence coding for an ERV syncytin;
b) incubating the transfected cells obtained in a), so that they produce the stable lentiviral particles pseudotyped with an ERV syncytin, respectively, and packaging the heterologous gene of interest; and
c) harvesting and concentrating the stable lentiviral particles obtained in b), preferably wherein the concentration of step c) comprises centrifugating and/or purifying the harvested stable lentiviral particles obtained in b).
3. The method according to claim 2 , wherein the retroviral rev, gag and pol genes are lentiviral rev, gag and pol genes; preferably HIV-1 rev, gag and pol genes.
4. Particles obtained by the process of any one of claim 2 or 3 .
5. Particles according to claim 1 or 4 , or the method according to any one of claims 2 to 4 , wherein the ERV syncytin is selected from the group consisting of HERV-W, HERV-FRD, murine syncytin-A, murine syncytin-B, syncytin-Ory1, syncytin-Car1 and syncytin-Rum1, preferably the ERV syncytin is selected from the group consisting of HERV-W, HERV-FRD and murine syncytin-A and even more preferably the ERV syncytin is HERV-W or HERV-FRD.
6. Particles according to claim 1 or 5 , or the method according to any one of claims 2 to 4 , wherein the high infectious titer is a titer of infectious particles produced at the end of step c), higher than 2 E+04 TU/ml, preferably higher than 1 E+05 TU/ml, preferably higher than 1 E+06 TU/ml, preferably higher 5 than 2 E+06 TU/ml, and/or wherein the high physical titer is a titer of particles produced at the end of step c) higher than 0.7×105 ng p24/mL, notably higher than 1×105 ng p24/mL, preferably higher than 1.1×105 ng p24/mL, more preferably higher than 1.5×105 ng p24/mL.
7. Particles according to any one of claim 1 , 5 or 6 , for use as a medicament, preferably for use in gene therapy or immunotherapy or as a vaccine or in immunoprophylaxis.
8. In vitro use of the particles according to any one of claim 1 , 5 or 6 , for the transduction of immune cells, preferably B cells or myeloid cells.
9. In vitro use of the particles according to any one of claim 1 , 5 , 6 or 8 , for biotechnology engineering, preferably for producing immunoglobulins.
10. Particles according to any one of claims 1 or 5 to 7 , for use for therapy by transducing immune cells, preferably for use for treating immune deficiencies, auto-immunities, infectious diseases or B cell-related cancers.
11. A sample of immune cells infected with the particles according to any one of claim 1 , 5 or 6 , for use as a medicament, or for a diagnosis purpose.
12. An ex vivo process for obtaining immune cells modified to express a heterologous gene of interest, comprising a step of infecting immune cells, preferably naïve immune cells optionally previously stimulated, with the particles according to any one of claim 1 , 5 or 6 .
13. The ex vivo process of claim 12 , wherein it is performed in the presence of a LAH4 peptide or a functional derivative thereof, preferably the LAH4-A4 vectofusin-1, and/or wherein the immune cells are chosen from B cells, T cells, dendritic cells, monocytes and macrophages, preferably are B cells.
14. The ex vivo process of any one of claim 12 or 13 , wherein it comprises the following steps:
optionally stimulating naïve immune cells by incubating them in a medium comprising IL-7, and
infecting the naïve immune cells, stimulated or not, with said particles according to any one of claim 1 , 5 or 6 , in the presence of a LAH4 peptide or a functional derivative thereof.
15. The immune cells, preferably B cells, more preferably naïve B cells, comprising said heterologous gene of interest obtainable by the ex vivo process according to any one of claims 12 to 14 .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/929,816 US20230203537A1 (en) | 2016-04-21 | 2022-09-06 | Stable pseudotyped lentiviral particles and uses thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16305466.1A EP3235828A1 (en) | 2016-04-21 | 2016-04-21 | Stable pseudotyped lentiviral particles and uses thereof |
EP16305466.1 | 2016-04-21 | ||
PCT/EP2017/059465 WO2017182607A1 (en) | 2016-04-21 | 2017-04-21 | Stable pseudotyped lentiviral particles and uses thereof |
US201816095098A | 2018-10-19 | 2018-10-19 | |
US17/929,816 US20230203537A1 (en) | 2016-04-21 | 2022-09-06 | Stable pseudotyped lentiviral particles and uses thereof |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/095,098 Division US11993781B2 (en) | 2016-04-21 | 2017-04-21 | Stable pseudotyped lentiviral particles and uses thereof |
PCT/EP2017/059465 Division WO2017182607A1 (en) | 2016-04-21 | 2017-04-21 | Stable pseudotyped lentiviral particles and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230203537A1 true US20230203537A1 (en) | 2023-06-29 |
Family
ID=55809054
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/095,098 Active 2038-07-10 US11993781B2 (en) | 2016-04-21 | 2017-04-21 | Stable pseudotyped lentiviral particles and uses thereof |
US17/929,816 Pending US20230203537A1 (en) | 2016-04-21 | 2022-09-06 | Stable pseudotyped lentiviral particles and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/095,098 Active 2038-07-10 US11993781B2 (en) | 2016-04-21 | 2017-04-21 | Stable pseudotyped lentiviral particles and uses thereof |
Country Status (6)
Country | Link |
---|---|
US (2) | US11993781B2 (en) |
EP (2) | EP3235828A1 (en) |
JP (1) | JP7078547B2 (en) |
KR (1) | KR102445700B1 (en) |
CN (1) | CN109563139B (en) |
WO (1) | WO2017182607A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111225682A (en) * | 2017-10-20 | 2020-06-02 | 吉尼松公司 | Use of syncytin for targeted delivery of drugs and genes to lung tissue |
CA3078096A1 (en) * | 2017-10-20 | 2018-10-19 | Genethon | Use of syncytin for targeting drug and gene delivery to regenerating muscle tissue |
KR20210070305A (en) | 2018-09-18 | 2021-06-14 | 브이엔브이 뉴코 인크. | ARC-based capsids and uses thereof |
JP2022529680A (en) | 2019-04-19 | 2022-06-23 | ジェネトン | Gene therapy for fibroblast growth factor 23-related hypophosphatemic disease |
US20220184225A1 (en) * | 2019-04-23 | 2022-06-16 | Case Western Reserve University | Fusogenic particles and related methods for delivering therapeutic agents to cells |
US11129892B1 (en) | 2020-05-18 | 2021-09-28 | Vnv Newco Inc. | Vaccine compositions comprising endogenous Gag polypeptides |
TW202227636A (en) * | 2020-09-08 | 2022-07-16 | 美商賽特免疫治療公司 | Methods and compositions of infecting, activating, and expanding immune cells |
WO2023217904A1 (en) | 2022-05-10 | 2023-11-16 | Institut National de la Santé et de la Recherche Médicale | Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells |
KR102496745B1 (en) * | 2022-11-18 | 2023-02-07 | 대한민국 | Method and composition for electing b cell |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE383172T1 (en) * | 1996-05-20 | 2008-01-15 | Us Gov Health & Human Serv | OLIGONUCLEOTIDES WHICH SPECIFICALLY BIND RETROVIRAL NUCLEOCAPSID PROTEINS |
FR2797889A1 (en) | 1999-09-01 | 2001-03-02 | Bio Merieux | METHOD FOR DETECTING THE EXPRESSION OF ENVELOPE PROTEIN FROM A HUMAN ENDOGENEOUS RETROVIRUS AND USES OF A GENE ENCODING SAME |
GB0009760D0 (en) * | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
WO2004087748A1 (en) * | 2003-04-04 | 2004-10-14 | Centre National De La Recherche Scientifique | Protein with fusogenic activity, nucleic acid sequences encoding said protein and pharmaceutical compositions comprising the same |
GB0325379D0 (en) * | 2003-10-30 | 2003-12-03 | Oxford Biomedica Ltd | Vectors |
JP4956427B2 (en) * | 2004-07-21 | 2012-06-20 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Lentiviral vectors and uses thereof |
WO2009019612A2 (en) * | 2007-08-03 | 2009-02-12 | Institut Pasteur | Lentiviral gene transfer vectors and their medicinal applications |
US20110207226A1 (en) * | 2008-08-20 | 2011-08-25 | Virxsys Corporation | Non-integrating lenti/adeno-associated virus hybrid vector system |
PT2456786E (en) * | 2009-07-24 | 2014-03-25 | Immune Design Corp | Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein |
ES2639307T3 (en) | 2011-06-30 | 2017-10-26 | Genethon | Peptides with properties that enhance viral infection and their use |
CN104845993A (en) * | 2015-05-13 | 2015-08-19 | 宝瑞源生物技术(北京)有限公司 | Pseudovirion containing hepatitis c virus RNA (Ribonucleic Acid) fragment and preparation method thereof |
CN104830908B (en) * | 2015-06-02 | 2018-04-10 | 中国食品药品检定研究院 | Pseudovirus packaging system and application thereof |
-
2016
- 2016-04-21 EP EP16305466.1A patent/EP3235828A1/en not_active Withdrawn
-
2017
- 2017-04-21 CN CN201780033565.1A patent/CN109563139B/en active Active
- 2017-04-21 US US16/095,098 patent/US11993781B2/en active Active
- 2017-04-21 KR KR1020187033579A patent/KR102445700B1/en active IP Right Grant
- 2017-04-21 WO PCT/EP2017/059465 patent/WO2017182607A1/en active Application Filing
- 2017-04-21 JP JP2018555222A patent/JP7078547B2/en active Active
- 2017-04-21 EP EP17720405.4A patent/EP3445774A1/en active Pending
-
2022
- 2022-09-06 US US17/929,816 patent/US20230203537A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2019514369A (en) | 2019-06-06 |
EP3235828A1 (en) | 2017-10-25 |
EP3445774A1 (en) | 2019-02-27 |
KR102445700B1 (en) | 2022-09-23 |
JP7078547B2 (en) | 2022-05-31 |
WO2017182607A1 (en) | 2017-10-26 |
KR20180135034A (en) | 2018-12-19 |
US11993781B2 (en) | 2024-05-28 |
US20190300902A1 (en) | 2019-10-03 |
CN109563139A (en) | 2019-04-02 |
CN109563139B (en) | 2022-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230203537A1 (en) | Stable pseudotyped lentiviral particles and uses thereof | |
Juno et al. | Cytotoxic CD4 T cells—friend or foe during viral infection? | |
US20180305435A1 (en) | Engineering Antiviral T Cell Immunity through Stem Cells and Chimeric Antigen Receptors | |
JP6643311B2 (en) | Vector production | |
JP2021530985A (en) | Fososome composition and its use | |
US20210353543A1 (en) | Targeted lipid particles and compositions and uses thereof | |
WO2018028157A1 (en) | Vc-car molecule and application thereof to hiv-1 infection cell clearing | |
US20220347316A1 (en) | Cd25 pre-selective combination anti-hiv vectors, targeting vectors, and methods of use | |
CN112673094A (en) | Viral vector production | |
WO2023115041A1 (en) | Modified paramyxoviridae attachment glycoproteins | |
JP2024073653A (en) | Method for producing genetically modified lymphocytes | |
CA3219487A1 (en) | Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses | |
WO2023115039A2 (en) | Modified paramyxoviridae fusion glycoproteins | |
Coquin et al. | Syncytins enable novel possibilities to transduce human or mouse primary B cells and to achieve well-tolerated in vivo gene transfer | |
US20240254168A1 (en) | LIPID PARTICLES CONTAINING A TRUNCATED BABOON ENDOGENOUS RETROVIRUS (BaEV) ENVELOPE GLYCOPROTEIN AND RELATED METHODS AND USES | |
WO2024081820A1 (en) | Viral particles targeting hematopoietic stem cells | |
WO2024044655A1 (en) | Delivery of heterologous proteins | |
Panchal | Developing novel therapies for X-linked lymphoproliferative disease type 1 | |
WO2023150518A1 (en) | Cd3-targeted lentiviral vectors and uses thereof | |
WO2020043765A1 (en) | Ldlr negative packaging cell line for the production of vsv-g pseudotyped retroviral vector particles or virus particles thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |